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1 Introduction  
In the industrialised countries, cancer is one of the biggest challenge mankind must overcome. 
With 14 million new cases and 8 million cancer-related death in 2014, it has become the second 
most common death causes worldwide. 1 First-line therapies are chemotherapy, surgery and 
radiotherapy. Chemotherapy is often painful and tortuous with low response rates. Surgery is 
limited to tumours which are accessible and radiotherapy often impairs healthy tissue as well. 
In addition, the high diversity of tumours based on diverse mutation profiles represents a ma-
jor hurdle in these treatments. That means that tumours often overexpress proteins like recep-
tors in comparison to healthy cells or even express specific proteins on the cell surface. There-
fore, a personalised therapy by tumour vaccination seems to offer a chance to combat the high 
mortality. The specific expression pattern is the target of the immunotherapy as well as of the 
targeted chemo- and radiotherapy. With the help of modern sequence methods like next gen-
eration sequencing (NGS), the specific protein structures of an individual patient can be ana-
lysed. The so-called mutanome comprises all the tumour specific properties and is the basis 
for the production of an individual tumour therapy. After administration into the patient’s 
body, the found protein structures are presented to the immune systems which then recognise 
these structures as foreign substances. Thereby, an immune response is started so that the 
body should able to recognise and combat the tumour cells on its own. The rough principle is 
illustrated in Fig. 1. 
First attempts for tumour vaccination as a novel treatment concept were already made in the 
19th century by William B. Coley, who injected attenuated bacteria to stimulate the immune 
system for cancer treatment. 2 Since then, many other approaches to stimulate the immune 
systems were found in the following decades. Viruses (Hepatitis B), proteins, peptides, deox-
yribonucleic acid (DNA), ribonucleic acid (RNA) and recently Messenger-RNA (mRNA) are 
considered as possible tumour vaccines. In contrast to the usage of proteins or peptides, DNA 
or mRNA consist of the corresponding nucleic acid structure and do not transport the active 
substance itself, but the genetic information for the production of the active substance in the 
human body.  
First achievements with mRNA were made in 1990 when Wolff et al.3 could detect the result-
ing protein in the skeletal muscle of mice after injection of the corresponding mRNA into the 
muscle. 3,4 Just a few years later in 1995, Conry et al.5 investigated a response of the immune 
system by measuring generated antibodies, also after intramuscular (i.m.) injection of mRNA. 5 
Introduction 
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Shortly after this, Boczkowski et al.6 could determine specific T-cell production after (in vitro) 
vaccination of DCs with mRNA, followed by a measurable antitumoural effect. 6 In the course 
of time, mRNA incorporated in lipid-based delivery systems and administered locally have 
shown impressive immune responses for active immunisation. 7 Recently, in mice studies test-
ing immunisation against Zika virus infection, the local administration of mRNA has had a 
higher immune response in comparison with the use of DNA. 8 Until now, several ways of 
application (intranodal, intravenous, subcutaneous, intratumoural) were found to show im-
mune response. 9–12  
 
Figure 1: The principle of the individual tumour therapy using mRNA incorporated into a lipid-based 
drug delivery system 
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1.1 Nucleic acids for antigen delivery 
1.1.1  Nucleic acids 
mRNA 
The structure of RNA is similar to DNA but differs on some significant issues. While DNA 
can form a double strand, RNA is single-stranded. The monomer is composed of a phosphate 
group, a five-carbon sugar and 4 different nitrogen-containing nucleobases. The bases adenine, 
guanine, cytosine are same in DNA. Instead of thymin, uracil which lacks the 5‘methyl group 
is the fourth base. The sugar is ribose, which has hydroxyl bonds in 2‘position whereby it is 
more reactive compared to 2‘deoxyribose of DNA and also not stable under alkaline condi-
tions. Larger grooves also promote instability because enzymes can attack more easily.  
Under physiological conditions, the phosphate group of nucleic acids is charged negatively 
which facilitates complexes with positively charged delivery systems. RNA can appear in dif-
ferent types, like transfer RNA (tRNA), ribosomal (rRNA) or messenger RNA (mRNA). 
mRNA acts as a working copy of the genetic information provided by the DNA and is needed 
for the protein synthesis.  
As shown in Fig. 2, the structure of mature eukaryotic mRNA can be divided into different 
parts: the poly-A tail, the 3'untranslated region (3’UTR), the coding region, the 5'untranslated 
region (5’UTR) and the 5‘cap.  
The coding region is the important part for the protein synthesis because it consists of nucle-
otide triplicates which code for the protein sequence. The 5‘cap is a modified guanosine and 
promotes protection from 5‘exonucleases. Furthermore, it supports the proper attachment to 
the ribosome. The 3‘poly-A tail comprises many adenine nucleotides and is important for the 
stability because it serves as a protection from degradation. Most important is that it promotes 
the transport out of the nucleus to the cytoplasm. Finally, also the untranslated regions (UTRs) 
support the stability but also the localisation of mRNA and effects the translation efficiency.  
 
Figure 2: Scheme of mature eukaryotic mRNA 
Introduction 
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siRNA 
Another type of RNA is small interfering RNA (siRNA). It was not used in the experiments 
but it is mentioned several times in this thesis due to comparative reasons. siRNA consist of 
short double stranded RNA-molecules (20 to 25 base pairs) with two overhanging nucleotides 
at both hydroxylated 3’ends. The main function of siRNA is RNA-interference which de-
scribes the targeted deactivation of genes. In presence of siRNA, all corresponding mRNA 
structure in this cell are destroyed which impeded the production of the derived proteins. 
RNA-interference is a natural mechanism in eukaryotic cells, but is nowadays also used as a 
therapeutic method to prevent the endogenous production of pathological proteins (gene si-
lencing). 13  
Plasmid DNA 
Plasmids consist of small circular, double-stranded DNA molecules which exist normally in 
bacteria cells but can also be present in eukaryotic organisms. They are located separately from 
the chromosomal DNA and can replicate independently. In nature, they are used to carry var-
iable genes to support the survival of the organism (e.g. resistance to antibiotics, virulence 
factors). The size of plasmids can vary from less than 1 kilobase pairs up to several megabase 
pairs whereas structure differ just slightly. Plasmids are composed of the gene for the plasmid-
specific replication initiation protein (Rep), the iterons (repeating units), DnaA boxes (replica-
tion ignition factor) and an adjacent AT-rich region. For reproduction, smaller plasmids use 
replicative enzymes of the host whereas larger plasmids often carry their own genes for the 
replication.  
1.1.2  Mode of action 
In principle, there are at least two different possibilities in which mRNA can act as a tumour 
vaccination agent. In the first method, mRNA is either taken up by myocytes or immune cells 
like dendritic cells (DCs) after i.m. injection. In myocytes, mRNA is translated into the corre-
sponding antigen. Then, the antigen is released by the cells and can be taken up by DCs, de-
graded into peptides and presented by major histocompatibility complex (MHC) class II mol-
ecules on the cell surface. This leads to an activation of CD4+ T cells. The other possibility is 
the direct uptake of mRNA by DCs as illustrated roughly in Fig. 1. After translation and deg-
radation, peptides are presented via MHC I molecules, which leads to an activation of CD8+ 
T cells. Humoral and cellular immune reactions are possible. The humoral one takes place by 
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the presence of Interleukin (IL-) 4. CD4+ T cells differentiate into Th2 cells, which secrete IL-
4/5/13. Consequently, B cells differentiate into plasma B cells, which produce antigen-specific 
antibodies to mark tumour cells for destruction, and memory B cells. For a cellular immune 
reaction, IL-12 is necessary. In this case, CD4+ T cells differentiate into Th1 cells, which secrete 
Interferon (IFN)-γ. First, CD8+ T cells develop into cytotoxic T cells (Tc cells). Through the 
secretion of perforin and granzymes, apoptosis of tumour cells is induced. Moreover, the ac-
tivation of macrophages leads to lysis of tumour cells due to nascent nitric oxide and reactive 
oxygen. T cells can also form memory cells. Just like the memory B cells, these cells can remain 
silent for a long time and get reactivated by another contact with the antigen. 14 Nevertheless, 
presentation of the applied antigen by MHC II receptors is not always guaranteed. By adding 
a secretion signal to the coding sequence of mRNA, which leads to secretion of the protein 
into the extracellular space and uptake as an exogenous protein, the MHC class II processing 
pathway can be achieved as well. 4 
1.1.3  Advantages of mRNA over proteins or DNA 
Cancer therapy is one of the oldest approaches for the preclinical and clinical use of mRNA. 
In the beginning, it was used for an ex vivo transfection with DCs (in vitro pulsation of DCs). 
In contrast, the current research focus is more on direct in vivo transfection. 4 Besides the in vitro 
pulsation of DCs, mRNA can be administrated via several routes like intravenous, intradermal, 
subcutaneous, intranodal, intrasplenic or by a gene gun 15. Vaccination with mRNA was more 
effective than with peptides because mRNA acts as a continuous source for generating new 
peptides. 6 There are several more reasons for the use of mRNA instead of the protein itself: 
– mRNA can encode any peptide or protein.  
– mRNA can encode not only one but several proteins.  
– Only the sequences directly needed for the gene expression are necessary.  
– Varying the protein just changes the sequence of mRNA, but not the 
physicochemical properties.  
Consequently, the same delivery system and the preparation procedure can be used for differ-
ent mRNA sequences. This is time- and cost-effective. On the contrary, changing a formula-
tion with a protein, can lead to completely different properties, so that adjustments in the 
manufacturing process would be necessary. 16 In comparison with DNA, application of mRNA 
has led to equivalent transfection as shown by Wolff et al. 3 In addition, mRNA has several 
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advantages in the translation process. For example, mRNA does not have to enter the nucleus 
to be active since the mode of action takes place in the cytoplasm. Because of this, mRNA is 
not integrated into the genome so that mutagenesis cannot occur. Since it is degraded in the 
serum after several days, mRNA has just a transient effect. Hence, safety problems are re-
duced. 17 Furthermore, it is said, that mRNA has additional adjuvant effects on the innate im-
mune system by costimulating pattern recognition receptors like Toll-like receptors on the 
surface of immune cells. 18 This so-called danger signal is needed for an effective adaptive 
immune response. 16 However, this multiple pattern recognition can entail severe immune re-
actions, particularly in susceptible individuals. Modifications of mRNA can counter these 19, 
but sometimes the co-dosing with an immunosuppressor is necessary. 7 In comparison to plas-
mids, synthetic mRNA is not categorised by the FDA as a genetically modified organism. 20 
Since single-stranded mRNA is not as stable as double-stranded DNA, modifications of the 
strand are necessary to increase the stability. mRNA is also active after lyophilisation 21 and 
can be stored in solution for two years at room temperature (RT) 22, but in contact with 
RNases, it degrades immediately. The median intracellularly half-life is said to be 7.1 h tested 
in mouse cell lines 23 and 10 h when using human hepatoma cells. 24 Values for the peak protein 
translation ranges from 6 25,26 to 24 h 27, so that it is not clear whether the intracellular stability 
is high enough. A poly(A)tail at the 3’ end and a cap at the 5’ increase the stability, but also 
influence the translation. Both structures serve as frames for the coding sequences, so they 
have to be chosen carefully. 16,28 The open reading frame (ORF) is flagged by a start and stop 
codon with untranslated regions (UTRs) around it. The production of mRNA in comparison 
to DNA is quite simple, fast and cheap using in vitro transcription. DNA serves as a template 
for all structures except the 5’cap, which is done enzymatically. The DNA is digested by 
DNases afterwards. 4 
Until today, the problems of low stability and short half-life of mRNA have been solved by 
structural modifications, so that other hurdles are now in the focus. For an effective treatment 
with fewer side effects, it is necessary to target special organs and cells in vivo. Since mRNA is 
not the pharmacologically active agent, bioavailability is difficult to predict. The relationship 
between mRNA dose, the encoded protein and the corresponding effect has to be investigated 
carefully. 4 
Two types of mRNA can be used, non-amplifying mRNA (IVT-mRNA) and self-amplifying 
mRNA (replicon-mRNA). In comparison, the former one is smaller (2 to 3 compared to 9 to 
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10 kb) and does not contain further encoded proteins which lower the risk of unwanted im-
mune responses. Due to its self-amplification, replicon-mRNA has a longer half-life and in 
vivo-expression can last almost 2 months. In contrast, replicon-mRNA is much more sensitive 
to structural modification. 29 For this work, only IVT-mRNA was used.  
1.1.4  Necessity of delivery systems 
For transport of mRNA, nanoparticulate formulations are often used. A suitable vehicle needs 
various functions, leading to heavy demands in development:  
– Interactions with unwanted components in the serum, as well as aggregation, should 
be avoided. 
– Drug delivery systems should enable transport over cell membranes, since large and 
highly charged molecules such as mRNA are normally not able to cross cellular mem-
branes. 30,31 Furthermore, the anionic charge of mRNA hinders penetration into DCs. 11  
– Drug delivery systems should enable the uptake into cells as well as an endosomal 
release. 4 Those cells which take up naked mRNA spontaneously use endocytosis. 
Hence, mRNA is accumulated and degraded in the lysosomes and just a small amount 
is secreted into the cytoplasm. 
– Although the stability of mRNA is increased by modification of the mRNA strand, it 
is still necessary to protect the mRNA from RNases which are ubiquitous in the human 
body.  
– The drug delivery system should target e.g. dendritic cells (DCs), best located in the 
lymphatic organ because these cells are potent antigen-presenting cells (APCs). 
– At the target site, the uptake of mRNA into cells as well as the translation of mRNA 
should be facilitated.  
– The formulation of other factors needed for an effective transfection should be possi-
ble. As written before, several antigens are often needed. Although mRNA has self-
adjuvating properties, the addition of adjuvants seems to be beneficial. 32 Encoding of 
immunomodulating molecules like CD40L or CD70 has led to a higher immune 
response to the antigen. 33 Factors which have an impact on the local microenviron-
ment at the tumour site could also be essential. 
– The possibility of a manufacturing under GMP-conditions is required for a successful 
application. 32 
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1.1.5  Current challenges in clinical trials 
Most of the clinical trials in the last 20 years were performed with the ex vivo administration of 
mRNA to DCs 34,35 which should not be part of this work. In the last years, focus was more 
on the direct administration of mRNA with targets like metastatic melanoma 36, renal cancer 
carcinoma 37 or prostate cancer. 38 In some of the earlier studies, the outcome was not as suc-
cessful as expected 36,39–41 and also rare cases of severe side effects like a Bell palsy occurred 
21,42, which raises questions concerning the safety. In general, application of mRNA-based vac-
cines was safe 40,43, well-tolerated and led to tumour antigen-specific immune responses 43. Lo-
cal side effects like pain, swelling or erythema and systemic adverse reactions like fever, fatigue 
or headache 21 can always occur for preventive vaccination procedures.  
A weak immune response could not be the only explanation for the failure of such vaccines. 
Moreover, it seems to be due to a complex host-tumour relationship which comprises re-
sponse, editing, escape, and adaption of the hosts immune system. 39,44 So far, the overall clin-
ical benefit of cancer vaccination in comparison to general treatment is just about 20 %. 45 
Therefore, modifications of the vaccinations are necessary. Independent on the active sub-
stance, targeted therapy bases on recognition of protein structures which are normally upreg-
ulated on tumour cells. Nevertheless, these structures can also be found on the surface of 
healthy cells which lowers the specificity. In addition, vaccination with just one antigen is not 
reasonable due to a possible resistance. Combinations of more than one antigen can increase 
the specificity, in case more receptors are upregulated on the tumour surface. The higher the 
difference between tumour and healthy cells, the higher the success of a therapy can be. Hence, 
mutated antigens seem to be beneficial over non-mutated antigens 43,46,47. In addition, the de-
livery system has a huge influence on the immune response and needs to be optimised as 
well. 45 
Several clinical trials are performed to evaluate the therapeutic effect of mRNA, not only for 
treatment of cancer. In many of these studies, mRNA is applied nakedly without a delivery 
system (e.g. AGS-0003-LNG, AGS-003, IVAC mutanome/warehouse. In addition, lipid-
based delivery systems are often used as well (e.g. Lipo-MERIT, TNBC-MERIT, mRNA-1325, 
mRNA-2416), which shows the suitability of these systems for the use as a delivery system for 
mRNA. 32,48  
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1.2 Lipoplexes for nucleic acid delivery 
1.2.1  Liposomes  
Since liposomes were first mentioned in 1965 by Alec Bangham 49, they have been investigated 
intensively. In general, liposomes are spherical vehicles, consisting mainly of lipophilic phos-
pholipids. In contrary to micelles, they have at least one lipid bilayer with an entrapped hydro-
philic volume. Due to their similarity to cell membranes, liposomes are often used as model 
membranes whereas research focus is on their use as a drug delivery system. 50 Although lipo-
somes are now investigated for more than five decades, only a few products are approved by 
the regulatory authorities and available on the market (DaunoXome®, AmBisome®, DOXIL®, 
Epaxal®, Lipodox®, Visudyne®, AMPHOTEC®, Marqibo®, ABELCELT®, Myocet®). 7,51 Rea-
sons for the lack of market approvals are e.g. the missing long-term stability, a difficult scale-
up of the production with high effort to fulfil all the regulatory norms and the recognition of 
liposomes by the mononuclear phagocytic system (MPS) followed by a fast clearance from the 
blood. 51 Despite these problems, liposomes were chosen as the delivery system for this work 
because they have many advantages:  
– They are biocompatible and biodegradable along with a low toxicity and immunogen-
icity.  
– The self-assembled structure of liposomes can be varied through the composition as 
well as the preparation method. For example, the size ranges from 20 nm up to a few 
micrometres while at the same time the number of bilayers can be tuned (Fig. 3).  
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Figure 3: Classification of liposomes 
– Due to the possibility of encapsulation of hydrophilic as well as lipophilic drugs, lipo-
somes offer a wide range of formulation approaches. In general, by encapsulation, 
the toxicity and therefore the side effects of the therapeutic agent is reduced, which 
improves anticancer treatments. 51,52 It is possible to maintain a high drug concentra-
tion until the disintegration of the liposomes at the target region in the patient. 
– Furthermore, active targeting by linkage of suitable structures like antibodies, pro-
teins, Fab’ fragments or carbohydrates on the surface, as well as passive targeting via 
the EPR-effect in tumour tissue, is feasible. 53 
– Due to the variability in properties, encapsulation and surface modifications, lipo-
somes can be used for a wide range of therapies and also as a diagnostic agent as il-
lustrated (Fig. 4). 54 
 
  Introduction 
23 
 
 
Figure 4: Different types of therapeutic liposomes (drawn after 54) 
1.2.2  Mesomorphic phases 
The formation of liposomes from lipids is an entropy-driven self-assembling process. Due to 
the molecular shape of the lipid 55, different mesomorphic phases exist (Fig. 5): 
– Lamellar phase (Lα): The hydrocarbon chains are directed towards each other and 
the polar headgroups form the outer layer on both sides of the resulting bilayer. 56 
– Cubic phase: Different forms exist. The easiest one is an oil-in-water micelle assem-
bly, where the hydrocarbon chains are all directed to one centre and the polar head-
groups form the interface to the surrounding polar phase.  
– Reverse cubic phase: Again, the easiest one is a water-in-oil micelle assembly, 
where the polar headgroups are all directed to one centre and the hydrocarbon chains 
form the interface to the surrounding lipid phase. 57 
– Hexagonal phase (HI): Inwardly directed hydrocarbon chains form cylindrical ag-
gregates with the polar headgroups as an interface to the surrounding polar phase. 
– Inverse hexagonal phase (HII): Cylindrical aggregates are formed by inwardly di-
rected polar headgroups and hydrocarbon chains represent the interface to the sur-
rounding lipid phase. 58 
Introduction 
24 
 
 
Figure 5: Exemplary illustration of lipid phases formed depending on the lipid shape (taken from 55) 
For transport of nucleic acids and uptake of the liposomes into the cells by lipid membrane 
fusion 59, two phases and their transitions are most important. The lamellar structure represents 
stability since all cell membranes are associated in bilayers. Nevertheless, for transport of huge 
hydrophilic molecules, this structure is not beneficial. For uptake and release out of the endo-
some, the inverse hexagonal HII phase is beneficial since it leads to a destabilisation. This mes-
omorphic phase is supposed to take place during the mitosis or invasion of viruses. 55 For 
evaluation of the ability of lipids to change from lamellar to hexagonal phase, the temperature 
of this transition can be measured. This transition depends on lipid shape, surrounding ionic 
conditions, hydration, temperature and pH. 60 
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1.2.3  Lipoplexes for nucleic acid transport 
Lipoplexes are the product of the formulation of nucleic acids with liposomes consisting of 
neutral, zwitterionic lipids like Egg-Phosphatidylcholine (EPC) or 1,2-Dioleoyl-sn-glycero-3-
phosphocholine (DOPC) and a cationic lipid for complexation of the negative mRNA. Posi-
tively charged lipoplexes are associated with higher transfection efficiency in comparison to 
neutral or anionic lipoplexes. 61 Cationic lipids are associated with toxicity because they lead 
e.g. to cell shrinking, vacuolisation of cytoplasm or the disruption of the cell cycle. 62 Lipids 
generally consist of three parts – the hydrophobic chain, the hydrophilic headgroup and the 
linker between both. All three parts are considered to have an influence on the transfection 
and the toxicity. For example, cholesterol-based chains show higher transfection but have also 
a higher toxicity in comparison to aliphatic chains. 63 The cationic lipids normally have a carbon 
chain length from 8 to 18. One double bond in the chain is associated with the highest trans-
fection efficiency, probably due to an increased fluidity of the membrane. 64 Single-tail chains 
are often more toxic than double-tail chains but can increase transfection as well. The linker 
bond between the hydrophobic chain and hydrophilic head can be either an ether, an ester or 
more recently also an amide or carbamate group. Ethers, like in 1,2-Di-O-octadecenyl-3-tri-
methylammonium propane (DOTMA), show good transfection but are too stable to be bio-
degradable. In contrast, esters like in 1,2-Dioleoyl-3-trimethylammonium-propane (DOTAP) 
result in lower toxicity because of a less stable bond, which can lead to degradation before 
reaching the target site. Carbamates or amides can circumvent these drawbacks. 65 The bonds 
are stable at neutral pH but are degradable in a more acidic area like the endosome. The head-
group bears the charge 63 which results in a higher impact on the transfection efficiency. 66 
However, it also has a huge influence on the toxicity because the positive charge favors inter-
actions with other components like proteins/enzymes. This leads to an increase in the particle 
size which can cause toxicity while circulating in the body. Furthermore, the charge is neutral-
ised which normally decreases the transfection efficiency. In general, these effects are more 
pronounced for quaternary amines than tertiary amines. 63 Despite their toxic potential, cati-
onic lipids are used to deliver mRNA because these lipids can serve as vaccine adjuvant as 
well. 67 
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1.2.4 Selective targeting of lipoplexes 
For tumour vaccination, activation of antigen-presenting cells (APCs) is prerequisite. Cova-
lently bound mannose is one of the used ligands to target DCs as the most important antigen-
presenting cells and can lead to higher transfection efficiency. 68,69 
Conversely, Kranz et al.10 showed another approach to achieve a targeting. Instead of a mo-
lecular ligand, the composition of mRNA-lipoplexes was varied, which has resulted in a selec-
tive transfection after i.v. injection into mice. Naked mRNA, coding for luciferase, showed no 
measurable signal while mRNA in lipoplexes composed of DOTMA and 1,2-Dioleoyl-sn-glyc-
ero-3-phosphoethanolamine (DOPE), all with a size of 200 to 400 nm, showed a characteristic 
pattern. Cationic lipoplexes with a nitrogen to phosphate ratio (N/P = ratio of positive to 
negative charge in the complex) around 5/1 displayed expression of luciferase above all in the 
lungs and just rarely in the spleen. With the decrease of cationic lipid, the luciferase expression 
was shifted from the lungs to the spleen, so that neutral and negatively charged lipoplexes 
resulted in an expression exclusively in the spleen. The expression was reduced with an increase 
of negative charge. A higher amount of unbound mRNA is said to be responsible for that. 
Slightly positive lipoplexes (N/P from 2.5/1 to 1.8/1) were unstable by forming large aggre-
gates after preparation so that these have been excluded from the experiments. This effect was 
also demonstrated with other cationic lipids like DOTAP. Although macrophages have the 
highest uptake of mRNA, the highest translation efficiency was shown in DCs. Furthermore 
it was shown, that lipoplexes are mainly taken up by macropinocytosis after binding to scav-
enger receptors. 10,70 Finally, these investigations have revealed that i.v. injection has advantages 
over local administration, tested with subcutaneous injection. 10 Nevertheless, local i.m. injec-
tion of lipid nanoparticles (LNPs) or cationic nanoemulsions (CNE) resulted in a strong stim-
ulation of the immune system as well. 29,71 
1.3 Liposomal pathway after administrations to humans 
The fate of the liposomal formulation depends on their way of administration. After intrave-
nous injection, lipoplexes circulate in the blood stream depending on their properties. This 
circulation can be prolonged by stealth modification of the vesicular surface using polyeth-
ylenglycol (PEG) or polyglycerol (PG). 72 The distribution of the lipoplexes can be controlled 
via active targeting by addressing targets through binding of e.g. antibodies or proteins on the 
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liposomal surface or passive targeting by exploiting the physicochemical properties of the ves-
icles itself. Usually, differences in the properties of healthy and diseased tissue are required for 
the latter 73 as explained with the enhanced permeability and retention (EPR)-effect for tu-
mours which is based on the leaky vasculature due to a rapid growth. 74,75 Finally, active and 
passive targeting cannot be separated completely since passive targeting enables accumulation 
of the particles in the target tissue. 76  
In this project, lipoplexes are supposed to be applied locally due to their high viscosity and 
missing size adjustment. Since skin is rich in DCs, an intracutaneous application is reasonable. 
The muscle as vaccination target is said to be favourable as well 77 since myocytes was shown 
to act as a depot for pDNA due to prolonged protein expression. 78 Casares et al.79 revealed, 
that antigen presentation by DCs occurs after uptake of DNA into dermal or muscle cells. 79 
Due to the local application, distribution issues are neglected and the focus is on the cell uptake 
of lipoplexes at the target site. 
1.3.1  Cellular uptake  
The uptake of naked mRNA was first investigated by Lorenz et al.80, who found endocytosis 
as the main mechanism. This endocytosis is dependent on the binding to receptors of the 
scavenger family, which are expressed nearly everywhere in the body. Hence, the encoded 
antigen has been measured in almost all cell types. These receptors are concentrated in lipid 
rafts rich areas of the cells. Lipid rafts are liquid ordered phases in the cellular membrane which 
are surrounded by liquid disordered phases. Lipid rafts also contain proteins like receptors 
which can induce signal transduction. In addition, lipid rafts can form caveolae which are 
needed for endocytosis or transcytosis. Rafts are dynamic assemblies and have a high content 
of sphingolipids and cholesterol. 81  
Within the endocytic uptake, the pH of the emerging endosome is more acidic. The cytoplasm 
including the plasma membrane has the same physiological pH as the blood (7.4). After con-
striction of membrane lamellae, the formed early endosome has a pH of 6.2. Over time, the 
early endosome develops into the late endosome, which is more acidic with a pH around 5.0 
to 5.5. After fusion with an early lysosome which contain hydrolytic enzymes and phosphatases 
for degradation of endogenous and exogenous components, late lysosomes are formed. The 
pH of these vesicles is around 4.6 to 5.0. 82,83 This pH decrease is necessary for maintenance 
of normal cell functions like processing of receptor-ligand complexes or the activity of the 
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degrading enzymes. 84 The mRNA accumulates in the lysosomes 80 which is quite typical for 
macromolecules taken up like this. 85 If they cannot escape before the formation of the late 
lysosome, the substances will be destroyed. Unfortunately, just small amounts of the mRNA 
can exit the endosome. In that case, the release happens spontaneously during vesicular rear-
rangements. 80 An endosomal escape is prerequisite for an assured and sufficient therapeutic 
effect. Until now, the actual uptake mechanism could not be identified explicitly. Endocytosis-
independent uptake mechanisms are not excluded 80 and Diken et al.86 described macropino-
cytosis as the mechanism for internalisation of mRNA into DCs. 86 However, the uptake of 
mRNA for all of the mechanisms is extremely low with less than 1 in 10 000. 4 
First attempts using cationic lipids to improve the transfection of DNA in cells have already 
been made during the late 1980s and the early 1990s 87–89, although the way of interaction was 
not clear at that time. A more detailed investigation to understand the interactions of liposomes 
with cells were done in 1995 by Wrobel and Collins 90 by using anionic liposomes. Cationic 
lipids like DOTAP and 3ß-[N-(N’,N’-dimethylaminoethane)-carbamoyl]cholesterol (DC-
Chol) mixed with DOPE are able to fuse with model membranes, while there is no fusion with 
DOPC. Furthermore, this fusion is independent on pH in a range from 4.5 to 7 as well as on 
the concentration of NaCl up to 150 mM. The same effect has been seen in mammalian cells. 
Furthermore, after blocking of the uptake route by depletion of adenosine-5'-triphosphate 
(ATP) or inhibition of clathrin-coated pits, also the lipid mixing has been inhibited. Hence, 
endocytosis is a prerequisite for lipid fusion although until now it is not completely clear why. 90 
Until now, the endocytic pathway has been discussed for the uptake of liposomes 91 and has 
been proven for liposomes with different surface charge recently. Depending on the cell type 
as well as the surface charge, endocytosis was either caveolae- or clathrin-mediated and is a 
result of macropinocytosis. 92 In addition, endocytosis was also demonstrated for mRNA-
based nanomedicines. 93,94 
1.3.2  Release of nucleic acids from lipoplexes 
In 1996, Xu and Szoka 95 published their theory on the release kinetics of DNA from lipo-
plexes, which has not been refuted until today. 64,95 After the first contact with the cell surface, 
the lipoplex is internalised into the endosome. Subsequently, the endosomal membrane is de-
stabilised by a flip-flop of anionic lipids, which can be found on the cytoplasmic side. This 
results in the formation of new complexes between these anionic lipids and the cationic ones 
from the lipoplexes. Hence, the DNA is released from the complex into the cytosol. In further 
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experiments, it has been proven that anionic lipids can displace DNA, thus leading to lipid 
mixing. This is also a reasonable explanation for the toxicity of some lipoplexes if this ion-pair 
formation takes place e.g. within the mitochondrial membrane. Furthermore, Xu and Szoka 95 
have proven, that heparin and dextran sulfate as highly charged anionic polymers have the 
same property to form complexes with cationic lipid thus mimicking nucleic acid release 
in vitro. Similar to Wrobel and Collins 90, they have not been able to explain why lipoplexes first 
need to be taken up by endocytosis if lipid mixing and destabilisation occur anyway. 95 
In addition to the studies of Xu and Szoka 95, Hafez et al.96 have investigated the detailed 
mechanism of the interaction between cationic lipid and the endosomal membrane. Due to 
electrostatic interactions, cationic lipid forms ion pairs with anionic lipids in an equimolar ratio. 
The cationic lipid normally tends to form bilayers due to a bigger ionised headgroup. While 
pairing with negatively charged lipids, neutralisation leads to the formation of an inverse hex-
agonal HII phase. Consequently, the endosomal membrane is destabilised. Most anionic lipids 
are located on the cytoplasmic side of the endosome, but it seems like a small amount is enough 
to trigger this reaction. The mechanism is illustrated in Fig. 6 with siRNA as a model for all 
nucleic acids. 96 
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Figure 6: Presumed mechanism for endosomal release of lipoplexes (taken from 7)  
According to these findings, a correlation between the lipid mixing and the release of DNA is 
obvious. However, four years later, Mui et al.97 have shown that there this no correlation be-
tween the mixing and the transfection efficiency. 97 Already in 1997, it has been shown by 
Stegmann et al.98, that lipid mixing is not always followed by DNA release and translation. 
They compared lipid mixing of either DOTAP or DOTMA alone and with DNA. The com-
plex of both lipids and DNA has a lower tendency to fuse, probably due to a strong electro-
static interaction between the cationic lipid and the DNA as well as a likely different membrane 
structure of lipoplexes. Furthermore, they have determined the transfection of lipoplexes in 
Chinese hamster ovary (CHO-K1) cells while measuring the mixing of these lipoplexes with 
the cells. Experiments have exposed that there is no correlation between both events. The 
influence of DOPE has been investigated in addition. Lipoplexes (cationic lipid/DNA- ratio 
of 0.5) in combination with DOPE have had higher transfection than these lipoplexes alone 
(200-fold for DOTMA, 20-fold for DOTAP), which reveals the benefits of DOPE. Surpris-
ingly, lipid mixing with DOPE has indeed increased transfection for DOTAP but has reduced 
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it for DOTMA. Obviously, the mechanism explained by Xu and Szoka 95 is taking place in vitro, 
but not exactly like this in vivo. 98 
1.3.3  Enhancement of endosomal release 
One approach to enhance the endosomal release is the “proton sponge” effect by use of pol-
ymers, which is not part of this work and will not be discussed here. 99 
Another often-used possibility is the addition of the fusogenic lipid DOPE. Its quality to en-
hance transfection has already been mentioned above. Because of its ability to change between 
different liquid crystalline structures, it facilitates the destabilisation of the endosomal mem-
brane. Normally in standard physiological conditions and neutral pH, pure DOPE forms the 
hexagonal HII (non-bilayer) phase. In a mixture with a cationic lipid, DOPE is able to form 
bilayers. After contact with the anionic lipids in the endosome (described above), the cationic 
lipid is removed from the formulation by complexation. Consequently, DOPE forms again 
non-bilayer structures and supports the destabilisation of the membrane so that mRNA can 
be released. 64 The formation of the hexagonal phase is essential, which was also proven by 
Zuhorn et al.100 in 2005. The cationic lipid SAINT-2 has been tested with DOPE and DPPE. 
Both facilitate the dissociation of DNA out of the complexes suggesting that the ethanolamine 
headgroup is responsible for this. The role of the PE head group is said to disturb the interac-
tion between cationic lipid and DNA (by reaction of the PE phosphate group with the amine 
group of the cationic lipid and the amine group of PE with the phosphate group of the DNA). 
Transfection of DOPE has been higher compared to DOPC. DOPC forms lamellar structures 
where no dissociation of the lipoplexes is visible. After mixing with anionic liposomes, a mixed 
lamellar-hexagonal phase occurs which explains the low but nonetheless present transfec-
tion. 100 
As described earlier, cationic lipids alone have the property to destabilise the endosomal mem-
brane, so that endosomal release can also occur without the addition of DOPE. Unfortunately, 
they are associated with toxicity. 63 Ionizable lipids like 1,2-dioleoyl-N,N-dimethyl-3-ami-
nopropane (DODMA) offer a chance to overcome this problem. Jeffs et al.101 investigated this 
pH-sensitive system for delivery of DNA. The apparent pKa of DODMA in a lipid layer has 
been determined at 6.8. Therefore, the lipid is not completely charged at the physiological pH 
of 7.4, which avoids or at least reduces aggregation of proteins and facilitates a prolonged 
circulation in the extracellular fluids e.g. blood. While entering the acidic endosome, the head-
group gets ionised so that the ion pair formation with the anionic lipids is possible and the 
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DNA can be released. They discovered, that an optimal encapsulation of DNA into the lipids 
needs an acidic pH from 4 to 6 as well. 101 Although an overall neutrally charged vesicle seems 
to be optimal to avoid complete aggregation in the serum, it is necessary to have at least a small 
excess of positive charge. The charge is needed so that the vesicle can bind to the cell surface 
via electrostatic interaction and enhance cellular uptake via endocytosis. 102 Apart from that, it 
has to be considered that cell surfaces are coated with membrane proteins 103 and that the 
lipoplexes will be covered with a protein corona after administration into the human 
body. 104,105 Due to the complexity, this should not be considered within this thesis. 
1.4 Structural analysis 
As described above, detailed information on the structure is essential for a prediction of the in 
vitro and in vivo behaviour of mRNA formulations. Several techniques are available to gain 
insight into the molecular organisation, so for this work only some were accessible. As a pri-
mary method, small-angle scattering (SAS) techniques were used, whereas e.g. dynamic light 
scattering (DLS) and electrophoretic light scattering (ELS), differential scanning calorimetry 
(DSC) and the determination of free mRNA with RiboGreen® Assay, provided supporting 
information. Transfection experiments have been carried out to test the principal functionality 
and to correlate the findings with the biological behaviour. 
Radiation describes the transport of energy through a medium or space and can be divided 
into particle radiation and electromagnetic radiation. The first describes the energy transport 
by the emission of particles such as neutrons or alpha- and beta radiation. In case of electro-
magnetic radiation, the energy is transported in the form of waves. Examples for this kind of 
radiation are X-rays, light and radio waves.  
In the context of the SAS experiments, there are three relevant types of interaction between 
radiation and matter. Radiation can be absorbed entirely by matter (absorption). In the case of 
coherent scattering, scattered radiation is characterised by a fixed phase relation of the scat-
tered waves. The phase relation is dependent on the structure of the scattering centre. Coher-
ence can occur either temporally or spatially. The wavelength of the scattered light needs to be 
the same (coherent scattering). In case of incoherent scattering, there is no fixed phase relation 
between incident light and scattered light and the wavelengths of the scattered radiation differ. 
Due to the structure of the scattering centres, the waves are scattered into different directions 
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(incoherent scattering). For SAS measurements, the wanted information are transported by the 
coherent scattering, while the incoherent scattering generates the background noise. 106 
In addition, scattering is further characterised by the energy transfer from the incident radiation 
to the medium. In case of elastic scattering, the particle's kinetic energy before and after the 
scattering process is the same. No energy is transferred to the scattering centre. For inelastic 
scattering, the kinetic energy of the scattered particles or waves is lower since some of the 
energy is transferred to the scattering centre. The quantity of transferred energy provides in-
formation on the structure and properties of the tested material. 107 
Scattering patterns can either be static or dynamic. Static patterns grow out of intramolecular 
interference of the amplitudes generated by the atoms in a molecule. Due to that, the molecular 
structure can be analysed. Dynamic scattering patterns arise from the interference of various 
particles or molecules that move in a dispersed solution. Therefore, it can just be used to obtain 
information about the particle size but not about the molecular structure.  
1.4.1  Small-angle scattering  
Lots of studies show the feasibility of SAXS and SANS for investigation of lipoplexes, in a 
way that the mesomorphic structures can be determined. 108–114 In 1963, Kratky published first 
SAXS experiments with lamella-shaped particles. 115 In 1974, Atkinson et al.108 carried out  
SAXS experiments with phosphatidylserine (PS) dispersions 108 and in 1987, Jousma et al.116 
characterised the multilamellar structure of liposomes composed of phosphatidylcholine (PC), 
PS and cholesterol after extrusion. 116 Nearly 20 years later, Lasic et al.117 described a lamellar 
organisation for self-assembled DNA-lipoplexes composed of 1,2-Dioleoyloxy-3-dimethyla-
mino-propane (DODAP) and cholesterol, where the DNA forms a lattice between the lipid 
layers. 117 Further experiments performed by Rädler et al.113 and Salditt et al.118 with a mixture 
of DOPC, DOTAP and DNA have proven the lamellar structure. 113,118 Shortly after, 
Koltover et al.112 have been able to detect the inverse hexagonal phases alone and in coexist-
ence with lamellar structures while using lipoplexes of DOPE and DOTAP 112. Since then, 
several studies have been conducted to investigate lipoplexes of different compositions under 
various conditions. 119–122 Nevertheless, most studies have used lipoplexes with DNA or 
siRNA 123,124, but none were undertaken using mRNA. It has been shown that it is possible to 
detect mRNA alone or in combination using X-ray scattering as reviewed by Chen and Pol-
lack. 125 
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1.4.2  Differential scanning calorimetry 
Another method for characterisation used in this thesis is the differential scanning calorimetry 
(DSC), which has been first mentioned in 1963. 126 The method can be used to determine the 
thermodynamical behaviour and complex formation of small molecules, polymers or lipid. A 
temperature program is applied to the sample as well as to a reference, while the amount of 
heat which is necessary to achieve this temperature is measured. Differences in the amount of 
heat can result from endothermic (e.g. melting) or exothermic (e.g. crystallisation) processes. 
For lipid formulations, the phase transition temperature (Tm) is a significant parameter since it 
represents the transition from the ordered gel-like state to the unordered liquid-like state of a 
lamellar order and is crucial for the stability of the system. Higher values for Tm mean more 
energy to destabilise the bilayers. The phase transition is dependent on the composition of the 
formulation and hydration of the lipids as well as the type and pH of the surrounding solvent. 
Depending on the geometry of the double bonds, unsaturated lipids can affect the packing of 
lipids. While the trans-position only has a slight influence on Tm, cis-double bonds can lead to 
a stronger decrease of Tm since the packing is no longer completely uniform. The packing of 
lipids can also be disturbed by impurities such as small molecules. 127 It has to be investigated 
if mRNA acts like an impurity. Furthermore, for storage liposomal formulations are often 
freeze-dried and result in an amorphous form. The glass transition temperature (Tg) is another 
parameter which can be determined to investigate the long-term stability. Summing up, DSC 
represents another important characterisation method for formulation development. 128  
1.4.3  Light scattering techniques  
Two fundamental characteristics for lipoplexes are size and zeta potential. Lots of different 
factors have to be considered when adjusting the particle size. In addition, it is still not clear if 
size is a determining factor for transfection since there is inconsistent data concerning that. 
Some studies could not found a dependency 98,129,130 while others identified an influence of the 
size. 131,132 Some studies even described size as the major factor for transfection efficiency. 133,134 
Nevertheless, some of the performed studies have shown, that large vesicles are not obstruc-
tive for transfection. For example, Turek et al.135 showed, that DNA-lipoplexes with a size 
smaller than 250 nm have only transfected efficiently in the absence of serum, while the ones 
with sizes over 700 nm have shown good transfection with or without serum. Since large-size 
complexes showed higher transfection efficiency, it was assumed that the smaller particles 
show lower efficiency because the serum prevents an aggregation of these particles 135 as well 
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as inhibit the contact of the particles with the cell surface. 136 Studies indicate that large lipo-
plexes can induce the formation of large intracellular vesicles, which can be disrupted more 
easily and therefore deliver the DNA with higher efficacy. 137 For lipofection (transfection with 
liposomes or micelles), larger vesicles have maximum contact with the cells which increase the 
probability of endocytosis. 138 In contrast to that, by using colloidal gold nanoparticles 
Jiang et al.139 showed that endocytosis was most efficient within the size range of 25 to 
50 µm. 139 It is discussed that in vitro and in vivo application can require different particle sizes. 140 
In general, the size of nanoparticles cannot be increased too much to avoid e.g. pulmonary 
embolism, strokes or myocardial infarctions. The smallest capillaries have a diameter of 5 to 
10 µm so that particles have to be much smaller than 5 µm and must not form aggregates. 141 
The increase of the particle size after contact with serum due to formation of a protein corona 
has to be considered as well. 105,142 On the contrary, very small particles (< 100 nm) tend to 
form aggregates as well. 143 Local administration was in the focus of this thesis so that the size 
of the vesicles is not such an essential factor because distribution of the particles over the 
blood stream is not needed. Hence, the size of the lipoplexes was not adjusted throughout the 
preparation. 
The zeta potential is defined as the potential difference between the stationary layer which is 
attached to a dispersed particle and the dispersion medium. It is measured as the overall charge 
of the lipoplexes and provides information on repulsive or attractive forces between particles. 
Aggregation, fusion or precipitation of particles is dependent on the charge so that zeta po-
tential can predict the stability of the system. Furthermore, modifications of the surface can 
also be observed by a change in this potential. 144 Just like the size, the zeta potential can change 
after administration into the human body due to the formation of a protein corona. 142 The 
absorption of positively or negatively charged proteins on the particle surface can favour ag-
gregation and increase the risk of an embolism or stroke.  
1.4.4  Encapsulation efficiency  
For the development of a structural model, it is necessary to know where the mRNA is located 
in the sample structure. Determination of free and bound mRNA gives information on the 
localisation of the mRNA molecules and can be done with the Quant-IT RiboGreen® Assay 
Kit provided by Thermo Fisher. The fluorescent dye only binds to free mRNA leading to a 
measurable fluorescence. By knowing the total concentration of mRNA in the sample, the 
complexed proportion can be calculated easily. 145 
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1.4.5  Determination of ionizable properties 
For the characterisation of formulations with an ionizable lipid, further characterisation is nec-
essary to determine the pKa. The 2-(p-toluidino)-6-naphthalenesulfonic acid (TNS) assay is a 
convenient method to perform an in situ measurement which was introduced by Eastman et 
al. in 1981. 146 The pKa of the lipid incorporated into the lipid membrane is measured so that 
influences on the dissociation of the amine group by the neighboring lipids or the membrane 
itself are considered. 147–149  
The importance of the pKa determination was emphasised by Jayaraman et al.148 in 2012. In 
this study, novel amino lipids with pKa values between 4.17 and 8.12 were synthesised by 
modification of the headgroup of the ionizable DLin-KC2-DMA. Importantly, there was no 
significant change in the molecular dimension of the hydrophilic region since a major change 
in the headgroup could lead to an alteration in the adoption of the inverted, non-bilayer struc-
ture. Lipids were formulated with siRNA in LNPs and tested for their in vivo hepatic gene 
silencing in mice. A pKa range of 6.2 to 6.5 was found as an optimum for this effect. Never-
theless, lipids with the same pKa showed differences in the potency, which indicated that the 
pKa is just one parameter for an effective in vivo activity. In addition, mixing two lipids to 
achieve a special pKa led to the same efficiency than one lipid with that pKa. For similar struc-
tures, the in vivo hepatic gene silencing was driven by the pKa rather than structural changes of 
the headgroup or the linker length. 148 
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2  Aim of the thesis  
mRNA nanomedicines have been gaining increasing interest for cancer therapy in the last 
years. They can be used for a wide range of therapeutic applications such as tumour therapy, 
vaccination or protein replacement therapy. Several products, most of them in for tumour 
therapy, have reached the level of clinical trials. Formulations are required for administration 
of the mRNA to achieve a protected and selective delivery as well as an efficient uptake and 
translation into the target cells. For a successful therapy, it is necessary to have detailed infor-
mation of the molecular structure of the formulation for development of a structure-activity 
relationship and the selection of the suitable composition.  
In this thesis, lipid-based carrier systems are used since barely any information about the struc-
ture of mRNA-lipoplexes is given. Most of the previous studies have dealt with DNA or 
siRNA. In the first part, cationic lipoplexes for local administration are used as a model system 
to characterise the structure when incorporating mRNA. DOPC acts as a matrix, into which 
the cationic lipid DOTAP is inserted in varying proportions. Several formulations with an 
excess of cationic lipid or negatively charged mRNA are prepared to investigated lipoplexes 
with different characteristic properties. The mRNA should be inserted into this highly con-
centrated DOPC matrix in a controlled way. It should be investigated if DOTAP acts as an 
anchor and is able to facilitate a controlled release of the mRNA.  
Unfortunately, cationic lipids are related to toxicity. Hence, the second part of the thesis 
focuses on ionizable lipids, because these lipids propose to offer less toxicity with higher effi-
cacy. The pKa of the used formulation is evaluated to find the best composition to enhance 
endosomal release. In addition, the structural changes of the membranes are investigated as a 
function of the pH. Moreover, by addition of heparin and the concurrent reduction of the pH, 
cellular contact is mimicked and endosomal release is triggered. Again, the changes of the mo-
lecular structure and the release of mRNA can be determined to obtain information about the 
fate of the lipoplexes after administration into the human body as well as about their behaviour 
at the point of action. 
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3 Materials and methods 
Partial results of the presented work have been published in:  
Ziller, A.; Nogueira, S. S.; Huehn, E.; Funari, S. S.; Brezesinski, G.; Hartmann, H.; Sahin, U.; Haas, 
H.; Langguth, P. Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration. Mol. 
Pharm. 2017, acs.molpharmaceut.7b01022. 150 
3.1 Materials 
3.1.1  Reagents and solvents 
Ampuwa® (aqua ad iniectabilia) Fresenius Kabi Deutschland GmbH, Bad 
Homburg vor der Höhe (Germany) 
Adenosine 5'-Triphosphoric Acid 
Disodium Salt (ATP) 
AppliChem GmbH, Darmstadt (Germany) 
Boric acid Sigma-Aldrich, St. Louis (USA) 
Cell Proliferation Kit II (XTT) Sigma-Aldrich, St. Louis (USA) 
Chloroform anhydrous Sigma-Aldrich, St. Louis (USA) 
Citric acid Sigma-Aldrich, St. Louis (USA) 
Coenzyme A P.J.K, Seoul (Korea) 
D(+)-Glucose anhydrous Merck Chemicals GmbH, Darmstadt (Ger-
many) 
Dithiothreitol (DTT)  AppliChem GmbH, Darmstadt (Germany) 
D-Luciferin Synchem UG & Co. KG, Felsberg (Germany) 
Dulbecco’s modified eagle medium 
(DMEM) 
Sigma-Aldrich, St. Louis (USA) 
D-(+)-Trehalosedihydrate from 
saccharomyces cerevisiae, BioReagent 
Sigma-Aldrich, St. Louis (USA) 
  Materials and methods 
 
39 
 
DPBS (Dulbecco’s Phosphate Buffered Sa-
line), no calcium, no magnesium 
Gibco® - Life Technologies, Carlsbad 
(USA) 
Sigma-Aldrich, St. Louis (USA) 
Eagle’s minimal essential medium 
(EMEM) 
Sigma-Aldrich, St. Louis (USA) 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth GmbH, Karlsruhe (Germany) 
Sigma-Aldrich, St. Louis (USA) 
Fetal bovine serum, 10 % Sigma-Aldrich, St. Louis (USA) 
Fetal calf serum (FCS) Sigma-Aldrich, St. Louis (USA) 
Formamide Sigma-Aldrich, St. Louis (USA) 
Glutamine Sigma-Aldrich, St. Louis (USA) 
Heparin sodium, BRP Sigma-Aldrich, St. Louis (USA) 
HEPES Carl Roth GmbH, Karlsruhe (Germany) 
Iscove’s modified dulbecco’s medium 
(IMDM) 
Sigma-Aldrich, St. Louis (USA) 
Isopropanol Carl Roth GmbH, Karlsruhe (Germany) 
jetPEI® Polyplus-transfection,  
Illkirch-Graffenstaden (France) 
Lipopolysaccharide (LPS) InvivoGen, Toulouse (France) 
Magnesiumsulfat * 7 H2O  Carl Roth GmbH, Karlsruhe (Germany) 
Mercaptoethanol  Carl Roth GmbH, Karlsruhe (Germany) 
Messenger RNA BioNTech AG, Mainz (Germany) 
Opti-MEMTM  Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Ovalbumin (OVA) AppliChem GmbH, Darmstadt (Germany) 
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Passive lysis buffer Promega Corporation, Madison (USA) 
pCMV_GFP_2A_click_beatle luciferase 
(Plasmid DNA) 
WG Prof. Grabbe/University hospital, 
Mainz (Germany) 
Penicillin  Sigma-Aldrich, St. Louis (USA) 
PierceTM Firefly Luciferase Glow Assay Kit Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Potassium phosphate monobasic Sigma-Aldrich, St. Louis (USA) 
Protamine sulfate salt from salmon, 
Grade X 
Sigma-Aldrich, St. Louis (USA) 
Puromycin InvivoGen, Toulouse (France) 
Quant-iTTM RiboGreenTM RNA Assay Kit Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
RNase Zap® Ambion® - Life Technologies, Carlsbad 
(USA) 
Roti®-Stock 100x TE-buffer Carl Roth GmbH, Karlsruhe (Germany) 
ROTIPUTAN® Ethanol Carl Roth GmbH, Karlsruhe (Germany) 
Sodium chloride Carl Roth GmbH, Karlsruhe (Germany) 
Sodium dodecyl sulfate (SDS) AppliChem GmbH, Darmstadt (Germany) 
Sodium hydroxide Sigma-Aldrich, St. Louis (USA) 
Sodium phosphate dibasic  Sigma-Aldrich, St. Louis (USA) 
Sodium phosphate monobasic Sigma-Aldrich, St. Louis (USA) 
Streptomycin  Sigma-Aldrich, St. Louis (USA) 
Thymidine (labelled with tritium) PerkinElmer LAS GmbH, Rodgau     
(Germany) 
2- (p-toluidino)-6-naphthalenesulfonic acid 
(TNS) 
Sigma-Aldrich, St. Louis (USA) 
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Tricin PUFFERAN® Carl Roth GmbH, Karlsruhe (Germany) 
Trisodium citrate Sigma-Aldrich, St. Louis (USA) 
XTT Cell Proliferation Kit II Sigma-Aldrich, St. Louis (USA) 
Water RNase-free, Nuclease-free  Carl Roth GmbH, Karlsruhe (Germany) 
3.1.2  Lipids 
 
Cholesterol Sigma Aldrich Co., St. Louis, Missouri 
(USA) 
3ß-[N-(N',N'-Dimethylaminoethane)-car-
bamoyl]cholesterol (DC-Chol) 
Avanti Polar Lipids, Inc., Alabaster (USA) 
Didodecyldimethylammonium (DDAB) Avanti Polar Lipids, Inc., Alabaster (USA) 
1,2-Dioleoyl-N,N-dimethyl-3- aminopro-
pane (DODMA) 
Corden Pharma GmbH, Plankstadt       
(Germany) 
1,2-Dioleoyl-sn-glycero-3-phosphocho-
line (DOPC) 
Merck & Cie, Schaffhausen (Switzerland) 
Lipoid GmbH, Ludwigshafen (Germany) 
1,2-Dioleoyl-sn-glycero-phosphoethano-
lamine (DOPE) 
Lipoid GmbH, Ludwigshafen (Germany) 
1,2-Dioleoyl-3-trimethylammonium-pro-
pane (DOTAP) 
Merck & Cie, Schaffhausen (Switzerland) 
Lipoid GmbH, Ludwigshafen (Germany) 
1,2-Di-O-octadecenyl-3-trimethylammo-
nium propane (DOTMA) 
Merck & Cie, Schaffhausen (Switzerland) 
Egg-Phosphatidylcholine 80% 
(EPC 80, Lipoid E 80) 
Lipoid GmbH, Ludwigshafen (Germany) 
Egg-Phosphatidylcholine 100% 
(EPC 100, Lipoid E 100) 
Lipoid GmbH, Ludwigshafen (Germany) 
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1,2-Dioleoyl-sn-glycero-3-phosphoethan-
olamine-N-(carboxyfluorescein) (PE-CF) 
Avanti Polar Lipids, Inc., Alabaster (USA) 
3.1.3  Laboratory disposables 
Aluminium crucible with lid, 40 µl Mettler-Toledo GmbH, Gießen         
(Germany) 
Copper grids Quantifoil R1.2/1.3 200 mesh Plano GmbH, Wetzlar (Germany) 
DTS1060/DTS1070 folded capillary cell Malvern Instruments GmbH, Herrenberg 
(Germany) 
Nylon Wool Fibre, steril Polyscience Europe GmbH, Hirschberg an 
der Bergstraße (Germany) 
Omnifix®-F syringes, 1 ml B. Braun Melsungen AG, Melsungen 
(Germany) 
PARAFILM® M Carl Roth GmbH, Karlsruhe (Germany) 
PierceTM Protein Concentrator PES, 100 K 
MWCO, 5 - 20 ml, 10 pk 
Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Rotilabo® Disposable cuvette, PS, 1.6 ml Carl Roth GmbH, Karlsruhe (Germany) 
Safe-Lock Tubes, 0.5 ml/1.5 ml Eppendorf AG, Hamburg (Germany) 
SafeSeal SurPhob Filter Tip, 10 µl/200 
µl/1000 µl 
Biozym Scientific GmbH, Hessisch Olden-
burg (Germany) 
SiLibeads Typ ZY, 0.8 - 1.0 mm Sigmund Lindner GmbH, Warmensteinach 
(Germany) 
Sterican®, disposable cannulae, 0.6 x 60 mm, 
23 G/0.8 x 40 mm, 21 G x 1 ½ , PP 
Carl Roth GmbH, Karlsruhe (Germany) 
Syringe filters, cellulose acetate, 0.2 µm, ø 
25 mm 
VWR International, Radnor (USA) 
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Tubes, Polypropylene, 15 ml/50 ml Greiner Bio-One, Kremsmünster (Austria) 
Twist top vials, 0.65 ml/2 ml SorensonTM BioScience, Salt Lake City 
(USA) 
24-well plates CELLSTAR®, clear, steril Greiner Bio-One, Kremsmünster (Austria) 
96-well clear bottom well plates, black, 
steril, treated with TC 
Biozym Scientific GmbH, Hessisch Olden-
burg (Germany) 
96-well plate LUMITRAC 200 immunology 
plate  
Greiner Bio-One, Kremsmünster (Austria) 
3.1.4  General equipment 
ABIMED Pipettes, 10 µl/200 µl/1000 µl Kinesis GmbH, Langenfeld (Germany) 
Centrifuge 5804 R Eppendorf AG, Hamburg (Germany) 
Centrifuge Heraeus® Multifuge® 1 L-R Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Cryoplunge 3 System Gatan, Inc., München (Germany) 
Drying cabinet  Fa. BINDER GmbH, Tuttlingen         
(Germany) 
DSC 1 STARe System Mettler-Toledo GmbH, Gießen (Germany) 
Glass flat-head stopper, NS 14/23 DURAN Group GmbH, Mainz (Germany) 
Harvester 96 Tomtec, Inc., Hamden (USA) 
Incubator CB 210  Fa. BINDER GmbH, Tuttlingen         
(Germany) 
Laminar Flow Cabinet SKANAIR VFC 120 SKAN AG, Allschwil (Switzerland) 
LIEBHERR Comfort Freezer Liebherr-International Deutschland GmbH, 
Biberach an der Riß (Germany) 
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NanodropTM 2000 Spectrophotometer Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Nylon wool column Do-it-yourself construction, WG Prof. 
Grabbe/University hospital, Mainz      
(Germany) 
pH meter pH 538  LaboTec GmbH & Co. KG, Dillenburg-
Manderbach (Germany) 
Refrigerated Condensation Trap RT 400 Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Rotavapor R-3 with Vacuum Pump V-700 
and Vacuum Controller V-850 
BÜCHI Labortechnik GmbH, Essen 
(Germany) 
SAVANT Speed Vac SVC 200 Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Semi-Micro-Balance LE225D-OCE Sartorius AG, Göttingen (Germany) 
SpeedMixerTM DAC 150.1 CM Hauschild & Co KG, Hamm (Germany) 
Storage vial kit, 12 ml - 19 x 65/4 ml - 15 x 
45, amber  
Agilent Technologies, Santa Clara (USA) 
TECAN infinite F200 Tecan Group Ltd., Männedorf  
(Switzerland) 
Test tubes 16 x 100 mm, NSH 14/23 DURAN Group GmbH, Mainz (Germany) 
Transmission electron microscope FEI 
TECNAI T12 
Thermo Fisher Scientific GmbH, Dreieich 
(Germany) 
Ultrasound bath RK 510 Brandelin, Berlin (Germany) 
Vortexer RS-VF 10 Phoenix Instrument GmbH, Garbsen  
(Germany) 
Zetasizer Nano ZS Malvern Instruments GmbH, Herrenberg 
(Germany) 
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3.1.5  Data progression 
Excel 2013/2016 Microsoft Corporation, Redmond (USA) 
Fit2D ESRF, Grenoble (France) 
Origin 7.5 Additive GmbH, Friedrichsdorf           
(Germany) 
Zetasizer Software 7.11 Malvern Instruments GmbH, Herrenberg 
(Germany) 
3.2 Methods 
3.2.1  Nucleic acids 
mRNA 
The mRNA used in this work had a modified structure for an increased stability and was syn-
thesised and provided by BioNTech AG (Mainz, Germany) 151. For cell experiments, the en-
coding proteins were either luciferase or green fluorescent protein (GFP). For structural anal-
ysis, noncoding out of specification- (OOS) mRNA was used instead. The total length of the 
mRNA strand was about 2000 bases including the poly-A tail. The stretched length of the 
mRNA strand is approximately 560 nm while the coiled length is around 30 to 70 nm. 152–154 
OOS-mRNA needed to be highly concentrated. PierceTM Protein Concentrators with a molec-
ular weight cutoff of 100 K were filled with the mRNA and centrifuged with Centrifuge 5804 R 
at 3000 RMP maximum until the needed concentration was achieved. The final concentration 
was determined with the NanodropTM 2000 Spectrophotometer.  
Plasmid DNA 
Plasmid DNA in water was provided by the working group of Prof. Dr. Grabbe from the 
University hospital (Mainz, Germany). Two plasmids (pGL3 and 1699), differing in their mo-
lecular weights, were tested at the beginning (data not shown) and 1699 was used for further 
experiments due to its higher efficiency.  
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3.2.2  RNase-free working 
RNases, which is the abbreviation for ribonucleases, are enzymes which degrade RNA by 
cleaving the phosphodiester bonds between the nucleotides. These enzymes can be found 
ubiquitously in and on the human body and serve as a protective barrier against foreign RNA 
like from bacteria. Therefore, they are considered stable and just small amounts are sufficient 
to destroy mRNA. Although RNases are essential for the human body, they have to be 
eliminated for development and manufacturing of RNA-lipoplexes. Therefore, some arrange-
ments have to be taken. It is always necessary to wear gloves and change them after contact 
with skin or unclean surfaces. As necessary for all parenteral administrations, a bench with 
laminar air flow and aseptic techniques is needed to avoid contamination of samples. In addi-
tion, contact with RNases can be prevented. Chemicals, water and laboratory disposables like 
tips are available in an RNase-free condition. Glassware needs to be heated up to 300 °C for 
at least three hours. At least, all surfaces and plastic items which are not available RNase-free 
can be treated with RNaseZAP (Ambion®, Thermo Scientific™, Darmstadt, Germany) to be 
decontaminated.  
Same procedures have to be done while working with DNA. Although DNA is more stable, 
degradation via DNases can occur as well.  
3.2.3  mRNA integrity 
The integrity of mRNA in the formulations after preparation was tested with the commercially 
available RNA 6000 Nano Kit using the Agilent 2100 Bioanalyzer (Agilent, Santa Clara, USA) 
lab-on-chip system that is based on a capillary electrophoresis. This system is similar to gel 
electrophoresis but is more comfortable and less amount of sample is required.  
Samples were mixed with an equal amount of formamide buffer (23.8 M formamide, 
8.7 mM SDS, 18.0 mM EDTA) before testing. A 1 µl sample corresponding to a mRNA-con-
centration of 25 to 250 ng/µl was filled into the wells in an appropriate chip. An electrical field 
is applied and hence, the mRNA moves through the microchannels which are filled with a 
sieving polymer and a fluorescent dye. Electropherograms were obtained by reaction with a 
fluorescent dye and translated into gel-like images (bands).  
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3.2.4  Lipoplex preparation 
Lipids were dissolved in chloroform (or ethanol) and the stock solutions were stored in the 
freezer at - 25 °C. Lipoplexes were produced by two different methods, the lipid film method 
and the dual asymmetric centrifuge (DAC). 
Lipid film method 
For the preparation of the lipoplexes, the appropriate amount of lipids were pipettes into a 
glass tube to obtain a homogenous mixture of lipid. The organic solvent was removed via 
rotary evaporation with a Büchi® Rotavapor R-3 or via centrifugal evaporation with a Savant® 
Speed Vac SVC 200. Dried lipid films were stored in the freezer at - 25°C and were thawed 
before further usage.  
Lipid amounts for samples containing DOPC and DOTAP are calculated in mol% (Table 1) 
while lipid amounts for samples with EPC 80 % and DOTMA or DODMA are stated 
in mg/ml.  
Table 1: Exemplary calculation for liposomes containing 90 mol% DOPC with 10 mol% 
DOTAP with a total lipid concentration of 100 mg/ml 
- 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫: 𝟎𝟎.𝟗𝟗 𝒎𝒎𝒎𝒎𝒎𝒎 ∗ 𝟕𝟕𝟕𝟕𝟕𝟕.𝟏𝟏𝟏𝟏𝟏𝟏 𝒈𝒈
𝒎𝒎𝒎𝒎𝒎𝒎
= 𝟕𝟕𝟎𝟎𝟕𝟕.𝟓𝟓𝟎𝟎𝟓𝟓 𝒈𝒈 
 
- 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫: 𝟎𝟎.𝟏𝟏 𝒎𝒎𝒎𝒎𝒎𝒎 ∗ 𝟕𝟕𝟗𝟗𝟕𝟕.𝟓𝟓𝟓𝟓𝟓𝟓 𝒈𝒈
𝒎𝒎𝒎𝒎𝒎𝒎
= 𝟕𝟕𝟗𝟗.𝟕𝟕𝟓𝟓𝟓𝟓 𝒈𝒈 
 
- 𝟕𝟕𝟎𝟎𝟕𝟕.𝟓𝟓𝟎𝟎𝟓𝟓 𝒈𝒈 + 𝟕𝟕𝟗𝟗.𝟕𝟕𝟓𝟓𝟓𝟓 𝒈𝒈 = 𝟕𝟕𝟕𝟕𝟕𝟕.𝟏𝟏𝟓𝟓𝟕𝟕 𝒈𝒈 
 
- 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫: 𝟕𝟕𝟕𝟕𝟕𝟕.𝟏𝟏𝟓𝟓𝟕𝟕𝒈𝒈
𝟏𝟏𝟎𝟎𝟎𝟎𝒎𝒎𝒈𝒈
= 𝟕𝟕𝟎𝟎𝟕𝟕.𝟓𝟓𝟎𝟎𝟓𝟓𝒈𝒈
𝒙𝒙
   𝒙𝒙 = 𝟗𝟗𝟏𝟏.𝟎𝟎𝟏𝟏 𝒎𝒎𝒈𝒈 
 
- 𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫𝑫: 𝟕𝟕𝟕𝟕𝟕𝟕.𝟏𝟏𝟓𝟓𝟕𝟕𝒈𝒈
𝟏𝟏𝟎𝟎𝟎𝟎𝒎𝒎𝒈𝒈
= 𝟕𝟕𝟗𝟗.𝟕𝟕𝟓𝟓𝟓𝟓𝒈𝒈
𝒙𝒙
  - 𝒙𝒙 = 𝟕𝟕.𝟗𝟗𝟗𝟗 𝒎𝒎𝒈𝒈  
  
For the DOPC/DOTAP-lipoplexes, a 0.27 M trehalose 155 solution containing the mRNA was 
added to obtain a lipid concentration of 100 mg/ml. For the EPC/DOTMA or 
EPC/DODMA-lipoplexes, a buffer solution with 10 mM HEPES and 0.1 mM EDTA con-
taining the mRNA was added to obtain a lipid concentration of 100 mg/ml. The suspensions 
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were vortexed at RT for 10 sec and allowed to stand overnight or at least for 8 h also at RT 
for full hydration. If the lipid film was not completed hydrated afterwards, further vortexing 
was applied until the dispersion was homogenous.  
Dual Asymmetric Centrifuge  
For the preparation of the lipoplexes, the appropriate amount of lipids (calculated in mol%) 
was pipetted into a sterile Twist top vial. The organic solvent was removed via centrifugal 
evaporation with a Savant® Speed Vac SVC 200. A small amount of the buffer containing the 
mRNA or plasmid DNA was added together with an appropriate amount of SiLibeads Type 
ZY 0.8–1.0 mm for a better mixing. In a Dual Asymmetric Centrifuge SpeedMixerTM 
DAC 150.1 CM, vials were mixed for 10 min at 3000 RPM. The rest of the buffer was added 
and the content was mixed again at 3000 RPM for 10 min. If dilution of the sample was nec-
essary, the appropriate amount of buffer was added and the sample was mixed again at 
3000 RPM for 30 sec.  
 
Figure 7: Schematic illustration of a dual asymmetric centrifuge 
For calculation of the N/P ratio, the molar mass of the cationic lipid (e.g. DOTAP: 670 g/mol) 
was used for one cationic charge while the molar mass of one nucleotide (330 g/mol) was 
assumed for one negative charge. Consequently, the same amount (in mg) of DOTAP and 
mRNA lead to a N/P ratio of 2/1.  
The principle of the DAC is displayed in Fig. 7. The adapter with the vial containing the mix-
ture moves in two different directions. This movement lead to special forces which are re-
sponsible for the liposomal formation. 
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3.2.5  Dynamic light scattering 
Dynamic light scattering (DLS), also known as photon correlation spectroscopy (PCS), was 
used for determination of the size distribution profile of the lipoplexes. For measurement, the 
particles are dispersed in a fluid, so that the hydrodynamic diameter is determined with this 
method. The dispersed particles show the Brownian motion. Larger particles move more 
slowly, while smaller particles move faster (because they are pushed more easily by the water 
molecules). DLS measures the speed of this motion. When light hits a particle, it gets scattered 
in all directions. The scattered light of different particles interferes. Due to the Brownian mo-
tion, the distance between the particles always changes which lead to fluctuations in the scat-
tering intensity. If this change in fluctuation is observed over a time period, it can give infor-
mation over the velocity and therefore over the size of the particles. For calculation of the 
diameter, the Stokes-Einstein equation is used: 
𝑑𝑑𝐻𝐻 = 𝑘𝑘𝑘𝑘3𝜋𝜋𝜋𝜋𝜋𝜋 
Equation 1: Stokes-Einstein equation from the diffusion coefficient D used for the size calculation 
where dH is the hydrodynamic diameter, k is the Boltzmann constant, T is the absolute tem-
perature of the system, η is the viscosity of the solution and D is the translational diffusion 
coefficient. D defines the velocity of the Brownian motion and contains e.g. the temperature. 
In addition, the speed of the Brownian motion is dependent on the particle size, the viscosity 
and the temperature. For determination of the particle size, the viscosity and temperature have 
to be constant.  
With the Zetasizer Nano ZS®, the so-called non-invasive backscatter (NIBS) detection can be 
used. 156 The angle of detection is 173° instead of 90° which avoids multiple scattering and 
minimises the detection of scattering caused by bigger particles like dust. Furthermore, arte-
facts due to multiple scattering are prevented.   
For measurement of DOPC/DOTAP-lipoplexes, samples were diluted with a 0.27 M treha-
lose solution to a final lipid concentration of 0.1 mg/ml and measured at 25 °C with a Malvern 
Zetasizer Nano ZS®. 
For measurement of EPC/DOTMA or EPC/DODMA-lipoplexes, samples were diluted with 
a 5 mM solution of NaCl to a final lipid concentration of 0.1 mg/ml and measured at 25 °C 
with a Malvern Zetasizer Nano ZS®. 
Materials and methods 
50 
 
3.2.6  Zeta potential 
The electrostatic interactions of particles dispersed in a fluid and ions can be described by the 
zeta potential, which is illustrated in Fig. 8. A liquid layer around a charged particle occurs and 
can be divided into two parts. The inner layer is called the Stern layer and includes ions which 
are strongly bound to the surface of the particle. The outer diffuse layer includes ions which 
are just associated loosely. The particle appears to be neutral. While moving in the fluid, the 
Stern layer is moving together with the particle which results in the hydrodynamic diameter. 
Some ions from the diffuse layer are removed by friction which leads to a potential of the 
particle. This is named the zeta potential and means the potential on the surface of the hydrated 
particle, also called the slipping plane. 
 
Figure 8: Principle of zeta potential and surface layers 
Charged particles have the tendency to move in an electric field, which is called electrophoresis. 
This phenomenon is used to measure the zeta potential. An electric field is applied and the 
particles migrate to the oppositely charged electrode. The velocity increases with a higher 
charge. The electrophoretic mobility can be evaluated by using the Henry equation: 
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𝑈𝑈𝐸𝐸 = 2 𝜀𝜀 𝜁𝜁 𝑓𝑓(𝑘𝑘𝑎𝑎)3 𝜋𝜋  
Equation 2: Henry equation for calculation of electrophoretic mobility 
where UE is the electrophoretic mobility, ε the dielectric constant, η the viscosity of the solvent, 
𝜁𝜁 is the measured zeta potential and f(ka) the Henry’s function, which means the ratio of the 
radius of the particle to the thickness of the electrical double layer. F(ka) can be either 1.5 or 1.0. 
For measuring in polar solutions with moderate electrolyte concentrations, where particles are 
much larger than the double layer thickness, f(ka) is set to 1.5. This is called the Smoluchowski 
approximation. 1.0 is used in non-polar solutions, where particles are smaller than the double 
layer thickness. This is called the Hückel approximation.  
The zeta potential is a good indicator of the stability of a system in a biological environment. 
Particles may tend to aggregation. If the repulsive forces are stronger than the attractive forces, 
aggregation is prevented. Repulsive forces can be induced by increasing electrostatic repulsion 
between the particles. Stable dispersions typically have a zeta potential higher than + 30 mV 
or lower than - 30 mV. Nevertheless, other factors like the nature of the counter ions or the 
pH can also have an influence on the interactions between the particles.  
For measurement of DOPC/DOTAP-lipoplexes, samples were diluted with a 0.27 M treha-
lose solution to a final lipid concentration of 0.08 mg/ml and measured at 25 °C with a Malvern 
Zetasizer Nano ZS® using the Smoluchowski approximation. 
For measurement of EPC/DOTMA or EPC/DODMA-lipoplexes, samples were diluted with 
a 5 mM NaCl solution to a final lipid concentration of 0.125 mg/ml and measured at 25 °C 
with a Malvern Zetasizer Nano ZS® using the Smoluchowski approximation. 
3.2.7  Differential scanning calorimetry 
DSC is a thermal analysis technique to determine the heat capacity of a material (Fig. 9). As a 
function of time, the differences in the amount of heat to increase the temperature of a sample 
in comparison to a reference of equal mass is measured. Differences in the amount of heat 
result from either endothermic or exothermic processes such as melting, curing, glass transi-
tion or phase changes. Changes in the heat flow relate to changes in the heat capacity of a 
sample.  
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Figure 9: Active principle of differential scanning calorimetry 
A characteristic parameter for lipids is the phase transition temperature (Tm). At this point, 
lipids change from an ordered gel state, with fully extended and closely packed hydrocarbon 
chains, to the disordered liquid crystalline phase, where the hydrocarbon chains are fluid and 
orientated in a random manner (Fig. 10). For example, DOPC has a Tm around - 20 °C so that 
liposomal membranes which are mainly composed of DOPC are always in the liquid crystalline 
phase when handling at RT. Despite, the determination of the phase transition with DSC can 
be used for evaluation of the stability of model membranes like liposomes. The higher the Tm 
of a liposomal membrane is, the more energy is necessary to destabilise the system. The input 
of higher energy level characterises a more stable membrane system. DSC can also be used 
easily for comparison of various lipid compositions. Furthermore, the influence of added 
mRNA can be investigated. Due to changes in the structural arrangement of the lipid mem-
brane, an altered Tm is plausible. 157 
 
Figure 10: Lipid transition between solid and fluid phase at the phase transition temperature Tm 
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For determination of the phase transition temperature, 20 µl of each formulation was filled 
into an aluminium crucible (Mettler-Toledo, aluminium crucible standard, 40 µl, with pin and 
lid), hermetically sealed and measured together with a trehalose sample as a reference since all 
samples were measured in presence of trehalose. The samples were cooled to - 40 °C with 
liquid nitrogen and subsequently heated up to 20 °C. The cooling rate was 2 °C/min while the 
heating rate was set to 1 °C/min. Reaching - 40 °C the temperature was held constant for 
5 min. The temperature program was repeated once. 
3.2.8  RiboGreen Assay 
Determination of free mRNA 
The amount of mRNA which is encapsulated in the lipoplexes was determined by measure-
ment of the amount of mRNA which is not bound to the lipoplexes. This was carried out with 
the commercially available Quant-iT™ RiboGreen® RNA Assay. 145After dilution of the sam-
ples, fluorescent dye was added and fluorescence intensity was detected with TECAN infi-
nite F200. In total, samples were diluted 1:16000 with TE-buffer for measurement (1:8 before 
the RiboGreen® RNA Assay, 1:2000 while performing the assay) to a final mRNA concentra-
tion between 20 ng/µl and 1 µg/ml. The used wavelengths were 465 nm for excitation and 
535 nm for emission. Samples were measured in 96-well clear bottom plates from below and 
the gain was adjusted to 130 for comparison of different measurements. The amount of free 
mRNA was subtracted from the total amount of mRNA to obtain the encapsulated or bound 
amount of mRNA. 
Release of mRNA from lipoplexes 
For measuring the release of mRNA after mimicking cellular contact, Quant-iT™ RiboGreen® 
RNA Assay was used again. To mimic the cellular contact, samples were mixed 1:4 with a 
buffer of pH 7.5 or 5 and an appropriate amount of heparin or liposomes composed of DOPG 
(5-fold excess of negative to positive charge). Samples were treated as described above and the 
amount of free mRNA was determined at several time points (5, 10, 20, 40, 60 min) after 
mixing. For each time point, a fresh aliquot was used.  
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3.2.9  Cryo-Transmission electron microscopy 
The tested lipoplex was composed of 95 mol% DOPC, 5 mol% DOTAP and 10 mol% mRNA 
(with regard to the total lipid concentration) in 0.27 M trehalose and prepared with the lipid 
film method as described above with a lipid concentration of 10 mg/ml.  
First, the carbon coatings of the copper grid Quantifoil R1.2/R1.3 were treated with a plasma 
cleaner to become hydrophilic. Under controlled humidity, 50 µl of the diluted sample with a 
0.5 mg/ml lipid concentration were transferred to the copper grids. For sample preparation, a 
modified version of the Cryoplunge Gatan CP3 was used. Excess sample were blotted by a 
filter paper for 1 sec. The copper grid with the sample dropped into liquid ethane for rapid 
cooling and was then transferred into liquid nitrogen. By constant cooling, the sample was 
transferred and measured in the transmission electron microscope TECNAI 12 in the Institute 
of Zoology at the Johannes Gutenberg-University Mainz.  
3.2.10 Transfection efficiency 
Transfection efficiency of mRNA lipoplexes 
C2C12 myoblast cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10 % fetal bovine serum (not inactivated) at 37 °C in an atmosphere with 5 % 
CO2. Cells were seeded in 96-well plates with a density of 5×103 cells per well for both lucif-
erase and XTT assay. After 24 h, the cells were washed with phosphate-buffered saline (PBS) 
and the appropriate amount of diluted lipoplexes containing 1 μg of luciferase-encoded mRNA 
in Opti-MemTM medium was added to each well. Cells were incubated for 6 h and the culture 
media was replaced with fresh culture medium afterwards. The culture media were removed 
after 24 h and cells were washed with 0.5 ml of PBS. 0.05 ml of PBS and reporter lysis buffer 
were then added to each well to lyse the cells. Additionally, the viability (which means the 24 h 
survival of the cells) was tested with XTT Cell Proliferation Kit II. Readout was done after 2 
h. All measurements were performed with a TECAN infinite P200 PRO. The wavelengths for 
measurement were set to 450 and 630 nm. Untreated cells were used as positive control, so 
that viability was calculated using the following equation:  
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝐶𝐶𝑣𝑣𝑣𝑣𝑣𝑣 = (𝑣𝑣𝑡𝑡𝐶𝐶𝑣𝑣𝑣𝑣𝐶𝐶𝑑𝑑 𝑐𝑐𝐶𝐶𝐶𝐶𝐶𝐶𝑐𝑐 − 𝑣𝑣𝐶𝐶𝑣𝑣𝑏𝑏𝑘𝑘)(𝑢𝑢𝑏𝑏𝑣𝑣𝑡𝑡𝐶𝐶𝑣𝑣𝑣𝑣𝐶𝐶𝑑𝑑 𝑐𝑐𝐶𝐶𝐶𝐶𝐶𝐶𝑐𝑐 − 𝑣𝑣𝐶𝐶𝑣𝑣𝑏𝑏𝑘𝑘) ∗ 100% 
Equation 3: Calculation of cell viability 
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Transfection efficiency of DNA-lipoplexes 
HEKs or DC2.4 were harvested with PBS supplemented with 2 mM EDTA when they have 
been 80 % confluent. Cells were washed with medium, centrifuged (8 min at RT with 300 g) 
and resuspended in 5 ml culture medium. Cells were counted and seeded at a density of 
2x105 cells/ml 24 h before the transfection (500 µl in 24-well plates correspond to 105). The 
following day, the serum-containing medium was removed, cells were washed twice with 
200 µl PBS and transferred to 500 µl serum-free transfection medium (EMEM). The lipo-
somes/lipoplexes were diluted 1:20 with serum-free transfection medium and the appropriate 
amount of lipoplex containing 1 µg DNA was added to each well. All samples were done in 
triplicates. Same DNA transfected with jetPEI® (commercially available transfection reagent 
composed of a linear polyethylenimine derivate) was used as positive control. The cells and 
cells transfected with DNA without transfection reagent were used as negative control. The 
serum-free medium was removed after 6 h of transfection and replaced with 1 ml of culture 
medium. Incubation was done for 48 h at 37 °C (under 5 % CO2 for HEK cells, under 10 % 
CO2 for DC2.4). After incubation, the medium was removed completely, and the cells were 
lysed with 100 µl of passive lysis buffer (Promega, Mannheim) for 10 to 15 min at RT. Lysates 
were stored at - 20 °C until measurement. For measurement, 20 µl of the lysate were trans-
ferred to a 96-well LUMITRAC plate and measured at the microtiter plate luminometer. The 
advice ads 100 µl of Firefly substrate to each sample and measures the luminescence for 10 sec 
after a delay of 3 sec. The Firefly substrate contains the protein luciferin, ATP and magnesium 
and can produce a greenish yellow light (550 to 570 nm) in the presence of oxygen.  
The medium for DC2.4 cells is composed of Iscove’s Modified Dulbecco’s Medium (IMDM) 
with 5 % of fetal calf serum (FCS), 2 mM of glutamine, 100 U/ml Penicillin, 100 µg/ml Strep-
tomycin and 50 µM ß-Mercaptoethanol. 
The medium for HEK cells is composed of Dulbecco’s Modified Eagle Medium (DMEM) 
with 10 % of FCS, 100 U/ml Penicillin and 100 µg/ml Streptomycin. 
DC-TC-Coculture with transfected DC2.4 with DNA-lipoplexes 
DC2.4 cells were harvested, washed and counted. 24 h before the transfection, cells were 
seeded in a 96-well flat bottom plate at a cell density of 5x105 cells/ml (100 µl/well). At the 
transfection day, the serum-containing medium was removed, cells were washed with PBS 
twice and 100 µl of serum-free transfection medium was added. Autoproliferation of DC2.4 
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was inhibited by addition of 0.5 mg/ml puromycine 45 min prior to transfection. After exces-
sive washing of the cells, liposomes/lipoplexes were diluted 1 to 10 with serum-free medium. 
Triplicates were done for 100 ng, 200 ng, 300 ng and 400 ng DNA/well and transfected for 
48 h. 
Following samples were transfected: 
1. Liposome/Lipoplex (pCMV_sOVA) 
2. Liposome/Lipoplex (pEF_IKK2_wt) 
3. Liposome/Lipoplex (pCMV_sOVA + pEF_IKK2_wt) 
4. Liposome/Lipoplex (pCMV_sOVA) + LPS 
5. OVA-Protein + Liposome/Lipoplex (pEF_IKK2_wt) 
6. Liposome/Lipoplex (Control plasmid) 
7. Liposome/Lipoplex (Control plasmid) + LPS 
For sample 5, DC2.4 cells were first loaded with soluble ovalbumin (OVA)-protein and trans-
fected the following day. Lipopolysaccharide (LPS) was added after 48 h of incubation and 
was left there for 16 h. Cells, cells with LPS, cells with OVA, cells with OVA and LPS and T-
cells were used as controls. 6 h after transfection, the transfection medium was replaced by 
culture medium.  
T-cells were isolated out of spleens of OT-I and OT-II mice by using a nylon wool column. 
Spleens were taken out, ground, the erythrocytes were lysed, and the cells were given on to an 
equilibrated nylon wool column. After incubation at 37 °C for 45 min, the bigger spleen cells 
adhered while the smaller T-cells could be eluted (drop speed: 1 drop/sec). T-cells were col-
lected, washed, counted and adjusted to 5x105 cells/ml. 100 µl of OT-I or OT-II T-cells were 
added to each well of DC2.4. After incubation or 72 h, the plates were pulsed radioactively to 
relate to the proliferation of the T-cells. 0.75 µCi 3H-marked thymidine (corresponds to 
27750 Bq) was added to each well and the plates were incubated for 18 h. Afterwards, the 
plates were harvested and measured in the ß-counter.  
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3.2.11 Small-angle scattering 
Small-angle scattering is a scattering technique where the coherent and elastic scattering of 
collimated radiation after interaction with sample structures is detected at very low an-
gles (0.01 to 30 Å). The applied wavelengths are much smaller than the detectable structures. 
With these techniques, information on size, shape and orientation of particles and even their 
inner structures can be obtained.  
 
Figure 11: Principal experiment setup of SAS 
SAS can be divided into SAXS using X-ray and SANS using neutrons. For both, radiation 
needs to be parallel (collimated) and the used slit defines the shape of the beam (e.g. square or 
circle). Furthermore, the measured size range can be adjusted by wavelength and distance (a) 
between the sample and the detector. The principle setup for both methods is comparable as 
shown in Fig. 11. The difference in the scattering of a macromolecular specimen to a solvent 
of low molecular mass is estimated. As a result, the particle scattering (SLD) correspond to the 
excess scattering length density with respect to the solvent. With SAXS, an equivalent tech-
nique exists in the anomalous scattering (ASXAS), but it depends on heavy elements so that it 
is not applicable for the mRNA-lipoplexes in this thesis. 158 
The SLD is an often-used parameter to describe the strength of the interaction between the 
neutron and the nucleus (SANS) or the X-ray and the atomic shell (SAXS). SAXS interacts 
with electrons in the atomic shells, thus the scattering power (cross section) of atoms for X-
ray photons increase with the atom number z. For neutrons (SANS), the cross section is dif-
ferent for each isotope. In contrast to X-ray photons, neutrons of SANS interact with the 
atomic nucleus in an isotope dependent way. Thus, scattering depends on the isotope and 
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magnetic fields as well. For SAXS experiments, the SLD consequently correlates with the num-
ber of electrons and thereby also with the atomic number z. In case of SANS, the SLD corre-
lates with the proton concentration. Comparing the intensity of both SAS methods, the prob-
ability for scattering is around 1000 times higher for neutrons by contrast with X-rays. How-
ever, the intensity for SANS measurements is lower because high flux reactor as a radiation 
source are much weaker compared to synchrotrons.  
By nuclear interaction phase, hydrogen has a negative SLD, while deuterium (a hydrogen iso-
tope with one neutron more in the core) has a strongly positive one. Consequently, the neutron 
scattering of one system can be varied by hydrogen-deuterium contrast variation, so that dif-
ferent structural parts can be investigated. Each material has a characteristic neutron SLD and 
since H2O and D2O represent the outer limits of the range of SLDs, every possible SLD of a 
bio-system can be mimicked by a mixture of H2O/D2O. As illustrated further down (Fig. 13), 
the point of mimicking a systems SLD so that it gets invisible for detection is called the contrast 
matching point. 159  
Lipoplexes are considered to be (partially) ordered and centre-symmetric. Such systems show 
characteristic Bragg peaks caused by Bragg diffraction. 160 Two beams with identical wave-
length and phase are scattered off two different atoms with distance d. This so-called construc-
tive interference occurs when the path difference is equal to an integer multiple of the radiation 
wavelength.  
Using the Bragg peaks, d-spacing can be calculated as another indicative parameter with the 
following equations:   
𝑑𝑑 = 𝑏𝑏 2 𝜋𝜋
𝑞𝑞max (𝑛𝑛) 
Equation 4: Calculation of d-spacing  
𝑞𝑞 = 4 𝜋𝜋
𝜆𝜆
∗ sin𝜃𝜃 
Equation 5: Calculation of the scattering vector (momentum transfer) 
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with q as the momentum transfer, the reflex order n and the peak position qmax of the Bragg 
peak, the wavelength λ and the angle θ. 
The scattering vector describes the difference in the incident wave k0 and the expiring 
wave kS and characterise the momentum transfer from the particle to the wave (Fig. 12).  
 
Figure 12: Scattering vector q 
For evaluation of the exact peak position and for further analysis of the scattering curves, the 
Lorentz function can be applied and gives information about peak area and the peak width at 
half-height (FWHM): 
𝑣𝑣 = 𝑣𝑣0 + 2 𝐴𝐴𝜋𝜋 ѡ4 (𝑥𝑥 − 𝑥𝑥𝑐𝑐)2 + ѡ2 
Equation 6: Lorentz function for peak analysis 
with y0 as the offset, xc as the peak centre, ѡ as the FWHM and A as the peak area.  
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Small-angle X-ray scattering 
The SAXS experiments were carried out at different facilities (Table 2).  
Table 2: Overview of the performed SAXS experiments 
Facility 
[Beamline] 
ESRF Grenoble [ID02], France / Synchrotron 
Set up Source: U21.4 and U35 undulator 
Monochromator: cryogenic (liquid nitrogen) cooled Si-111 channel-
cut, focusing toroidal mirror 
Detector: Rayonix MX-170HS 
Beam size (vert. x hor.): 200 µm x 400 µm 
Divergence (vert. x hor.):  20 µrad x 40 µrad 
Wavelength range: 0.1 nm (0.073 nm – 0.16 nm) 
Energy range: 12.4 keV 
Energy resolution: 1/100 ∆λ/λ 
Flux at sample position: 1014 photons/sec/100 mA 
Conditions Samples: EPC 80 % with DOTMA or DODMA and mRNA 
Buffers: phosphate buffer with two different pH values (7.5/5) and 
hepes 
Concentration for measurement (lipid): 25 mg/ml  
q-range: 0.005916 – 0.645377 Å-1 
Temperature: RT 
Performed 
experiments 
Structural investigation of mRNA-lipoplexes in dependence of the pH 
Data       
analysis 
1. Raw data conversion with the instrument software 
2. Data analysis with Origin 7.5 (Plotting of pure scattering curve + Lo-
rentz fit for peak properties)  
Facility 
[Beamline] 
BESSY II (HZB) Berlin [mySpot], Germany / Synchrotron 161 
Set up Source: 7T-WLS-1 (Wavelength Shifter) 
Monochromator: Multiple Crystal (Si 111, Si 311) and Multilayer mir-
ror (B4C/Mo, 2nm period)  
Flux: 1e12-1e13 
Detector: Mar X-ray CCD  
Energy range: 4 – 30 keV 
Energy resolution: 1/8000 – 1/500 ∆λ/λ 
Polarisation: horizontal 
Divergence horizontal/vertical: 1 mrad 
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Focus size (hor. x vert.): 400 x 400, 400 x 50 µm 
Conditions Samples: EPC 80 % with DOTMA or DODMA and mRNA 
Buffer: phosphate buffer with eight different pH values 
(8.0/7.5/7.0/6.5/6.0/5.5/5.0/4.5) 
Concentration for measurement (lipid): 25 mg/ml 
q-range: 0.000185 – 1.136304 Å-1 
Temperature: RT 
Performed 
experiments 
Structural investigation of mRNA-lipoplexes in dependency of the pH 
Data        
analysis 
1. Raw data conversion with Fit 2 D 
2. Data analysis with Origin 7.5 (Plotting of pure scattering curve + Lo-
rentz fit for peak properties) 
Facility 
[Beamline] 
EMBL (DESY) Hamburg [P12], German / Synchrotron 162 
Set up Source: Petra U29 undulator 
Monochromator: Double crystal Si (111) 
Energy range: 10 keV (4 – 20 keV) 
Wavelength range: 0.6 – 3 Å  
Flux: 5 x 1012 ph/s 
Beam size at sample: 0.2 x 0.3 mm2 (FWHM) 
Slits: Individually motorised blades of Hybrid Scatterless in a module 
from Xenocs 
Focal spot: 0.2 x 1.2 mm 
Detector: Pilatus 2M pixel detector (253 x 288 mm2) 
Sample - detector distance: 1.6 – 6.1 m 
Particle size range: 1000 Å – 8 Å 
Energy resolution: 1/1000 ∆λ/λ 
Sample changer: EMBL/ESRF new generation 
Conditions Samples: DOPC with DOTMA or DODMA and mRNA / DOPC 
with DOTAP and mRNA 
Buffer: phosphate buffer with eight different pH values 
(8.0/7.5/7.0/6.5/6.0/5.5/5.0/4.5) / trehalose solution 
Concentration for measurement (lipid): 12.5 or 25 mg/ml 
q-range: 0.002732 – 0.507534 Å-1 
Temperature: RT 
Sample - detector distance: 3.0 m 
Performed 
experiments 
Structural investigation of mRNA-lipoplexes in dependency of the pH 
Preliminary experiments for LNLS (data not shown) 
Data       
analysis 
1. Raw data conversion with the instrument software 
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2. Data analysis with Origin 7.5 (Plotting of pure scattering curve + Lo-
rentz fit for peak properties) 
Facility 
[Beamline] 
LNLS (CNPEM) Campinas [SAXS1], Brazil / Synchrotron  
Set up Source: Bending Magnet D01 exit B (15°) 
Monochromator: W/B4C Multilayer (500 double layers) on Si sub-
strate 
Detector: Pilatus 300K 
Energy range: 8 keV 
Energy resolution: 1/10 ∆λ/λ 
Beam size at sample: 1.5 mm2 x 1 FWHM 
Flux density at sample: 1010 – 1012 (ph/s)/mm2 
Particle size range: 1 – 100 nm 
Conditions Samples: EPC 80 % with DOTMA or DODMA and mRNA / DOPC 
with DOTAP and mRNA 
Buffer: phosphate buffer with two different pH values (7.5/5) with 
heparin/ D2O and H2O with trehalose  
Concentration for measurement (lipid): 12.5 mg/ml 
q-range: 0.012978 – 0.470028 Å-1 
Temperature: RT 
Performed 
experiments 
Time-dependent structural changes of lipoplexes by mimicking cell con-
tact  
Comparison of structure after mixing with D2O and H2O and different 
trehalose concentration 
Data       
analysis 
1. Raw data conversion with the instrument software 
2. Data analysis with Origin 7.5 (Plotting of pure scattering curve + Lo-
rentz fit for peak properties) 
 
A wide range of pH was measured within these experiments. To ensure that the salt composi-
tion was always nearly the same, Sörensen phosphate buffer was used. With different ratios 
between two salts, buffers with a pH range of 4.9 to 8.0 can be prepared.  
First, solution A was prepared with potassium dihydrogen phosphate (9.078 g/1000 ml) and 
solution B with disodium hydrogen phosphate-dihydrate (11.876 g/1000 ml) in RNase-free 
water. To achieve the appropriate pH, the number of ml in Table 3 is taken from solution B 
and filled up to 100 ml with solution A.  
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Table 3: Preparation of Sörenson phosphate buffer (required amounts of solution B for 
100 ml) 
pH .0 .1 .2 .3 .4 .5 .6 .7 .8 .9 
4          0.60 
5 0.95 1.35 1.80 2.30 3.00 3.90 4.90 6.20 7.90 9.80 
6 12.1 15.0 18.4 22.1 26.4 31.3 37.2 43.0 49.2 55.2 
7 61.2 67.0 72.6 77.7 81.8 85.2 88.5 91.2 93.6 95.3 
8 96.9          
 
For pH 4.5, a buffer with just potassium dihydrogen phosphate (6.8 g/1000 ml) was utilised.  
The experiments at the ESRF and BESSY synchrotron sources were performed to investigate 
the structural differences between lipoplexes with a cationic (DOTMA) and ionizable 
(DODMA) lipid at different pH. Lipoplexes composed of EPC 80 % and different propor-
tions of DOTMA or DODMA and mRNA were prepared with the lipid film method as de-
scribed above. For these measurements, lipoplexes were diluted 1 to 4 with buffer to a final 
lipid concentration of 25 mg/ml and measured afterwards (no accurate time). One of the buff-
ers was used to subtract the background although in some cases, background was not sub-
tracted with 100 %.  
The experiments at the EMBL synchrotron source were carried out to repeat the experiments 
performed at BESSY with DOPC instead of EPC 80 %. Lipoplexes composed of DOPC and 
different proportions of DODMA with and without mRNA were prepared with the lipid film 
method as described above. As reference, one formulation with DOTMA was used. For these 
measurements, lipoplexes were diluted 1 to 8 with buffer to a final lipid concentration of 
12.5 mg/ml and measured afterwards (no accurate time). For all samples, the appropriate buff-
ers were measured to subtract the background although in some cases, background was not 
subtracted with 100 %. 
The experiments at the LNLS synchrotron source were performed to investigate time depend-
ence of the structural changes between lipoplexes with a cationic (DOTMA) or ionizable 
(DODMA) lipid at different pH after mimicking cell contact. Lipoplexes composed of 
EPC 80 % and different proportions of DOTMA or DODMA and mRNA were prepared 
with the lipid film method as described above. Samples were diluted with a mixture of buffer 
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and an appropriate amount of heparin to a final lipid concentration of 12.67 mg/ml and meas-
ured immediately after mixing and 2.5, 5, 10, 20 min and for some samples also at 40 min. For 
each sample and time point, a separate solution was prepared. (Preliminary experiments with 
the same lipoplexes were performed at the EMBL synchrotron source. Due to a sample holder 
instead of a flow-through cell as used for all other measurements, each sample was measured 
at different time points after mixing. Data is not evaluable and hence, not shown here.) In 
addition to SANS experiments at FRM II facility, two DOPC/DOTAP-lipoplexes with low 
and high amount of mRNA were measured to investigate the effect of dilution with high con-
centrated trehalose solutions on the membrane spacing. Lipoplexes were prepared with lipid 
film method as described above. Both samples were diluted with H2O and D2O containing a 
low and a high concentration of trehalose. For all samples, the appropriate buffers were meas-
ured to subtract the background although in some cases, background was not subtracted with 
100 %. 
Small-angle neutron scattering 
As named above, the scattering effect which is dependent on the isotope is used for this meas-
urement technique. Hydrogen has a negative SLD, while deuterium has a strongly positive one. 
The scattering of one system can be varied by contrast variation, so that different structural 
parts can be investigated. 163 Each material has a characteristic neutron SLD and since H2O 
and D2O represent both outer limits of the range of SLDs. Every possible SLD can be mim-
icked by a mixture of H2O/D2O as solvent. The point of mimicking a systems SLD so that it 
gets invisible for detection is called the matching point. The principle of contrast variation is 
illustrated in Fig. 13, together with neutron SLDs for typical macromolecules. The SLD for 
RNA, proteins and water changes due to exchangeable protons of the molecules 159. Another 
way of varying the SLD is the deuteration of the sample e.g. by using deuterated lipids. This 
method was not used within this thesis. Since the lipoplexes were prepared with a very high 
concentration, the required amount of lipid would be very high.  
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Figure 13: Principle of contrast variation [left] and average SLD for typical macromolecules (taken 
from 159) [right] 
The Guinier plot gives information on the gyration radius and is suitable for analysis of SAXS 
and SANS data. When evaluating SANS data, the Kratky-Porod plot can be used to determine 
the membrane span. This plot is not commonly used for SAXS since the contrast of liposomes 
in H2O is really low for X-rays.  
 
ln (𝐼𝐼(𝑔𝑔) = ln(𝐼𝐼0) − 𝑅𝑅 𝑔𝑔23 ∗  𝑞𝑞2  ln�𝐼𝐼𝑑𝑑(𝑞𝑞)� = ln(𝐼𝐼𝑑𝑑0) − 𝑅𝑅𝑑𝑑2 ∗ 𝑞𝑞2 
Equation 7: Logarithmic plot for Guinier [left] and Kratky-Porod [right] function 
𝑑𝑑 = 𝑅𝑅𝑑𝑑 ∗  √12 
Equation 8: Membrane thickness 
with Rd as the thickness radius obtained from the logarithmic evaluation of the thickness pro-
file Id(q) which is determined from the middle part of the scattering profile I(q) which is mul-
tiplicated by the thickness factor q2. 164  
The SANS experiments were carried out at two different facilities (Table 4).  
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Table 4: Overview of the performed SANS experiments 
Facility 
[Beamline] 
FRM II (JCNS) Garching [KWS-2], Germany / High flux reactor 
Set up Neutron flux: 2.5 x 107 N/(cm2 sec) 
Beam cross section: 8 x 10 mm 
Wavelength range: 0.4533 nm (0.4 – 1.5 nm) 
Detector: 6Li (60 x 60 cm2) 
Detector distance: 2, 4, 8, 14 and 20 m  
Energy range: 10 or 20 % (∆λ/λ) 
Conditions Samples: DOPC with DOTAP and mRNA 
Buffer: mixture of H2O- and D2O-buffers for eight different D2O con-
tents (0, 11.11, 16.16, 22.22, 33.33, 44.44, 55.56, 66.67, 77.78 %) con-
taining 1.31 M trehalose  
Concentration for measurement (lipid): 10 mg/ml  
q-range: 0.00309 – 0.47395 Å-1 
Temperature: RT 
Detector distance: 2, 8 and 20 m  
Performed 
experiments 
Detailed structural investigation of mRNA-lipoplexes for proof of 
structural model  
Data       
analysis 
1. Raw data conversion with the instrument software 
2. Data analysis with Origin 7.5 (e.g. Guinier plot) 
Facility 
[Beamline] 
NIST Delaware [nSoft], USA / Medium flux reactor  
Set up Source: Neutron Guide (NG-B) 
Beam cross section: 60 x 60 mm 
Monochromator: Mechanical velocity selector with variable speed and 
pitch 
Particle size range: 1 – 200 nm 
Wavelength range: 4 – 20 Å 
Detector: 3He position-sensitive proportional counter (640 x 640 mm) 
with a 5.08 x 5.08 mm resolution 
Source – sample distance: 1 – 3 m 
Sample – detector distance: 1.3 – 5.2 m  
Energy resolution: 9 – 30 % (∆λ/λ) (FWHM) 
Conditions Samples: DOPC with DOTAP and mRNA, pure DOPC 
Buffer: mixture of H2O- and D2O-buffers for three different D2O con-
tents (77.78, 85, 90 %) containing 0.27 or 1.31 M trehalose  
Concentration for measurement (lipid): 10 mg/ml or 100 mg/ml 
  Materials and methods 
 
67 
 
q-range: 0.006 – 0.5 Å-1 
Temperature: RT 
Detector distance: 10 m 
Performed 
experiments 
Detailed structural investigation of mRNA-lipoplexes and the osmotic 
effect of Trehalose 
Data       
analysis 
1. Raw data conversion with the instrument software 
2. Data analysis performed by the instrument’s scientists   
 
SANS experiments at the FRM II facility were carried out to get a further insight into the 
molecular structure of the DOPC/DOTAP-lipoplexes. The KWS-2 instrument of the 
Jülich centre of neutron scattering (JCNS) at the FRM II high flux reactor of the Maier-Leib-
nitz research centre (MLZ) at Garching was used. Lipoplexes were prepared with lipid film 
method as described above and were composed of DOPC and DOTAP and two different 
proportions of mRNA. Previous experiments (data not shown) pointed out, that dilution in 
the cuvettes with 0.27 M trehalose solution led to strong aggregation and sedimentation so 
that measurements could not be performed. Therefore, samples were diluted with 1.31 M tre-
halose solution to a final lipid concentration of 10 mg/ml. Buffers for contrast variation were 
composed of either H2O or D2O containing 20 m/g glucose, 2.38 mg/g HEPES and 
9 mg/g NaCl and different proportions of D2O (0, 11.11, 16.16, 22.22, 33.33, 44.44, 55.56, 
66.67 and 77.78 %). For 0 to 22.22 % of D2O, cuvettes with a thickness of 1 mm and a sample 
volume of 200 µl and for all others 2 mm cuvettes with a volume of 400 µl were used. Meas-
urements were carried out at three different sample-detector distances, whereas measurement 
time needed to be adjusted to the distance (Table 5). For each sample, the appropriate buffers 
were measured under similar conditions to subtract the background. Transmission of samples 
was measured in addition and used to calculate the real D2O content. The content of D2O (%) 
differed from the calculated content because of the high proportion of trehalose which 
changed the number of hydrogen atoms as well as the density of the buffer. 
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Table 5: Measurement schedule of experiments performed at FRM II – KWS-2 (in min/sam-
ple) showing the measured time in min  
 Sample 
D2O [%] 
20 m 
Sample 
20 m 
Buffer 
8 m 
Sample 
8 m 
Buffer 
2 m 
Sample 
2 m 
Buffer 
Trans-
mission 
0 30 50 20 30 10 10 1 
11.11 50 50 20 30 10 10 1 
16.16 50 50 20 30 10 10 1 
22.22 50 50 20 20 10 10 1 
33.33 - - 20 30 10 10 1 
44.44 - - 10 15 5 5 1 
55.56 30 30 10 15 5 5 1 
66.67 20 20 10 15 5 5 1 
77.78 20 20 10 15 5 5 1 
 
Experiments at the NIST facility were carried out to extend the data from the experiments at 
FRM II and to investigate the osmotic effect of high concentrations of trehalose on the lipid 
membrane. Samples were shipped to Delaware by flight. Lipoplexes were prepared with lipid 
film method as described earlier and composed of DOPC with two different amounts of 
DOTAP and the same amount of mRNA. Further on, pure DOPC was used as a reference 
system. All three samples were measured pure with the final concentration of 100 mg/ml and 
diluted to 10 mg/ml with different buffers. Buffers were composed as buffers used at FRM II, 
but with higher proportions of D2O (77.77 %, 85 %, 90 %) and either 0.27 M or 1.31 M 
trehalose. All buffers were measured to subtract the background. 
3.2.12 Determination of pKa 
For further characterisation of ionizable lipids, TNS assay is applied to determine the apparent 
pKa of each formulation. With this assay, the pKa can be measured in situ while the lipid is 
incorporated into the lipid membrane of the formulation. Therefore, influences on the amine 
group by neighbouring lipids or the membrane itself are considered. The negatively charged 
fluorescent dye is only attracted to the ionizable lipid when the ionizable lipid is charged. With 
a subsequent adsorption to the membrane, the TNS gets more lipophilic which leads to a 
removal of the water molecules that otherwise quench the fluorescence 147. By lowering the 
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pH, the positive charge increases and so does the fluorescence. A 100 % fluorescence is as-
sumed when the ionizable lipids are completely ionised. Nevertheless, the TNS concentration 
used in the assay is much lower in comparison with the amount of the ionizable lipid. Hence, 
it is assumed that a small fraction of ionised lipid is enough for the determination 149. By using 
curve-fit analysis (Boltzmann equation), the apparent pka can be determined at the point, where 
50 % of the lipid is charged.  
Lipoplexes composed of EPC 80 % or DOPC and DOTMA or DODMA were prepared with 
the lipid film method as described earlier. Same compositions were tested with or without 
mRNA. Pure lipids were measured as a reference. Different buffers were used to obtain a pH 
range from 3 to 10 (10 mM citrate: 3, 4, 5, 6; 10 mM phosphate: 6, 7, 8; 10 mM borate: 9, 10). 
For some of the experiments, buffers contained 150 mM NaCl. 90 µl of each buffer and 2 µl 
of a 300 µM stock solution of TNS in DMSO were added to a 96-well plate. Lipoplexes were 
diluted with water to a final concentration of 22 µM (either total lipid or cationic lipid concen-
tration) and 10 µl of this dilution was added as well. The fluorescence was measured using the 
TECAN infinite F200 with 360 nm as excitation wavelength and 430 nm as wavelength for 
emission. The signal was normalised to either pH 3 or 4 and plotted against the pH. 
The experiments were carried out under different conditions as explained in chapter 4.2.2.  
3.2.13 Overview of tested formulations 
In Tables 6 to 13, all tested samples with the implemented experiments are listed. 
Table 6: Tested systems with EPC 80 % as matrix lipid and different proportions (mol%) of 
DOTAP and mRNA with the resulting N/P ratios (+/-) (taken from 150) 
    mRNA 0 5 10 
DOTAP 
0 0 * 0 * 0 * 
5 0 * 1/1 * 1/2 * 
10 0 * 2/1 * 1/1 * 
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Table 7: Tested systems with DOPC as matrix lipid and different proportions (mol%) of 
DOTAP and mRNA with the resulting N/P ratios (+/-) (taken from 150) 
   mRNA 0 2.5 5 10 20 
DOTAP 
0 0 * # $ 0 * 0 * # 0 * 0 *       ° 
1 0 #   1/5 #     
2 0 #   1/2.5 #     
2.5 0 * 1/1 * 1/2 * # 1/4 * 1/8 * + x 
3 0 #   1/1.67 #     
4 0 #   1/1.25 #     
5 0 * # 2/1 * § / 1/1 * # $ 1/2 * § &/  1/4 * + x 
7.5         1/3 + x 
10 0 * # 4/1 * 2/1 * # $ 1/1 * 1/2 * + x ° 
11.4         1/1.75 + x 
13         1/1.5 + x 
15         1/1.33 + x 
16         1/1.25 + x 
17.4         1/1.12 + x 
20         1/1 + x ° 
25         1.25/1 + x 
30         1.5/1 + x ° 
35         1.75/1 + x 
40         2/1 + x ° 
45         2.25/1 + x 
50         2.5/1 + x ° 
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Table 8: Implemented measurements for samples listed in Tables 5 and 6 
+ Zeta potential 
x Free mRNA 
# DSC 
° Transfection efficiency  
* SAXS – Mainz University 
/ SAXS – EMBL (Hamburg) 
& SAXS – LNLS (Campinas) 
§ SANS – FRM II (Garching) 
$ SANS – NIST (Delaware) 
 
Table 9: Tested systems with EPC 80 % as matrix lipid and different proportions (mg/ml) of 
DOTMA or DODMA and mRNA with the resulting N/P ratios (+/-) 
  mRNA 0 2.5 5 10 
cat. lipid 
DOTMA 
0 0 *   0 * 0 * 
2.5 0 °   1/4 & °   
5 0 * °   1/2 * & ° 1/4 * 
10 0 * 2/1 & x 1/1 * +&° 1/2 * 
20 0 °   2/1 °   
50 0 °       
DODMA 
0 0 * °   0 *  0 * 
2.5 0 °   1/4 & °   
5 0 * °   1/2 * & ° 1/4 * + 
10 0 * ° 2/1 & x 1/1 * +&° 1/2 * + 
20 0 °   2/1 °   
50 0 °   5/1 °   
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Table 10: Tested systems with DOPC as matrix lipid and different proportions (mg/ml) of 
DOTMA or DODMA and mRNA with the resulting N/P ratios (+/-) 
  mRNA  0 2.5 5 10 
cat. lipid 
DOTMA 
10     1/1 / °   
DODMA 
10     1/1 / °   
20     2/1 / °   
 
Table 11: Implemented measurements for samples listed in Tables 8 and 9 
* SAXS – ESRF (Grenoble) 
+ SAXS – BESSY (Berlin) 
& SAXS – LNLS (Campinas) 
/ SAXS – EMBL (Hamburg) 
° TNS Assay 
x Free mRNA 
 
Table 12: Tested systems with EPC 100 % as matrix lipid, different cationic or ionizable li-
pids (20 mol%) and plasmid DNA (1 mg/ml) 
    DOPE 0 20 
cat. lipid 
DOTAP * + x * + x 
DDAB * + x * + x 
DC-Chol * + x * + x 
DOTMA * + x * + x  
DODMA * + x * + x # 
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Table 13: Implemented measurements for samples listed in Table 12 
* Size  
+ Zeta potential 
x Transfection efficiency  
# T-cell proliferation  
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4  Results 
4.1 mRNA-lipoplexes of DOPC and DOTAP 
Partial results of the presented work have been published in:  
Ziller, A.; Nogueira, S. S.; Huehn, E.; Funari, S. S.; Brezesinski, G.; Hartmann, H.; Sahin, U.; Haas, 
H.; Langguth, P. Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration. Mol. 
Pharm. 2017, acs.molpharmaceut.7b01022. 150 
Partial results of the presented work have been taken from the  unpublished thesis of Dr. Eva Hühn 
(“Rational Design of Sustained Release Liposomal mRNA Formulations for Parenteral Administration and 
Image-Guided Assessment of in Vivo Performance, 2013”). 165 
4.1.1  SAXS experiments 
First experiments were performed with lipoplexes composed of EPC 80 % and DOTAP with 
different amounts of mRNA using small-angle X-ray scattering (SAXS). Scattering of such 
samples shows typical features of lipid systems. First, Bragg peaks indicated the molecular 
structure, which can be derived from the ratio of the reoccurring peak positions on the q-scale 
as listed in Table 14.  
Table 14: Determination of the molecular structure with the help of the peak position 
Molecular structure Peak position at q-scale 
Lamellar  1, 2, 3, 4, 5, … 
Cubic 1, √2, √3, 2, √5, … 
Hexagonal 1, √3, 2, √7, 3, … 
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Figure 14: X-ray scattering data of lipoplexes composed of either EPC 80 % [top left] (with pure 
EPC 80 % [black], EPC 80 % in presence of 5 mol% mRNA [red], EPC with 5 mol% DOTAP [green], 
EPC 80 % with 5 mol% DOTAP and 5 mol% mRNA [blue], and EPC 80 % with 5 mol% DOTAP and 
10 mol% mRNA [cyan]) or DOPC [top right and bottom] (with pure DOPC [black], DOPC with 2.5, 5 or 
10 mol% DOTAP [red], DOPC with 2.5, 5 or 10 mol% of DOTAP and 2.5 mol% mRNA [green], DOPC 
with 2.5, 5 or 10 mol% of DOTAP and 5 mol% mRNA [blue], DOPC with 2.5, 5 or 10 mol% of DOTAP and 
10 mol% mRNA [cyan], and DOPC with 2.5, 5 or 10 mol% of DOTAP and 20 mol% mRNA [purple]) with 
different amounts of DOTAP and mRNA (taken from 150) 
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Scattering data can be seen in Fig. 14 [top left]. Lipoplexes with pure EPC 80 % showed typical 
Bragg peaks. The positions indicated a lamellar lipid structure. As soon as EPC 80 % was 
mixed with DOTAP, the Bragg peaks disappeared, and the signal was dominated by the un-
structured signal resulting from the individual bilayer scattering (form factor) between 0.05 and 
0.25 Å. Just a small peak at 0.0027 Å-1 indicates a large distance of about 230 Å between the 
lipid bilayers due to electrostatic interaction because of the introduced positive charge of 
DOTAP. After incorporation of mRNA into the lipoplexes, Bragg peaks were recovered, and 
positions referred to a lamellar structure again, which can be seen as integer multiples of the 
first q-value. For 5 mol% of mRNA, two clear Bragg peaks could be seen while for 10 mol% 
of mRNA, three clear Bragg peaks appeared. Furthermore, the peaks shifted to smaller q values 
with higher amounts of mRNA. 
Since EPC 80 % is a natural lipid mixture composed of 80 % egg-PC (mainly POPC), lipid 
composition varies slightly. To ensure consistent quality for pharmaceutical development and 
production, DOPC as a pure and synthetic lipid was chosen for further experiments. SAXS 
experiments were repeated with a wider range of compositions including three different 
amounts of DOPC and increasing proportions of mRNA. Results from DOPC-lipoplexes 
(Fig. 14) illustrated similar behaviour as lipoplexes with EPC 80 %. Briefly, pure DOPC 
showed a lamellar order indicated by two Bragg peaks. After incorporation of DOTAP, the 
resulting form factor between 0.05 and 0.25 Å and a small peak at around 0.027 Å referred to 
a loss of structure. Comparable to EPC 80 %, the small peak resulted from an extended d-
spacing at 230 Å. Again, with the incorporation of mRNA in the DOPC/DOTAP-lipoplexes, 
Bragg peaks recovered while peak positions were shifted to smaller q-values in comparison to 
pure DOPC. With increase amounts of mRNA, this shift became greater.  
D-spacing of all samples were analysed carefully and showed a typical behaviour of insertion. 
All results were plotted against the DOTAP/mRNA (N/P) ratio, irrespective of the 
DOPC/DOTAP ratio. For example, lipoplex with 2.5 mol% DOTAP and 5 mol% mRNA 
and lipoplex with 5 mol% DOTAP and 10 mol% mRNA have the same N/P ratio (1/2), thus 
they were plotted at the same position.  
With an excess of DOTAP (N/P ratio > 1), d-spacing as a function of N/P ratio changed only 
marginally. Close to the equilibrium and for samples with an excess of mRNA (N/P ratio < 1), 
d-spacing increased monotonously. For similar N/P ratios, similar d-spacings could be found. 
In conclusion, d-spacing was not dependent on the molar fraction of DOTAP but on the ratio 
of the amount of DOTAP and mRNA as it is illustrated in Fig. 15 [top].  
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4.1.2  Further characterisation 
 
Figure 15: Characterisation of lipoplexes showing the d-spacing of lipoplexes with different propor-
tions of DOPC, DOTAP and mRNA [top], zeta potential of lipoplexes with different amounts of 
DOPC, DOTAP and 20 mol% mRNA [middle] and amount of free mRNA from DOPC with differ-
ent amounts of DOTAP and 20 mol% mRNA [bottom]; plotted as a function of the N/P ratio 
(taken from 150) 
The amount of free mRNA was quantified with the commercially available Quant-iTTM Ri-
boGreenTM RNA Assay Kit (Fig. 15 [bottom]). The dye shows fluorescent only when it binds 
to mRNA which is not bound to lipid membranes and therefore accessible. With an excess of 
DOTAP (N/P ratio > 1), there was no free mRNA since no fluorescence is detectable. With 
an excess of mRNA (N/P ratio < 1), the fluorescence and thus the amount of free mRNA 
increased. In addition, zeta potential measurements were performed (Fig. 15 [middle]). Pure 
DOPC showed negative values, while there was a positive potential after incorporation. By 
incorporating both DOTAP and mRNA, the measured potential reflected the N/P ratio of 
the lipoplexes. Samples with a N/P ratio higher than 1 showed a positive zeta potential. This 
was not unexpected since there was an excess of DOTAP. With an excess of mRNA and 
therefore a N/P ratio lower than 1, the zeta potential switched to negative values. For better 
comparison, the fraction of free mRNA and the zeta potential were plotted over the same axis 
as for d-spacing. There seems to be a characteristic change at the N/P ratio of 1/1. First, d-
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spacing as well as the amount of free mRNA started to increase at this ratio. Furthermore, a 
change in the slope of the zeta potential occurred at this N/P ratio. Measured potentials above 
this ratio were positive, the ones below negative. Consequently, binding of mRNA to DOTAP 
seemed to occur in a manner of 1 to 1 (mol% to mol%). One molecule of DOTAP with one 
positive charge could bind one nucleotide of the mRNA strand with one negative charge.  
4.1.3  Determination of phase transition temperature 
For further analysis and proof of a homogenous insertion of DOTAP into the DOPC mem-
brane, phase transition temperature (Tm) was measured by the use of differential scanning cal-
orimetry (Fig. 16). At this point, transition from gel to liquid-crystalline phase can be observed 
and hence, it represents an indicator for the stability of a system. The higher this temperature 
is, the more energy is necessary to unstable it. Both samples with and without mRNA were 
tested.  
 
Figure 16: Phase transition temperature of lipoplexes with different proportions of DOPC, DOTAP 
and mRNA; plotted as a function of the amount of DOTAP (taken from 150) 
For all the lipoplexes, Tm was in the sub-zero temperature range. Pure DOPC had a transition 
temperature at around - 18°C, while with mRNA it was slightly higher. Increasing DOTAP 
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concentration in the samples, Tm of the samples first decreased, but then increased constantly 
as a function of the DOTAP content. The insertion into the gel and the liquid crystalline phase 
and also the molecular interactions in both phases have to be taken into account when inves-
tigating the influence of DOTAP on the phase transition of DOPC. 166,167 
In general, insertion of a non-interacting solute into the liquid-crystalline (fluid like) phase is 
expected to lead to a decrease of Tm as a function of the solute concentration as is stated in:  
𝛥𝛥𝑘𝑘𝑚𝑚 = −�RT𝑚𝑚2𝛥𝛥𝛥𝛥 � ⋅ 𝑥𝑥𝑎𝑎 
Equation 9: Calculation of the shift of the phase transition temperature 
with ∆Tm as the shift of the phase transition temperature, R as the gas constant, ∆H as the 
melting enthalpy and xa as the molar fraction of the solute in the solvent.  
In contrast, insertion of DOTAP into the DOPC matrix just led to a first decrease for the 
lowest fraction, followed by an increase of the transition temperature for higher fractions. This 
increase in stability could be explained by interactions between both lipids. There is a strong 
attraction between the positively charged trimethylammonium headgroup of DOTAP and the 
negatively charged phosphate group of the zwitterionic DOPC. The more DOTAP was incor-
porated, the stronger these attractions were which then led to an increased stability. For lipo-
plexes with mRNA, the same temperature course with only minor shifts in comparison to the 
mRNA-free lipoplexes could be seen. This indicate, that mRNA did not act like a disruptive 
factor, but the lipid system remained also on the binding of mRNA. Hence, in presence of 
mRNA, DOTAP could be inserted homogenously into the DOPC matrix without phase sep-
aration since this would have led to a reversion back to the phase transition temperature of 
pure DOPC. In addition, results of zeta potential measurements supported these findings. The 
effects on the zeta potential indicated that both mRNA and DOTAP could be inserted into 
the membranes.  
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4.1.4  Cryo-TEM pictures 
CryoTEM pictures indicated lipoplexes with different appearance (Fig. 17).  
a  b  
c  d  
Figure 17: CryoTEM pictures of lipoplexes with 95 mol% DOPC, 5 mol% DOTAP and 10 mol% 
mRNA  
Most of the vesicles had one or two lamellae. The membrane thickness differed slightly as is 
can be seen in Fig. 17 [d]. A thicker membrane can result from the accumulation of mRNA 
on the surface. The size ranged from 50 nm to about 500 nm. Most of the vesicles had a round 
shape while some of the lipoplexes appeared to be oval as well. Pictures revealed that some 
smaller vesicles were enclosed by larger vesicles forming multivesicular vesicles (MVV). In 
Fig. 17 [b], a typical multilamellar vesicle (MLV) with several membranes is depicted. With 
  Results 
 
81 
 
regard to the lipid film method as the preparation method, it would have been expected that 
more of the vesicles form MLV. Further on, the addition of negatively charged mRNA would 
favour the arrangement in lipid layers because it reduces the repulsion force between the neg-
atively charged lipid membranes. Possibly, the higher dilution of the liposomal suspension 
which was needed for this technique favours the formation of more unilamellar vesicles instead 
of MLV. Fig. 17 [a] showed some tendency of aggregation which was not that obvious in the 
other pictures. This aggregation is likely to be caused by the electrostatic interaction between 
the positively charged liposomal surface and the negatively charged mRNA which then im-
pedes an electrostatic repulsion between the cationic liposomes. This indicates that the mRNA 
is not only encapsulated into the vesicles but is also bound on the surface of the liposomes. 
Nevertheless, this phenomenon must be investigated more deeply since the pictures just show 
a small part of the whole sample and it could be due to the special preparation for CryoTEM.  
Contamination of ice crystals due to a high content of evaporated water appeared but did not 
impede a qualitative analysis. 
4.1.5  Transfection efficiency 
For evaluation of principal functionality, cell culture experiments were performed. Before ap-
plication to the cells, lipoplexes needed to be diluted. Therefore, it was tested if the structure 
of the lipoplexes remain the same while dilution. As an example, three different compositions 
with 90 mol% DOPC, 10 mol% DOTAP and 5, 10 and 20 mol% mRNA were measured with 
SAXS. The molecular structure was determined for four concentrations (100, 10, 2 and 
0.5 mg/ml.) as it can be seen in Fig. 18. As expected, the intensity decreased with lower lipo-
plex concentrations but, nevertheless, peak positions remained the same which indicate a 
preservation of the molecular organisation of the lipoplexes. Hence, the characterisation of the 
structure for the concentrated lipoplexes can be directly correlated with the results from the 
biological investigation. 
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Figure 18: Scattering curves (SAXS) from 
DOPC with 10 mol% DOTAP and 5 mol% 
mRNA [top], 10 mol% mRNA [middle] and 
20 mol% mRNA [bottom], diluted up to a li-
pid concentration of 0.5 mg/ml 
(taken from 150) 
Figure 19: Transfection in C2C12 cells [top] and 
cell viability [bottom] of lipoplexes with DOPC, 
different amounts of DOTAP and 20 mol% 
mRNA (taken from 150) 
In Fig. 19, results from the cell culture experiments using C2C12 murine myoblasts show that 
the mRNA inserted into the lipid membranes was functional. The luciferase activity was de-
pendent on compositions and hence on the characteristic of the respective formulation. An 
excess of DOTAP was associated with higher signals. Nevertheless, systems with an excess of 
mRNA showed activity as well. In addition, cell viability test led to contrary results. With higher 
amount of DOTAP, cell viability decreased because of the toxicity of cationic lipids in general.  
To ensure the applicability in different systems, the lipoplexes needs to be investigated in fur-
ther in vitro and in vivo studies. The systems are supposed to work as a depot for local admin-
istration so that the release of mRNA should be investigated as well. For each route of appli-
cation (e.g. intradermal, intramuscular or intratumoural), the most suitable formulation needs 
to be identified. 
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4.1.6  SANS experiments 
The information gained from the previous described methods was used to characterise the 
lipoplexes composed of DOPC and DOTAP and for the development of a structural model. 
Nevertheless, it was not possible to proof the exact position of the mRNA. It could just be 
assumed that the mRNA appears to be a layer on the top of each lipid bilayer and forms 
clusters by interacting with the cationic headgroup of DOTAP. Therefore, SANS measure-
ments were performed to proof the developed structural model. Using contrast variation, it 
should be possible to mimic the lipid bilayer and figure out the exact location of the mRNA.  
Two characteristic samples with 5 mol% DOTAP and either 2.5 or 10 mol% mRNA were 
used to investigate both an excess of DOTAP and mRNA. Unfortunately, first measurements 
carried out at the KWS-2 instrument at FRM II in Garching failed by sample preparation. 
Samples needed to be diluted to a lipid concentration of 10 mg/ml. Stabilisation of samples 
was necessary due to a long measurement time. Consequently, a higher content of trehalose 
(1.31 M instead of 0.27 M) was chosen for dilution of the samples and experiments at the 
instrument in Garching were repeated. Aggregation could be prevented. Both samples were 
adjusted to a lipid concentration of 10 mg/ml and nine different contents of D2O. Measure-
ment were performed at three different detector distances to achieve a broader q-range 
(2, 8 and 20 m).  
With the higher content of trehalose, another problem appeared. Trehalose has a lot of hydro-
gen atoms. By addition of a higher proportion, the initial ratio of deuterium to hydrogen is 
shifted in favour of hydrogen, additionally the density is modified. Consequently, the real con-
tent of D2O differed from the initially calculated one. This phenomenon was not considered 
before the experiments. Therefore, the real contents of D2O needed to be calculated afterwards 
from the neutron transmission values and are listed in Table 15. The transmission of each 
buffer was measured and compared to the transmission of buffers with a known D2O content. 
As expected, D2O contents were lower as initially calculated. Just for 0 and 11.11 %, the meas-
ured D2O content was higher which is due to changes in the density caused by the high content 
of trehalose (1.31 M).  
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Table 15: Comparison of calculated and real amount of D2O due to high content of trehalose 
(1.31 M)  
D2O calculated [%] D2O real [%] 
0 4.64 
11.11 12.7 
16.16 15.63 
22.22 20.39 
33.33 28.55 
44.44 34.09 
55.56 39.82 
66.67 46.29 
77.78 54.05 
 
Each contrast has to be analysed separately and different information can be gained by evalu-
ation of 2, 8 and 20 m. Background subtraction was corrected with the Porod plot. Data of all 
distances was merged. The linear part of the 20 m data at very low q-values was treated with 
the Guinier plot to gain forward intensity and radius of gyration of the particle, which describes 
the radius measured from the centre of mass. The Kratky-Porod plot was used for the linear 
part of the 8 m data at q values between 0.0004 to 0.001 Å to observe the thickness of possible 
flat areas (layer span thickness) within the system, which can occur due to bilayer membranes 
of the lipids. Exemplary, data treatment is shown for one sample with one D2O contrast in 
Fig. 20. Procedure was done for all contrasts and results are listed in Table 16.  
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Figure 20: Scattering profile [top], Guinier plot [bottom left] and Kratky-Porod [bottom right] of lip-
oplexes with 95 mol% DOPC, 5 mol% DOTAP and 10 mol% mRNA in 54 % D2O 
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Table 16: Results for radius of gyration as obtained from the Guinier plot and layer span 
thickness resulting from the Kratky-Porod plot 
Sample  
[% D2O real] 
Radius of gyration  
[nm] 
Layer span thickness 
[nm] 
95 mol% DOPC / 5 mol% DOTAP / 2.5 mol% mRNA 
4.64 54.77 3.87 
12.7 52.36 20.1 
15.63 57.03 19.39 
20.39 55.88 19.74 
28.55 - 8.78 
34.09 - 9.3 
39.82 56.19 10.0 
46.29 56.12 4.51 
54.05 53.2 5.64 
95 mol% DOPC / 5 mol% DOTAP / 10 mol% mRNA 
4.64 42.9 3.87 
12.7 49.16 5.17 
15.63 54.32 7.68 
20.39 53.20 4.47 
28.55 - 7.37 
34.09 - 6.73 
39.82 48.28 5.7 
46.29 48.36 4.83 
54.05 48.26 5.65 
 
Depending on the D2O content, certain structures within the lipoplex are matched and the not 
matched parts can be observed. A DOPC/DOTAP bilayer has a thickness between 33 and 
44 Å (3.3 to 4.4 nm) depending on the composition 168. Close to the matching point of the 
mRNA around 67 %, membrane thickness has to correspond to the thickness of pure 
DOPC/DOTAP. Unfortunately, this D2O content could not have been measured due to the 
high content of trehalose. Despite, these values could be proven for both samples since the 
D2O content of 46.29 % is quite close to the matching point of the mRNA and resulted in a 
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layer span thickness of 4.51 or 4.83 nm. The lowest content (4.64 %) shows the pure mRNA. 
The values show that the mRNA forms a thinner layer in comparison to the lipid membrane 
which is in line with the developed structural model.  
The mRNA is expected to form another layer on top of each side of the lipid bilayer. Hence, 
membrane thickness has to be higher than for pure DOPC/DOTAP membrane. Increasing 
the D2O content (12.7, 15.63 and 20.39 %), the layer span thickness is supposed to reflect the 
mRNA accumulated on the lipid membrane, so the values have to be higher. The sample with 
10 mol% shows a layer span thickness which indicate that one mRNA layer is on top of one 
lipid bilayer (7.58 nm for 15.63 %) which is in accordance to the developed model. In case just 
one side of the lipid bilayer is covered with mRNA. It has to be evaluated if a lipid bilayer can 
also be covered with mRNA from both sides. For the sample with 2.5 % mRNA, the values 
are much higher (19.39 to 20.1 nm). In the earlier performed SAXS experiments, this low 
content of mRNA led to a strong decrease of the d-spacing of the lipid bilayers in comparison 
to the same lipid sample without mRNA since the mRNA compensates the electrostatic re-
pulsion of the cationic membrane surface. Possibly, more layers of mRNA and lipid bilayers 
stick together and cannot be measured separately which led to such high values. In the same 
experiment, 10 mol% of mRNA increased the d-spacing in comparison to 2.5 mol% mRNA 
which was caused by a higher anionic charge and an increased requirement of space. Hence, 
lipid bilayers do not stick together which is accordance with the above-mentioned layer span 
thickness.  
The values for the gyration radius are all around 50 nm. This seems to be quite small. The 
CryoTEM-pictures (see Ch. 3.1.4) revealed vesicles with sizes ranging from 50 to a few hun-
dred nm. In addition, DLS experiments (data not shown) from the SANS experiments showed 
larger particles as well. These results can be caused by the curved instead of a linear Guinier 
plot at small q-values which can happen in samples that tend to aggregation. Due to that, the 
Guinier plot could just be performed with the minimum amount of data points.  
A crucial tool is the determination of the matching point. The matching point constitutes the 
D2O content, where the according substance has the same scattering length as the buffer. With 
the help of values based on literature (e.g. matching point of lipids: 11 %), it should be simple 
to determine the single components of the according structure. The matching point can be 
determined for the whole sample as well as for a single appearing peak to investigate the com-
position of the causing structure. It is also important to analyse the side peaks because they 
can give information on structural details.  
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For the matching point of the whole sample, Guinier plot is applied to calculate the matching 
point of the whole particle. Therefore, a linear area in the 20 m data is used to determine I0 
and its root is plotted over the corresponding D2O content. At y=0, the matching point of the 
whole particle can be determined. Both can be seen in Fig. 21. The graph is based on the real 
D2O values as listed in Table 15. In case of the sample with 5 mol% DOTAP and 2.5 mol% 
mRNA, the matching point occurred to be at a D2O content of 6.6 %. For the formulation 
with 10 mol% mRNA, it appeared to be 6.7 %.  
  
Figure 21: Matching point of lipoplexes with 95 mol% DOPC, 5 mol% DOTAP and a low [left] and 
a high [right] content of mRNA 
Lipids constitute the largest proportion in the formulation, so the matching point could be 
expected around 11 %. If the mRNA (matching point: 67 %) had a strong impact on the 
formulation structure, the matching point would be shifted to higher D2O contents. The 
matching point was shifted to lower contents, so that another ingredient seemed to have an 
impact in both samples. Since there was a large amount of trehalose in the samples (1.31 M), 
an influence of trehalose is expected. Normally, the errors are larger with lower contents. As 
it is obvious in Fig. 21, the error got larger with a higher content of D2O. This can be explained 
with the help of the Guinier plots. Instead of a linear course, the plot is curved at the smallest 
q-values which indicates aggregation of particles. With higher amounts of D2O, the aggregates 
got more visible. However, since the data points are nearly on one line, separation could not 
have been observed.  
Next step in evaluation would be the determination of the matching points of each peak to 
receive information on the structure which caused the respective peaks. Hence, exact structural 
characterisation would be possible. Nevertheless, with the currently available data, this analysis 
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is not possible. Reference measurement with empty liposomes containing DOPC alone and 
DOPC with different contents of DOTAP are needed. Although such data can be found in 
the literature, it cannot be used for these experiments. Since the high content of trehalose 
influences the scattering profile, the references measurements have to be performed in the 
same buffer. Further experiments are planned to complete the data set. Therefore, analysis of 
the single peaks is not part of this work. With these reference measurements, it will also be 
easier to evaluate the data. Until now, the influence of the trehalose on the results cannot be 
clarified completely.  
Comparison between SAXS and SANS 
For comparison, samples with the same composition were also tested at the BioSAXS beam-
line at EMBL in Hamburg. Scattering curves from SAXS and SANS were plotted together in 
Fig. 22. For better comparison, just the data from 2 and 8 m are shown since most of the 
information is in this q-range.  
  
Figure 22: Comparison of SAXS [highest one] and SANS [lower ones, 77.77 % to 0 % D2O from top 
to bottom] curves from lipoplexes with 95 mol% DOPC, 5 mol% DOTAP and a low [left] and a 
high [right] content of mRNA 
The highest curves, which has a different appearance, is the SAXS curves while the curves 
beyond show the different D2O contents from 77.77 % at the top going down, in linear steps 
of 11.11 %, to 0 % at the bottom; with 16.16 % as an additional measuring point. As expected, 
the plot revealed varied intensities of the scattering curves generated by SAXS and SANS. This 
is due to higher concentration for SAXS but also stronger scattering effects for electrons. 
Moreover, peaks generated by SAXS were much clearer while the peaks for SANS formed just 
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shoulders instead of peaks. These narrow peaks are caused by the strictly monochromatic ra-
diation used at a SAXS beamline which results in very small energy resolutions (e.g. 10-3 ∆λ/λ 
for the ID02 beamline at ESRF facility). In contrast, the energy resolution of the radiation 
used in SANS experiments is higher (e.g. 20 % (∆λ/λ) for the KWS-2 instrument at the FRM II 
facility) which lead to strong smearing of the peaks. The scattering intensity of the SANS 
curves increased with higher D2O contents due to stronger coherent scattering of deuterium 
compared to hydrogen. SAXS data confirmed the results illustrated earlier in Ch. 4.1.2. The 
peak positions revealed a lamellar structure with two orders which is dependent on the com-
position. With an excess of DOTAP, peaks positioned at 0.093 Å-1 and 0.186 Å-1 while the 
excess of mRNA resulted in peaks at 0.081 Å-1 and 0.162 Å-1 which meant a bigger d-spacing 
for the latter sample.  
Analysis of the peaks generated by SANS was more difficult. The sample with an excess of 
mRNA pictured two peaks which were shifted to smaller q-values in comparison to the SAXS 
curve. The excess of DOTAP led to one broad peak which was assembled by several peaks. 
Possible 2nd order peaks were difficult to determine because of the strong background noise at 
larger q-values. Although samples had the same composition, peak pattern appeared differ-
ently. Both samples were prepared in 0.27 M trehalose. For SAXS, samples were diluted with 
the same concentration while a solution with 1.31 M trehalose was utilised for SANS. This was 
the only difference in the measured sample so that further analysis of this phenomenon was 
necessary. 
Therefore, the sample with 5 mol% DOTAP and 10 mol% mRNA was measured with either 
0.27 M or 1.31 M trehalose at the SAXS1 beamline at LNLS in Campinas. Furthermore, H2O 
and D2O was used as base for dilution medium to exclude a possible influence. Scattering 
curves of all four conditions are illustrated in Fig. 23. Samples with D2O were shifted along 
the y-axis, just for a better display. Further analysis of the peak pattern can be seen in Fig. 23 
as well. Variations between H2O and D2O appeared just for the peak areas but not for the d-
spacing. Unfortunately, the scattering curves showed two lamellar systems although this sam-
ple normally just caused one lamellar system as it can be seen in other experiments. The main 
system appeared around 85 Å and the second one at 68 Å. Dilutions with the lower amount 
of trehalose showed four peaks whereas the higher amount led to just three peaks. While the 
peaks at a spacing of 85 Å just shifted slightly by increase of the trehalose content, there was 
a clear shift for the peaks from 68 Å to 60 Å.  
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Figure 23: SAXS curves [left] and peak analysis [right] of lipoplexes with 95 mol% DOPC, 5 mol% 
DOTAP and 10 mol% mRNA mixed with 0.27 and 1.31 M trehalose in either H2O or D2O 
SANS measurement in cooperation with NIST (Delaware) 
Further investigation on the effect of the high trehalose content was done at the nSoft instru-
ment at NIST in Delaware. Two samples with 10 mol% mRNA and either 5 or 10 mol% 
DOTAP as well as pure DOPC with 100 mg/ml as reference were prepared. Samples were 
measured pure and diluted with 0.27 M or 1.31 M trehalose solution. Since equivalent D2O 
contents were always lower because of the high trehalose amount, 77.78, 85 or 90 % were 
adjusted to achieve a preferably high D2O content. Nevertheless, the equivalent content of 
D2O was not determined within this experiment.  
Fig. 24 displays results for pure DOPC and mixed with two different D2O contents as well as 
the two trehalose amounts. Intensity of pure DOPC was higher because samples was measured 
without dilution. A shift to larger q-values was observed and d-spacing was calculated by the 
help of the peak position. More trehalose correlated with a stronger shift since the shift for 
0.27 M was 7 Å and for 1.31 M trehalose about 10 Å. In contrast, D2O concentration had no 
influence.   
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Figure 24: Scattering curves of pure DOPC and mixed different amounts of D2O and trehalose 
This comparison was done similar for both samples as illustrated in Fig. 25. D-spacing differed 
for the pure samples with a larger spacing for the sample with less DOTAP (5 mol%: 73 Å 
and 10 mol%: 69 Å). All measured conditions (90 and 85 % D2O for 0.27 and 1.31 M trehalose 
and 77.78 % D2O for 0.27 M trehalose) resulted in a comparable shift. Peaks for the sample 
with 5 mol% DOTAP were shifted 16 Å while the shift for 10 mol% DOTAP was just 9 Å. 
For the latter, peaks of the generated scattering curve just differed in intensity but not in shape. 
Scattering curve of the formulation with 5 mol% DOTAP showed various appearance. Peaks 
generated by 0.27 M trehalose were more defined than the peaks for the high concentration. 
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Figure 25: Scattering curves of lipoplexes with 5 mol% [top] and 10 mol% DOTAP [bottom] with 
different amounts of D2O and trehalose 
Comparison of the pure samples are presented in Fig. 26. Pure DOPC showed a peak at the 
highest q-value. With the addition of DOTAP and mRNA, peaks shifted to smaller q-values 
whereas lower amount of DOTAP related to a stronger shift. This is in line with earlier results.  
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Figure 26: Comparison of pure DOPC and two lipoplexes with 5 and 10 mol% DOTAP and 
10 mol% mRNA 
4.1.7  Reproducibility of preparations 
Beamtime at a synchrotron is rare so that samples can often just be measured once. Despite, 
reproducibility is an important criterion for the preparation of pharmaceutical formulations. 
Preparation of the same sample by different persons as well as repeated measurements and 
measurements at different facilities should lead to the same results. For this work, samples 
could be prepared by different persons and could also be measured at different beamlines. 165 
A comparison of these samples is shown in Table 17.  
Concentration for measurement varied between the different experiments, but this has no in-
fluence on the d-spacing as shown earlier in Ch. 4.1.5. Samples were prepared and diluted with 
a 0.27 M trehalose solution. The d-spacing for the samples prepared by Eva Hühn represented 
both peaks of the lamellar system. It is evident, that results from earlier measurements by 
Eva Hühn could be replicated successfully. 165 Lamellar orders were identical and d-spacing 
varied in an acceptable range.  
Just for the sample with 5 mol% DOTAP and 10 mol% mRNA one repetition led to a different 
result. Since this is one out of four experiments, it could be an artefact or due to insufficient 
transportation to the facility. The sample had to be carried to Brazil and sufficient and contin-
uous refrigeration during the trip could not be guaranteed.  
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Table 17: Properties of same MLV sample prepared for different beamtimes  
100 mol% DOPC 
Producer Eva Hühn Antje Ziller   
Facility Mainz University NIST   
Lamellar sys-
tems 
1 (2 orders) 1 (2 orders po-
tentially) 
  
Experiment SAXS SANS   
D-spacing 66.5 Å 66 Å   
95 mol% DOPC / 5 mol% DOTAP / 2.5 mol% mRNA 
Producer Eva Hühn Antje Ziller   
Facility Mainz University EMBL (DESY)   
Experiment SAXS SAXS   
Lamellar sys-
tems 
1 (2 orders) 1 (2 orders)   
D-spacing 66.5 Å 67.9 / 68.5 Å   
95 mol% DOPC / 5 mol% DOTAP / 10 mol% mRNA 
Producer Eva Hühn Antje Ziller Antje Ziller Antje Ziller 
Facility Mainz University EMBL (DESY) NIST LNLS 
Experiment SAXS SAXS SANS SAXS 
Lamellar sys-
tems 
1 (2 orders) 1 (2 orders) 1 (2 orders po-
tentially) 
2 (2 orders) 
D-spacing 75.0 Å 75.6 / 75.9 Å 73 Å 84.5 / 84.4 Å 
68.2/ 68.7 Å 
90 mol% DOPC / 10 mol% DOTAP / 10 mol% mRNA 
Producer Eva Hühn Antje Ziller   
Facility Mainz University NIST   
Experiment SAXS SANS   
Lamellar sys-
tems 
1 (2 orders) 1 (2 orders po-
tentially) 
  
D-spacing 68.4 Å 69 Å   
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4.2 mRNA-lipoplexes with ionizable lipoplexes 
The evaluation of lipoplexes with ionizable lipids was the overall aim of the following work. 
By using the homologous lipids DOTMA and DODMA, the structural behaviour of formula-
tions with ionizable lipids in comparison with permanently cationic lipids could be investi-
gated. Both are nearly the same lipids but differ slightly in their headgroup. DOTMA has a 
quaternary amine which lead to a constantly charged headgroup. In contrast, DODMA has a 
tertiary amine resulting in a pH-dependent protonation so that the positive charge is affected 
by the actual environment. Both lipids were embedded in a zwitterionic base lipid, which was 
either EPC 80 % or DOPC.  
After subtraction of the buffer scattering, the Lorentz fit was applied to determine the exact 
peak position and area. The absolute values of the areas can just be compared while measuring 
at the same beamline since the intensity between different beamlines differs. D-spacing was 
calculated from the peak position according to Eq. 5. Both the scattering curve prior to fitting 
and the data obtained by fitting are used for evaluation and will be discussed. Peak analysis is 
shown in the results part while the corresponding scattering curves can be found in the appen-
dix. For better comparison, scattering curves are plotted semi-logarithmic while a linear plot 
was used for fitting.  
4.2.1  pH dependent structural changes  
I. Comparison of structures at pH 7.5 and 5 with EPC 80 %-lipoplexes using SAXS  
Figs. 27 to 29 show the results of the different formulations plotted over the amount of added 
mRNA. For better comparison, both pH values are placed in the same graph. Data of pH 5 is 
marked with solid line and squares while dashed lines and triangles are used for pH 7.5. In 
addition, each occurring peak is marked with another colour.  
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Figure 27: Peak analysis of lipoplexes with EPC 80 % and 
different amounts of mRNA, measured in pH 7.5 and 5 
Exemplary for Fig. 27, four different peaks appeared at pH 5 as well as four peaks at pH 7.5. 
According to the peak positions (Table 14), a lamellar structure of all lipoplexes can be as-
sumed. In comparison, more peaks (especially q > 2) are visible with the semi-logarithmic plot 
(Appendix I). Therefore, some of the peaks at q-values higher than 2 were not available for 
fitting since the linear plot was used for the Lorentz fit. Considering the position, these peaks 
always belonged to one of the present lamellar orders and therefore, indicate only a higher 
level of order/structure.  
Pure EPC 80 %-lipoplexes, as it can be seen in Fig. 27, formed two orders of lipid lamellae 
around 61 and 67 Å, which also existed after addition of 5 and 10 % of mRNA. The constant 
area of each peak indicated a continuance of the orders. Just slight differences between both 
pH values appeared. Both lamellar orders formed a double peak, which indicated two in par-
allel existing lamellar systems. 
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Figure 28: Peak analysis of lipoplexes with EPC 80 % and different amounts of DOTMA and 
mRNA, measured in pH 7.5 and 5 
Afterwards, lipoplexes with 5 and 10 % of DOTMA were measured to investigate structure 
with a permanently charged lipid. Formulations without mRNA showed rather broad peaks, 
while the peaks got sharper after addition of mRNA (Fig. 28). Due to these broad peaks, a 
direct comparison between the formulations without and with mRNA is difficult. Fitting of 
these broader peaks is sometimes not explicit and can lead to varying peak positions and larger 
peak areas than actually present. In comparison to pure EPC 80 %, lipoplexes with DOTMA 
but without mRNA had a larger range of d-spacing while the intensity was similar. In the 
presence of mRNA, lipoplexes with a higher amount of DOTMA showed also a higher degree 
of structure. With 5 % DOTMA, two lamellar system with up to three successive peaks were 
detected. Furthermore, peaks were not separated completely. The area of the peaks changed 
just slightly while increasing the amount of mRNA. In contrast, lipoplexes with 10 % of 
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DOTMA showed just one lamellar order with up to four successive peaks. There was also a 
strong increase of the peak area of the main peak with an increase of mRNA from 5 to 10 %, 
which could be observed for both pH values.  
 
Figure 29: Peak analysis of lipoplexes with EPC 80 % and different amounts of DODMA and 
mRNA, measured in pH 7.5 and 5 
Same experiments were carried out with 5 and 10 % of DODMA (Fig. 29). Results for d-
spacing and peak area were in the same magnitude as for DOTMA. Although more peaks were 
visible for lipoplexes with DODMA, samples had a lower degree of structure. For 5 % of 
DODMA, not all peaks could be assigned to a lamellar order which was the same for both pH 
values. Lipoplexes with 10 % of DODMA behaved differently. For pH 7.5, two lamellar orders 
could be detected while still double peaks appeared. By lowering the pH to 5, only one lamellar 
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system was measured. For both 5 and 10 % DODMA, a slight increase of the d-spacing could 
be observed with the increase of mRNA while there was no clear change in the peak areas. 
II. Investigation of pH dependent structural transition with EPC 80 %-lipoplexes 
The experiments performed at the ESRF showed differences in the structure of lipoplexes 
with DOTMA and DODMA when mixed with a buffer of neutral or acidic pH. Further meas-
urements on this behaviour were necessary to investigate a wider range of pH values and find 
the pH at which the transition of structure takes place. These experiments were performed at 
the mySpot beamline at BESSY in Berlin. Due to a time limitation, only characteristic samples 
of the ones measured at ESRF were chosen. Three lipoplexes with DODMA varying in the 
N/P ratio and one lipoplex with DOTMA as a reference were used. Again, the scattering 
curves prior to fitting and the results from Lorentz fit were included into the evaluation. d-
spacing was calculated and plotted over the tested pH values, same was done for the peak area. 
Square data points and solid lines were used to illustrate the 1st order peaks while triangle data 
points and dashed lines were used for 2nd order peaks. Peaks are numbered consecutively. 
Compared to the scattering curves of ESRF data, the 3rd peaks did not occur, also not in the 
semi-logarithmic graphs. Due to the higher intensity of ESRF beamline, this was not unex-
pected.  
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Figure 30: Peak analysis of lipoplexes with EPC 80 %, 10 mg/ml DOTMA or DODMA and 
5 mg/ml mRNA, measured from pH 8 to 4.5    
In Fig. 30, results from two formulations with the same composition (90 mg/ml EPC 80 % 
and 5 mg/ml mRNA) but with either 10 mg/ml DOTMA (left) or DODMA (right) are illus-
trated. Both samples showed different behaviour after mixing with various pH buffers between 
8 and 4.5. At neutral pH, values for d-spacing (70 to 85 Å) were comparable while the range 
of d-spacing at acidic pH developed differently. For both lipoplexes, some peaks remained at 
the same d-spacing (peak 4, 5, 6, 10, 11 for DOTMA and peak 2, 3, 4, 5 for DODMA). De-
velopment of the remaining peaks showed differences. Peaks for the DOTMA sample in-
creased in d-spacing (peak 2, 3, 7). Peaks for the DODMA samples either increased (peak 6, 
8) or decreased in d-spacing (peak 1, 8). Peaks appearing for the DOTMA sample drifted apart 
from each other (peak 3, 4) whereas peaks for the formulation with DODMA seemed to fuse 
together (peak 5, 6). This led to smaller values and a tighter range of d-spacing compared to 
DOTMA (DODMA: 70 to 75 Å, DOTMA: 70 to 105 Å). This means, DODMA had just one 
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lamellar system while DODMA showed two systems with different spacing. Comparing the 
area as a proportion of the total amount of structural elements, differences can be seen as well. 
The lipoplexes with DOTMA had one dominating peak which did not change over the pH 
range. All the other peaks were less than half of this area and just varied slightly. The formu-
lation with DODMA did not show one dominant peak. Nevertheless, it can be seen that the 
area of some peaks increases with lowering the pH (peak 5, 6, 8) which underlines the phe-
nomenon of the peak fusion. This can also be seen in the scattering curve of this sample, that 
shows less but larger peaks at acidic pH.  
In Fig. 31, data of the other tested samples is illustrated. One sample contains 5 mg/ml 
DODMA and 10 mg/ml mRNA (left) and one sample is composed of 10 mg/ml DODMA 
and also 10 mg/ml mRNA (right). In comparison to the DODMA samples discussed above, 
both similarities and differences are visible. First, the tendency of peak fusion with a reduction 
in the number of peaks was apparent.  
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Figure 31: Peak analysis of lipoplexes with EPC 80 %, different amounts of DODMA and 10 mg/ml 
mRNA, measured from pH 8 to 4.5   
For lipoplexes with 5 mg/ml of DODMA, more peaks occurred in comparison with the others 
which was visible above all for neutral and slightly acidic pH values. The scattering curve re-
vealed that most of the peaks were not completely separated. Moreover, the range of d-spacing 
was quite large with varying between 60 and 90 Å. Three different lamellar systems were clearly 
visible. Lowering the pH to 5 and 4.5, most of the peaks disappeared finally. Due to the shift 
of certain peaks, d-spacing of the lamellar systems approached a range between 75 and 85 Å 
at a pH of 4.5, which is slightly higher than the range of the first DODMA sample. Neverthe-
less, the final peaks at pH 4.5 were also no clear single peaks but double peaks as it can be seen 
in the scattering curve. Again, the illustrated peak area emphasised the peak fusion since the 
area of the 1st order peaks increased through fusion.  
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The formulation with 10 mg/ml of DODMA and mRNA showed the observed phenomenon 
in the strongest manner. This composition led to less peaks compared to all the others while 
the range of d-spacing (60 to 85 Å) at neutral pH was comparable. Despite, three different 
lamellar systems were visible. The one system around 60 Å showed just one order and disap-
peared at pH 6. At the same pH, the two main lamellar systems below and above 75 Å fused 
to one lamellar system. This effect is supported by the illustrated peak area below. Peak 1 and 
2 fused together followed by a strong increase of the resulting peak area. The same event 
happened with the 2nd order peaks 5 and 6. Surprisingly, the peak area of this sample was much 
higher than the others (see different scale). 1st order peaks showed larger areas than 2nd order 
peaks. In general, this effect is expected and was also observed for all samples but to a different 
degree.  
III. Investigation of pH dependent structural transition with DOPC-lipoplexes 
EPC 80 % is a natural lipid mixture which contains around 20 % of other lipid components 
like PC, which is mostly POPC. For pharmaceutical products, a consistent composition and 
quality is necessary. Therefore, the synthetically produced DOPC was used instead of 
EPC 80 %. The further experiments to analyse the pH transition of these samples were carried 
out at the BioSAXS beamline of EMBL at DESY in Hamburg. For better comparison with 
earlier measurements, a formulation with 10 mg/ml DODMA was prepared. Since higher 
amounts of ionizable lipids seem to have a higher influence on the structure, one formulation 
with 20 mg/ml of DODMA was tested. As a reference, 10 mg/ml DOTMA was used again. 
All samples contained 5 mg/ml mRNA. For a better outcome, 10 mg/ml DODMA were also 
tested without the addition of mRNA. Data was analysed as before and d-spacing and area of 
each sample was plotted about each other.  
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Figure 32: Peak analysis of lipoplexes with DOPC, different amounts of DOTMA or DODMA with 
or without 5 mg/ml mRNA, measured from pH 8 to 4.5  
In Fig. 32, peaks of all measured samples are illustrated comparative. Square data points and 
solid lines are used for the 1st order peaks and triangle data points and dashed lines for 2nd order 
peaks. At first glance, there were less peaks for all samples with DOPC, but the general course 
over the pH range resembled the formulations with EPC 80 %.  
The reference sample with DOTMA can be seen on the left side. Next to some single peaks 
(peak 1, 2, 4, 5), just one main lamellar system with a first and second order (peak 3, 6) can be 
observed around 72 Å. Both orders behave identically. D-spacing decreased marginally from 
72.7 and 72.9 Å to 71.5 and 71.6 Å. Furthermore, the peak areas also just increased slightly 
while the 1st order peak was the dominating structure. At pH 8 and 7.5, there was another 
lamellar system at around 85 Å. In contrast to the diagram, two orders were observable in the 
scattering curve (Appendix II). Due to the position and size, the 1st order peak could not be 
fitted.  
Second column in the diagram represents the reference sample without mRNA. At pH 8 to 7, 
d-spacings ranged from 60 to 75 Å with two lamellar systems with each 1st and 2nd order peaks. 
With lowering the pH, most of the peaks disappeared. One lamellar system remained until 
pH 4.5 whereas the d-spacing of both peaks increased to a range of 85 to 90 Å. The course of 
d-spacing of 1st and 2nd order peaks over the pH range was not on the top of each other as it 
would have been expected. Furthermore, peak area of the 2nd order peak seemed to be larger 
than the area of the 1st order peak. As visible in the scattering curve of this formulation, peaks 
got quite broad by decreasing the pH. At neutral pH, DODMA was nearly uncharged and 
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behaved more like pure DOPC. With a more acidic pH, headgroups got protonated and led 
to electrostatic interaction between the bilayers. Due to the broad peaks, fitting is not always 
exact so that peak position and area can differ which is a possible explanation for this phe-
nomenon. Furthermore, the scattering curves revealed that all the peaks from one order fused 
together.  
The lipoplexes with 10 and 20 mg/ml DODMA showed similar peak distributions. The range 
of d-spacing at pH 8 was between 60 and 80 Å for both. Furthermore, one lamellar system 
with 1st and 2nd order appeared over the whole pH range. As for the samples with EPC 80 %, 
peaks were drifting together so that the range of d-spacing become narrower with lower pH 
values (see peak 1, 2 for sample with 10 mg/ml and peak 1, 3 for sample with 20 mg/ml 
DODMA). The scattering curves of both samples pointed out, that the peaks were not com-
pletely separated even before the fusion around pH 7. The course of the peak area underlined 
this behaviour although it was more pronounced with 20 mg/ml of DODMA. After the fusion 
of peak 1 and 2, the area of this peak proliferated. For both samples, 1st order was in greater 
proportion as it was also indicated by a much larger peak area of the 1st order compared to the 
2nd order peak. Compared to the formulation without mRNA, clear and narrow peaks devel-
oped by lowering the pH.  
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IV. Determination of pKa out of the scattering data 
The pKa is the pH at which 50 % of the headgroups are said to be ionised. This ionisation is 
associated with structural changes due to electrostatic interactions which are supposed to be 
visible in the scattering experiment. Hence, the scattering profiles are supposed to give infor-
mation concerning the pKa. The data was analysed with regard to structural changes at specific 
pH values. The observations for both samples with DODMA and DOTMA are listed in the 
Tables 18 and 19.  
Table 18: Structural behaviour of lipoplexes with EPC 80 % and DOPC as matrix lipid and 
different proportions of DODMA and mRNA 
Basis DODMA 
[mg/ml] 
mRNA 
[mg/ml] 
Behaviour 
BESSY 02/2015 
EPC 80 % 10 10 
Distinct transition 
at pH 6 with a loss 
of peaks and an oc-
currence of one new 
structure due to 
peak fusion 
EPC 80 % 10 5 
Gradual transition 
with a change in 
structure around 
pH 5.5 to 5 
EPC 80 % 5 10 
Gradual transition 
with a loss of some 
structures at pH 5 
and 4.5 
EMBL 12/2017 
DOPC 20 5 
Gradual transition 
with a peak fusion 
at pH 7.5 
DOPC 10 5 
Gradual transition 
with a peak fusion 
at pH 7 
DOPC 10 0 
Gradual transition 
with a loss of peaks 
at pH 6.5 
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Table 19: Structural behaviour of lipoplexes with EPC 80 % and DOPC as matrix lipid and 
different proportions of DOTMA and mRNA 
Basis DOTMA 
[mg/ml] 
mRNA 
[mg/ml] 
Behaviour 
BESSY 02/2015 
EPC 80 % 10 10 
Gradual transition 
over the whole pH 
range, but no loss of 
peaks 
EMBL 12/2017 
DOPC 10 5 No transition over the whole pH range  
4.2.2  Determination of pKa without SAXS 
The TNS assay was performed in different ways. As a first test, pure EPC 80 % and samples 
with half of EPC 80 % and DOTMA or DODMA were used to test the suitability of the TNS 
assay for this kind of samples. The number of added samples was adjusted to 22 µM in 102 µl 
per well.  
The total volume of sample per well was doubled to 204 µl due to the responsiveness of the 
fluorimeter. However, fluorescence of EPC 80 % was too low, so the lipid concentration of 
stock solution was increased tenfold (to 220 µM). Despite this increase, the fluorescence in-
tensity of pure EPC 80 % was still lower. Since the fluorescence intensity was always normal-
ised to pH 3, comparison with the other samples was not impeded. Fig. 33 [left] illustrates the 
expected behaviour of all three samples. Higher fluorescence intensity is correlated with a 
stronger binding of TNS to the cationic charged lipid headgroup. With the shift to neutral pH 
values, charge of ionizable lipids is reduced what led to less binding of TNS. This effect can 
be seen for the sample with DODMA whereas the intensity of the sample with DOTMA 
remained constant. Furthermore, intensity for EPC 80 % remained constant as well but with 
a much lower absolute intensity as explained earlier.  
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Figure 33: Reference measurements for TNS assay at different pH values [left] and comparison of in-
tensity of lipoplexes with 50 mg/ml DODMA with and without mRNA at different pH values [right] 
(test conditions 1 and 2) 
Further experiments were carried out to investigate whether the amount of ionizable lipid in 
the formulation influences the apparent pKa. Therefore, 2.5, 5, 10 and 20 mg/ml DODMA 
was tested in comparison to the same amounts of DOTMA as reference. In addition, all of 
them were also prepared with 5 mg/ml mRNA to see a possible impact of that as well. Proof-
ing reproducibility, two individual samples for 20 mg/ml were used. Due to better responsive-
ness, fluorescence was now measured with a TECAN infinite F200. Furthermore, measured 
lipid amount per well was 100-fold higher than in the first experiments while the total volume 
per well was 102 µl.  
Samples were measured in duplicates to grasp an idea of the standard deviation. For compari-
son with the first experiments, lipoplexes with 50 mg/ml of DODMA were tested again and 
results are illustrated in Fig. 33 [right] after normalisation of intensity. It is obvious, that the 
tested concentration did not have an influence on the measurement since the course of the 
graphs is similar within the standard deviation. The addition of mRNA did not have an influ-
ence as well. Nevertheless, standard deviation was higher compared to the formulation without 
mRNA. This could be due to some aggregation of sample which favours inaccuracies in pipet-
ting. Fig. 34 shows the overview of all the other tested samples. Again, most of the samples 
with mRNA had higher standard deviations than the formulations without mRNA while the 
standard deviation differed quite a lot between the different compositions. Nevertheless, the 
expected course was visible since a decrease in the intensity was provable for all DODMA 
samples. In comparison, samples with DOTMA led to less decrease in fluorescence intensity 
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while higher amounts of DOTMA showed more pronounced results. Findings were reproduc-
ible since all samples with 20 mg/ml DODMA and DOTMA with and without mRNA led to 
comparable results.  
 
Figure 34: TNS assay of lipoplexes with EPC 80 %, different amounts of DOTMA or DODMA with 
or without mRNA (test conditions 2) 
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The previous experiments focused on the total lipid 
concentration as basis for the calculation of added 
sample. Depending on the composition, this led to 
different amounts of ionizable or cationic lipid per 
well. The fluorescence is related to the amount of 
bound TNS which of course will be higher for more 
ionizable lipid. Then again, the fluorescence inten-
sity is normalised. Hence, influence of the absolute 
amount of ionizable lipid was not clear. Therefore, 
next experiments were carried out with focus on the 
amount of ionizable lipid. Furthermore, EPC 80 % 
as base lipid was exchanged with DOPC. For com-
parison, one formulation still contained EPC 80 %. 
Influence of lipid concentration should be investi-
gated as well. In addition to 22 µM, 222 µM as cati-
onic lipid concentration was tested as well. Further-
more, buffers contained 150 mM of NaCl to mimic 
physiologic conditions. All samples were measured 
in duplicates. Results are presented in Fig. 35. The 
expected decrease of intensity with higher pH val-
ues was not as obvious as with the previous experi-
ments. While formulation with EPC 80 % showed 
good results in previous experiments, a tendency of 
decrease was just slightly visible for 22 µM. A test 
with 222 µM led to no response. This phenomenon 
was also pronounced for all samples. In addition, 
high standard deviations impeded the evaluation.  
Table 20 shows a summary of the conditions used 
in the experiments with the help of two different 
compositions. The calculation can be seen under-
neath with the composition of 50 mg/ml 
EPC 80 % and 50 mg/ml DODMA as an example 
(Table 21). All samples were calculated in the same 
way.  
Figure 35: TNS assay of lipoplexes 
with DOPC, different amounts of 
DODMA with or without mRNA (test 
conditions 3) 
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Table 20: Different test condition for TNS assay 
# Composition 
Amount of 
formulation 
per 102 µl 
Conc. of  
cationic   li-
pid 
Conc. of  
total lipid Buffers 
1 50 mg/ml EPC 80 %, 
50 mg/ml DODMA 0.01616 µl 11.8 µM 22 µM 
3 – 10, 
no NaCl 
2 50 mg/ml EPC 80 %, 
50 mg/ml DODMA 1.614 µl 1.18 mM 2.2 mM 
4 – 10, 
no NaCl 
 90 mg/ml EPC 80 %, 
10 mg/ml DODMA 1.702 µl 250 µM 2.2 mM 
4 – 10, 
no NaCl 
3 90 mg/ml EPC 80 %, 
10 mg/ml DODMA 0.1505 µl 22 µM 0.19 mM 
4 – 9, 
150 mM NaCl 
 90 mg/ml EPC 80 %, 
10 mg/ml DODMA 1.5 µl 220 µM 1.9 mM 
4 – 9, 
150 mM NaCl 
 
Table 21: Calculation of formulation amounts needed for TNS assay 
- 22 µM of lipid in 102 µl solution in 96-well plate correspond to 0.000022 mol/l 
- 50 % EPC 80 % (MW = 768 g/mol) + 50 % DODMA (MW = 670.575 g/mol) result 
in an average MW of 719.288 g/mol  
- 719.288 g/mol * 0.000022 mol/l = 0.0158 mg/ml lipid concentration 
- 0.0158 mg = 1000 µl  0.001616 mg of lipid in a well with 102 µl  
- concentration of samples is 100 mg/ml  0.01616 µl of formulation for one well 
(Stock solution: 1.616 µl of sample in 1000 µl of water = 0.1616 mg/ml) 
- 0.01616 µl formulation correspond to 0.000808 mg DODMA (50 mg/ml per well 
- 0.000808 mg in 102 µl  0.00792 mg/ml  
- 0.00792 mg/ml correspond to 0.0118 mmol/l (MW of DODMA: 670.575 g/mol) 
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Determination of pKa 
The pKa represents the point with half of the maximum fluorescence and can be determined 
with the help of a sigmoidal fit (Boltzmann). Unfortunately, this fit converged just for the 
sample with 50 mg/ml DODMA. For the remaining formulations, the pKa could only be de-
termined manually at the normalised intensity of 50 %. In order to ensure comparability, all 
samples were evaluated in the same way.  
The listed values in Table 22 highlight several dependencies. The pKa was dependent on the 
amount of DODMA as higher properties shifted the pKa to smaller values. Furthermore, the 
complexation of mRNA had an influence. As long as there was an excess of ionizable lipid 
over mRNA, there was a left shift of the pKa. With equal amounts or excess of anionic charge, 
the pKa values were shifted to higher values. The exchange of EPC 80 % with DOPC as base 
lipid led to different values. Finally, the influence of the test conditions has to be evaluated in 
detail. The pKa of the formulation with 50 mg/ml DODMA fluctuated within one unit with 
different conditions. In contrast, the formulation with 10 mg/ml DODMA and 5 mg/ml 
mRNA were in the same range of pKa although measurements were performed with and with-
out addition of NaCl.  
The determination of the pKa for the formulations containing DOTMA was just possible for 
very few samples, as listed in Table 23. This was not surprising. Since DOTMA has a perma-
nently charged headgroup, a variation in the pH must not change the lipid status. 
The evaluated data showed quite high standard deviations. Hence, experiments need to be 
repeated under ideal conditions to proof the present results.  
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Table 22: pKa values for lipoplexes with EPC 80 % or DOPC, different amounts of DODMA 
with or without mRNA (measured with the test conditions listed in Table 20) 
Basis DODMA 
[mg/ml] 
mRNA 
[mg/ml] 
pKa 
Test condition # 1 
EPC 80 % 0 0 - * 
EPC 80 % 50 0 5.754 
Test condition # 2 
EPC 80 % 50 0 6.729 
EPC 80 % 50 5 6.065 
EPC 80 % 20 0 8.179 / 7.544 
EPC 80 % 20 5 7.142 / 6.997 
EPC 80 % 10 0 7.9 
EPC 80 % 10 5 8.502 
EPC 80 % 5 0 8.136 
EPC 80 % 5 5 8.904 
EPC 80 % 2.5 0 8.085 
EPC 80 % 2.5 5 8.687 
Test condition # 3 (22 µM) 
DOPC 20 5 8.839 
DOPC 10 0 8.396 
DOPC 10 5 8.336 
EPC 80 % 10 5 8.791 
Table 23: pKa values for lipoplexes with EPC 80 %, different amounts of DOTMA without 
mRNA (measured with the test conditions listed in Table 20) 
Basis DOTMA 
[mg/ml] 
mRNA 
[mg/ml] 
pKa 
Test condition # 2 
EPC 80 % 5 0 9.621 
EPC 80 % 2.5 0 9.783 
  Results 
 
115 
 
4.2.3  mRNA-release dependent structural changes 
I. Investigation on structural changes with SAXS 
After uptake into a cell, lipoplexes needs to be released out of the endosomes to have an effect. 
Since this release is crucial and formulations often end up being digested in the late endo-
some/lysosome, it has to be investigated more in detail. Furthermore, a change in the molec-
ular structure of liposomal systems is necessary to facilitate this release. Therefore, measure-
ments were done to investigate the structural changes after addition of heparin which mimic a 
cellular contact. Moreover, experiments were carried out at two different pH. pH 7.5 repre-
sented the condition around and inside the cell while pH 5 should mimic the acidic condition 
in the endosome. The experiments were carried out at the SAXS1 beamline at the LNLS in 
Campinas. Four different compositions were tested with either DOTMA or DODMA. Sam-
ples were mixed with the buffer and the adequate amount of heparin (fourfold excess of pos-
itive charge over the negative charge of the mRNA, neglecting the positive charge of the lipid). 
After mixing, samples were measured immediately which was around 60 to 90 sec and after 
2.5, 5, 10 and 20 min. Some samples were also measured after 40 min. Due to time and sample 
limitations; this was not possible for all samples. Data was treated in the same ways as before.  
Results 
116 
 
 
Figure 36: Peak analysis of lipoplexes with EPC 80 %, 10 mg/ml DOTMA or DODMA and 
5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 
In Fig. 36, results of the first two samples with 10 mg/ml DOTMA [top] or DODMA [bottom] 
and 5 mg/ml mRNA are shown. Data of pH 7.5 is on the left, data of pH 5 on the right side. 
The formulation with DOTMA can be seen on the top. For both pH, there were two lamellar 
systems with two orders around 60 to 80 Å. Peak areas for the 1st order had comparable values 
at the beginning. During time, the proportion of the lamellar systems shifted which led to one 
dominating lamellar system while the other one disappeared. For pH 7.5, this shift happened 
faster since the 2nd order peak 4 disappeared after 10 and 1st order peak 2 after 20 min. In 
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addition, peak area of peak 2 decrease continuously. At the scattering curve, this peak was still 
visible, but it was too small to be fitted. In general, the decrease of the peak areas indicated a 
disintegration of the system. For pH 5, both lamellar systems existed until 40 min. Just one 
2nd order peak disappeared after 20 min. The development of the peak areas underlined the 
shift since peak 3 increased while peak 1 decreased. Larger peak areas in comparison to pH 7.5 
indicated stronger structures for this pH.  
The sample with DODMA was just measured until 20 min which impeded a complete com-
parison. Two lamellar systems at the same range of d-spacing occurred. At pH 7.5, one lamellar 
order remained while peak 1 and 3 disappeared. Peak area of the dominating peak 2 got smaller 
as well which entailed a disintegration. Same happened for pH 5, but there were still two peaks 
at 70 and 80 Å. By a look at the scattering curve, these were no real peaks but part of a shoulder 
at the left side of the main peak. With the available data set, it is not possible to predict of the 
areas would increase after 20 min as it happened with the DOTMA sample at pH 5.  
More samples with 10 mg/ml of DOTMA or DODMA but just 2.5 mg/ml of mRNA were 
measured and illustrated in Fig. 37. First, it is obvious that the peak distribution changed for 
the formulation with DOTMA. Above all, smaller peaks could not always be fitted that accu-
rate as for the samples with higher amount of mRNA. The range of d-spacing enlarged from 
60 to 130 Å with four lamellar systems at pH 5 and three at pH 7.5. At acidic pH, two systems 
dominated at the beginning whereas one increased and one decreased during time, observable 
also by the change of the areas of peak 3 and 4. Moreover, some of the structures disappeared 
completely (peak 1, 5, 6). Scattering curve at pH 5 showed, that the shift of the two main peaks 
happened in the same way. By a look at the peak area, it is not so obvious since areas change 
similar. This can be due to the broadness of peak 2. 
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Figure 37: Peak analysis of lipoplexes with EPC 80 %, 10 mg/ml DOTMA or DODMA and 
2.5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 
Same sample with DODMA showed a peak pattern which is more comparable to the samples 
with 5 mg/ml mRNA. Two lamellar systems around 60 to 80 Å occurred while one of them 
disappear after 20 min for both pH 5 and 7.5. Peak areas at pH 5 were slightly smaller than 
pH 7.5 and both indicated the disintegration of the lamellar structures.  
With the next samples, illustrated in Fig. 38, the amount of DOTMA and DODMA was low-
ered to 5 mg/ml with 5 mg/ml mRNA. In general, scattering curves indicated, that the peaks 
of the 1st order were not separated. The range of d-spacing was slightly higher and ranged from 
60 to 90 Å, whereas there was also one peak at 120 Å for the DOTMA formulation at pH 5. 
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For the lipoplexes with DOTMA, three lamellar systems occurred over the whole time while 
the peak around 75 Å had no 2nd order. This peak was much lower than the two surrounding 
ones but had a much larger area after 20 min. One dominating systems at the beginning, re-
sulted in three quite consistent peaks which was underlined by the peak area (see peak 2, 3, 5). 
The peak pattern for pH 7.5 did not differ from the acidic pH. The scattering curve demon-
strated again a shift in the dominating lamellar system, which could be seen for both 1st and 
2nd order. Area of peak 1 and 3 were similar but drifted apart during time.  
 
Figure 38: Peak analysis of lipoplexes with EPC 80 %, 5 mg/ml DOTMA or DODMA and 5 mg/ml 
mRNA after addition of heparin in pH 7.5 and 5 
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The same composition but with DODMA showed clear differences between pH 7.5 and 5. 
For pH 5, two lamellar systems with 1st and 2nd order (around 65 and 82 Å) and one lamellar 
system in between at around 72 Å remained over the whole 20 min. One dominating system 
at the beginning, changed to three consistent systems after 20 min. The course of peak areas 
stressed this as well. By mixing this sample with pH 7.5, just two lamellar systems occurred 
where just one remained. Furthermore, peak area indicated a much larger 1st order peak in 
comparison to the other three peaks. Summing up, the diagram of the DODMA sample at 
pH 5 is comparable to the DOTMA sample both at pH 7.5 and 5. 
 
Figure 39: Peak analysis of lipoplexes with EPC 80 %, 2.5 mg/ml DOTMA or DODMA and 
5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 
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The amount of DOTMA or DODMA was again reduced to 2.5 mg/ml with a mRNA con-
centration of 5 mg/ml. Data are shown in Fig. 39. The lipid structures were really reduced 
within these samples. For both pH values, the formulation with DOTMA had just one lamellar 
system which remained constant during the time. The 2nd order always remained but could not 
be fitted for all data points. As expected, 1st order peak had a much larger area. The peaks were 
even broader at pH 7.5 with a slight tendency for peak splitting after 10 min.  
The sample with DODMA showed two lamellar systems in a smaller range of d-spacing 
(60 to 70 Å), which did not change in position or area during the time. The scattering curves 
revealed a huge peak splitting into two peaks at the top. This splitting was more pronounced 
at pH 7.5. In general, DODMA samples formed more accurate peaks than the DOTMA sam-
ples. 
II. Investigation of mRNA release  
In parallel to the SAXS studies concerning the structural changes, the RiboGreen® Assay was 
used to investigate the release of mRNA after a cellular trigger. Two formulations with 
90 mg/ml EPC 80 %, 2.5 mg/ml mRNA and 10 mg/ml of either DOTMA or DODMA were 
prepared as explained earlier. Samples were mixed with a buffer of pH 5 and an appropriate 
amount of heparin or DOPG (fivefold excess of positive charge over the negative charge of 
the mRNA, neglecting the positive charge of the lipid) and the resulting amount of free mRNA 
was detected at several time points after mixing. The formulation containing DODMA was 
tested over 120 min, while the lipoplex with DOTMA was tested twice over shorter intervals. 
Results are shown in Fig. 40. The amount of free mRNA at neutral pH and without the addi-
tion of heparin was set as starting point. Around 5 % of the added amount was determined as 
free which is quite low and in line with similar experiments performed with lipoplexes com-
posed of DOPC and DOTAP. After imitation of cellular contact by adding heparin or DOPG, 
an increase of free mRNA was observed. Heparin led to a higher release up to 18 % of the 
added amount of mRNA for both samples while the addition of DOPG just led to a doubling 
of the free mRNA.  
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Figure 40: mRNA release out of lipoplexes with EPC 80 %, 10 mg/ml DOTMA or DODMA and 
2.5 mg/ml mRNA after addition of heparin or DOPG 
4.3 DNA-lipoplexes  
As explained earlier, mRNA has several advantages over DNA. Despite, the usage of DNA 
for vaccination or related strategies is still common. Therefore, lipid systems were also utilised 
for the encapsulation of plasmid DNA (pDNA). The influence of several cationic or ionizable 
lipids, also in presence of DOPE, was investigated: DOTAP, DC-Chol, Didodecyl dime-
thylammonium bromide (DDAB), DOTMA and DODMA. Lipoplexes were composed of 
either 80 mol% EPC 100 % and 20 mol% of cationic or ionizable lipid or 60 mol% 
EPC 100 %, 20 mol% cationic or ionizable lipids and 20 mol% DOPE with 1 mg/ml of 
pDNA. For preparation, DAC was applied as described earlier.  
4.3.1  Characterisation of lipoplexes with different cationic lipids  
Determination of size and zeta potential was used for characterisation. Results are shown in 
Figs. 41 and 42. Except for DODMA, size was nearly 200 nm with a PDI ranging from 
0.2 to 0.3. Slight changes occurred with the addition of DOPE. Lipoplexes composed of 
EPC 100 % and DODMA had a size of 600 nm which decreased to 400 nm with the addition 
of DOPE. PDI changed from 1 to 0.6 through the presence of DOPE. Zeta potential was 
positive for all formulations. The combination of EPC 100 % and DOTAP showed the highest 
value around 50 mV while EPC 100 %, DC-Chol and DOPE achieved the smallest potential 
with nearly 25 mV. In general, zeta potential was lower for the formulations with DOPE. Just 
in the case of DODMA, it was the opposite.  
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Figure 41: Size distribution of lipoplexes with EPC 100 %, different cationic or ionizable lipids with 
or without DOPE 
 
Figure 42: Zeta potential of lipoplexes with EPC 100 %, different cationic or ionizable lipids with or 
without DOPE 
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4.3.2  Transfection efficiency in DC2.4  
The result of the transfection experiments with DC2.4 is depicted in Fig. 43. Transfection 
efficiency differed depending on the composition. Best transfection was caused by the positive 
control jetPEI® as none of the samples reach 100 % of transfection. Formulations with 
DOTAP, DC-Cholesterol and DDAB showed no significant effects. The formulations with 
DOTMA and DODMA caused a significant increase in the uptake in comparison to free 
DNA. The formulation with DOTMA and DOPE did not reach a significantly higher uptake 
than DOTMA without DOPE, while the formulation with DODMA and DOPE showed even 
higher uptake rates. Consequently, formulation with DODMA and DOPE was selected for 
further experiments. 
 
Figure 43: Transfection efficiency of lipoplexes with EPC 100 %, different cationic or ionizable lipids 
with or without DOPE 
4.3.3  Lipoplexes for transport of combined DNA vaccines 
In the human body, two main types of T-cells with different functions exist. The CD8+ cells, 
so-called cytotoxic T-cells, recognise infected cells after protein presentation of DCs and elim-
inate these. The CD4+ cells, so-called t-helper cells, release cytokines that affects the cellular, 
but also the humoral immune response. To investigate the effect of both cell types separately, 
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transgenic OTI (CD8+) and OTII (CD4+) mice were used. Since CD8+ cells are most important 
for the antitumour response, differentiation between proliferations of both types is necessary. 
Data is shown in Fig. 44. Comparing the different lipoplexes in OTI-cells, soluble OVA-pro-
tein together with the DNA of IκB kinase-β (IKK) showed higher efficiency than LPS with 
DNA coding for OVA. Two explanations are possible. Either IKK is a better activator than 
LPS or the intracellular production of OVA out of the DNA limit the effect of presentation 
followed by a lower immune response. Signal was highest for the combined application of the 
soluble forms of OVA and LPS. Since proteins do not have to localise in the nucleus for 
transcription and afterwards be translated, this result is not surprising. In OTII-cells, the high-
est signal was higher than any signal for OTI-cells. In general, CD4+ cells show a more unspe-
cific presentation of proteins, which explains this phenomenon. Again, the combined applica-
tion of OVA-protein and LPS showed a higher efficiency compared to OVA encoding DNA 
in lipoplex with LPS. Furthermore, LPS had nearly no influence on the efficiency of OVA in 
lipoplexes. Surprisingly, the best effect could be seen for the lipoplex with IKK in combination 
with soluble OVA. For CD4+ cells, IKK seemed to be a better DC-activator than LPS, even 
though it had to be transcripted and translated in DCs. Application of only IKK showed a low 
immune response for OTI- and OTII-cells, since there was no protein available for presenta-
tion on the cell surface. 
 
Figure 44: T-cell proliferation after transfection of DCs with different proteins and DNA in lipo-
plexes composed of 60 mol% EPC 100 %, 20 mol% DODMA and 20 mol% DOPE 
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5 Discussion 
Cancer is one of the most common cause of death worldwide. The current first-line therapies 
often entail adverse side effects and in addition, the high diversity of tumour cells lowers the 
therapeutic success. Within the research on alternative and more personalised therapeutic op-
tions, nucleic acids such as mRNA or DNA have gained much interest in the last years. The 
nuclei acids encode for proteins that target structures which are specifically expressed on tu-
mour cells. Thus, the healthy cells are less effected and severe side effects can be lowered. 
Using tumour vaccination as a therapeutic option, the immune system is trained to find and 
combat against tumour cells on its own. Thus, even small metastases which are difficult to 
localise with the current methods can be accessible.  
Although the application of naked mRNA or DNA is currently applied successfully, drug de-
livery systems offer several benefits. Depending on the properties of the vehicle, the nucleic 
acids can be encapsulated for protection and selective transport to various targets in the body. 
A huge number of different particles, mostly in the nanosized range, are available and investi-
gated intensively. Lipid-based nanocarriers constitute one option. Beside LNPs or micelles, 
lipoplexes show a great advance in the delivery of e.g. mRNA for therapeutic approaches. 
Lipoplexes normally consist of a zwitterionic base lipid and a cationic lipid which complex the 
anionic nucleic acid. A cationic charge is also necessary to facilitate a binding to the negatively 
charged cell membrane 169 so that particles are uptaken via endocytosis. 90,170 Unfortunately, 
just small amounts of the uptaken mRNA show a therapeutic effect because large amounts are 
trapped in the endosome. After uptake into the cell, nanoparticles are transported via endo-
some which gets more acidic during time due to the uptake of protons like H+ via an energy-
dependent proton pump. With the stage of late endosome or lysosome, nanoparticles will be 
destroyed. Hence, an endosomal release of the mRNA is crucial for a successful delivery. Cat-
ionic lipids have shown to favour this endosomal release by destabilisation of the endosomal 
membrane. 171–173  
As part of a drug delivery system, cationic lipids have three different functions which improve 
the transport and therapeutic effect of nucleic acids. In order to find the appropriate compo-
sition for the respective application, a detailed characterisation of formulations composed of 
cationic lipids and nucleic acids is required. In addition, a better understanding of the behav-
iour after application into the human body as well as at the point of action is needed.  
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5.1 mRNA-lipoplexes with cationic lipids  
Partial results of the presented work have been published in:  
Ziller, A.; Nogueira, S. S.; Huehn, E.; Funari, S. S.; Brezesinski, G.; Hartmann, H.; Sahin, U.; Haas, 
H.; Langguth, P. Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration. Mol. 
Pharm. 2017, acs.molpharmaceut.7b01022. 150 
For these studies, mRNA was incorporated into high concentrated lipid-based membrane sys-
tems for local administration. As zwitterionic base lipid, DOPC was chosen. For complexation 
of the negatively charged mRNA, cationic DOTAP as a commonly known transfection reagent 
was used. As mentioned earlier, DOPC forms only lamellar bilayers so that dissociation of the 
lipoplexes does not happen. 100 Furthermore, it does not fuse with the endosomal membrane. 90 
Hence, it was possible to investigate solely the influence of DOTAP on the uptake of the 
mRNA. Several different compositions were assembled to gain detailed information on the 
molecular structure. Formulations were prepared with an excess of either cationic lipid or neg-
atively charged mRNA to widen the portfolio of lipoplexes with different characteristics for 
various applications.  
5.1.1.  Development of a structural model 
The aim of these experiments was the controlled insertion of mRNA into highly-concentrated 
lipid matrices as well as a controlled release of mRNA at the point of action. For the insertion 
of the mRNA, the lipid film method was used. Afterwards, the insertion was proven with 
several experimental techniques. The amount of free mRNA was determined to investigate to 
which extend the mRNA is bound to the cationic lipid surface. The zeta potential was meas-
ured to define the overall charge. In addition, it can be used as an indicator for the stability of 
the formulation. SAXS was applied to obtain information on the structural assembly of the 
lipid layers. Using DSC, the phase transition temperature was measured to determine in which 
way the DOTAP is inserted in the DOPC matrix. As an indicator for the stability, it can be 
used to evaluate if the inserted mRNA disturbs the bond of the lipid membrane. For one 
composition, cryo-TEM pictures were taken to support the findings. The release of mRNA 
out of lipoplexes and hence, the functionality of the systems was demonstrated in cell culture 
experiments. Summary of all data led to the development of a concise model which explains 
the insertion of mRNA in the lipid bilayers (Fig. 45). As already mentioned earlier, the exact 
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position of the mRNA could just be assumed and not proven with the named methods. There-
fore, SANS experiments were performed additionally.  
  
 
Figure 45: Lattice model (top view) of lipid layers illustrating the tentative organisation of mRNA at 
the lipid layer [top] and side view of a lipid bilayer illustrating the insertion of a DOTAP molecule 
and a nucleotide into the lipid membrane [bottom] (drawn after 150) 
Structural changes between the individual samples could be observed by attractive or repulsive 
effects due to electrostatic interactions between the components. First of all, it could be shown 
that DOTAP was inserted homogenously into the DOPC matric. This is indicated by the mo-
notonous increase of the phase transition temperature with higher fractions of DOTAP 
(Ch. 4.1.3). If there had been a phase separation, phase transition would have taken place at 
the temperature of pure DOPC. Phase separation is an often observed phenomenon when 
mixing two different lipids 174,175, which can be induced by e.g. polycationic ions 176 or peptides 
or proteins. 177 In contrast, mRNA does not induce such a phase separation between DOPC 
and DOTAP.  
Furthermore, the influence of the electrostatic interactions on the structure is indicated by the 
enormous increase of the d-spacing, which led to a loss of correlation between the bilayers. 
Repulsive forces between the positive charges in the membranes after incorporation of 
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DOTAP can be named as a reason for that. In addition, the zeta potential changed from neg-
ative for pure DOPC to positive for the DOPC/DOTAP matrix (Ch. 4.1.2).  
If mRNA is present, systems with pure DOPC remain unchanged as it could be indicated by 
the d-spacing in the SAXS experiments (Ch. 4.1.1). This phenomenon could be explained by 
electrostatic interactions occurring between the charged moieties in the membranes. Lipids are 
amphiphilic molecules and self-assemble to bilayers while they are in contact with water. Alt-
hough EPC 80 % and DOPC have cationic headgroups, they do not interact with the nega-
tively charged mRNA because of their zwitterionic character. Consequently, there is no struc-
tural change in liposomes of these pure neutral lipids with or without mRNA. After incorpo-
ration of DOTAP, the presence of positively charged headgroup results in repulsion between 
the membranes and leads to a strongly extended d-spacing. In the presence of mRNA, the 
negative charge in the aqueous space between the membranes compensates the positive charge 
of DOTAP and shield the electrostatic repulsion. Consequently, d-spacing decrease and the 
lamellar structure is recovered. 
In case of the mixed lipid membranes, DOTAP acts as an anchor for the mRNA. 1/1 to 2/1 
was figured out to be the stoichiometric ratio between the positive DOTAP and the negative 
mRNA. Furthermore, the N/P ratio of DOTAP to mRNA was significant for the properties 
of the different formulations. On the one hand, there are lipoplexes with an excess of DOTAP 
and a N/P ratio higher than 1/1. These lipoplexes showed lamellar structures which are com-
parable to the lipoplexes of pure DOPC. The incorporation of mRNA into the lipid mem-
branes lead to a strong decrease in the d-spacing compared to formulations with DOPC and 
DOTAP. Hence, the negative mRNA is possible to compensate the repulsive interactions due 
to DOTAP in opposing membranes even in the presence of an excess of DOTAP with respect 
to mRNA. For these lipoplexes, the mRNA is completely inserted into the lipid membranes 
and bound to the DOTAP molecules. As shown in Ch. 4.1.2, the zeta potential is positive for 
all of these formulations which prove as well that the mRNA is inserted completely without 
any contact to the outer surface of the lipoplexes. In addition, no free mRNA could be de-
tected. Hence, the mRNA can be encapsulated without any influence on the distance between 
the bilayers.  
In contrast, some lipoplexes were prepared with an excess of mRNA and a resulting N/P ratio 
lower than 1/1. First, the amount of free mRNA increased which shows that not all of the 
mRNA is bound to the DOTAP molecules. In addition, zeta potential switched to negative 
values which means that mRNA is also located in the surrounding medium. Nevertheless, at 
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least a part of the excess mRNA seems to be inserted between the bilayer since the d-spacing 
increased with higher amounts of mRNA (Fig. 15). Nevertheless, as it can be derived from the 
following calculation, the mRNA can only account for a small fraction of the hydrophilic slab 
between the lipid bilayers:  
For all systems containing DOPC and DOTAP, the d-spacing is between 70 and 80 Å. Pure, 
dehydrated DOPC-MLV have a d-spacing of 40 Å, so that the water layer between the lamellae 
is 20 Å. The highest fraction of DOTAP was 10 mol%. With an estimated area per lipid of 
around 75 Å2 178, the hydrophilic volume of DOTAP can be calculated as: 
75 Å2 ∗ 10 ∗ 40 Å2 = 15000 Å3 
Equation 10: Available volume for a nucleotide when binding to one DOTAP molecule   
using 75 Å2 as the area per lipid, 40 Å as the d-spacing of dehydrated DOPC and the factor 2 
since two bilayers always share one hydrophilic slab. Factor 10 is used because one DOTAP 
molecule corresponds to nine DOPC molecules. A mRNA nucleotide binds just to DOTAP 
headgroups whereby the area of the DOTAP and the DOPC molecules can be occupied by 
one nucleotide. The results for different fractions of DOTAP are listed in Table 24.  
Table 24: Calculated volume fraction of the mRNA in the aqueous slab for different amounts 
of DOTAP (taken from 150) 
Fraction DOTAP 
[mol%] 
Area per DOTAP 
[Å2] 
Water slab volume 
/ DOTAP (20 Å) 
Volume fraction of 
nucleotide [%] * 
2.5 3000 60000 2.5 
5 1500 30000 5 
10 750 15000 10 
*(available volume per nucleotide about 15000 Å3) 
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In addition, the volume of a nucleotide can be calculated as:  330 𝑔𝑔𝑚𝑚𝑚𝑚𝐶𝐶1,5 𝑔𝑔𝑐𝑐𝑚𝑚3 ∗ 1024 Å3𝑐𝑐𝑚𝑚36 ∗ 1023 1𝑚𝑚𝑚𝑚𝐶𝐶 = 367 Å3𝑀𝑀𝑚𝑚𝐶𝐶𝐶𝐶𝑐𝑐𝑢𝑢𝐶𝐶𝐶𝐶 
Equation 11: Required volume of one nucleotide 
330 g/mol is the molar mass of one average nucleotide and 1.5 g/cm3 the density of the 
mRNA. 1024 presents the conversion factor from cm3 to Å3 since 1 cm3 is equal to 1024 Å3. 
Finally, division with the Avogadro constant leads to the volume which is needed per molecule.  
When comparing both values, the volume of one nucleotide is less than 10 % of the total 
available volume. Consequently, the mRNA in the bilayer is surrounded by a large excess of 
water. The mRNA is probably oriented flat on the surface of one bilayer forming clusters of 
negative charge which interacts with the positive charge of the DOTAP molecules. Further-
more, there seems to be no connection of two bilayers via the mRNA strand since the hydro-
philic slab in between is about 20 Å and one nucleotide is just about 5 Å.  
SANS was applied to prove the developed structural model. Unfortunately, the performed 
measurements are not sufficient to clarify the exact position of the mRNA (Ch. 4.1.6). The 
high content of trehalose, needed to stabilise the samples, hinders a complete evaluation of the 
current data. Nevertheless, first conclusions can be drawn. Differences in the peak distribution 
between the samples with low (2.5 mol%) and high (10 mol%) mRNA can be seen (Fig. 22). 
Nevertheless, evaluation seems to be easier for the sample with 10 mol% mRNA since data is 
more reasonable. In addition, the membrane span of the lipoplexes is larger in comparison to 
pure DOPC/DOTAP membranes (Table 16), so that the expected position of the mRNA on 
top of each bilayer side seems to be likely.  
Apart from that, SANS measurements revealed another interesting result. With the addition 
of the high content of trehalose, the d-spacing of the membranes changed depending on the 
composition of the sample. While pure DOPC led to smaller d-spacings, samples composed 
of DOTAP and mRNA showed larger d-spacings with existing trehalose (Fig. 26). Such an 
increase in the d-spacing after addition of trehalose was also recently shown by Al-Ayoubi 
et al.179 using lipid bilayers composed of dimyristoyl-phosphatidylcholine (DMPC). Trehalose 
concentrations up to 0.7 M increased the d-spacing. 179 A decrease of van der Waals attraction 
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forces between the lipid bilayers are named as a reason for that. 180 Al-Ayoubi et al. 179 applied 
trehalose concentrations (0.15 to 1.4 M) comparable to the ones used in this thesis 
(0.27 and 1.31 M) and, among other things, SAXS pattern was investigated. A low amount of 
trehalose (0.15 M) showed a broadening of the Bragg peaks indicating a loss of the multilamel-
lar structure while high contents of trehalose (1.1 to 1.4 M) led to a peak splitting in the gel 
phase. In addition, an inhomogeneous distribution of trehalose in the intermembrane water 
space which leads to the formation of coexistence regions is discussed. Regions with trehalose 
clusters having a high concentration result in a larger d-spacing in comparison to regions with 
a lower trehalose content. 179 Although the study of Al-Ayoubi et al. 179 is not completely com-
parable to the experiments performed in this thesis, the shown influence of trehalose on the 
properties of the lipid bilayers underlines the importance of a deeper investigation on treha-
lose-containing lipoplexes.  
As in many pharmaceutical applications, trehalose was added as a cryoprotector if lyophilisa-
tion is necessary to achieve a long-term sample stability. Due to this property, several studies 
were performed to understand the mechanism. With the addition of trehalose to a vesicular 
formulation, an osmotic pressure appears. In addition, simulations revealed a stabilisation due 
to a replacement of water in the region of the lipid headgroup. Concentration was higher at 
the bilayer surface than in the bulk of the water phase. 181–183 A study performed in 2014 by 
Kent et al.184 led to contrary results. Using SANS, a Gaussian distribution of trehalose with a 
higher concentration in the centre was found. The interaction of trehalose with the lipid head-
groups was low. In contrast to earlier studies, these experiments were performed in a dehy-
drated state with multiple membranes instead. Earlier studies 181–183 were mainly performed 
with highly hydrated single layers of SUV and LUV while the study from 2014 184 used dehy-
drated multiple layers which is more comparable to the actual system of highly viscous lipo-
plexes. The distribution of trehalose is dependent on the concentration. At low concentrations, 
sugars interact more with the lipid headgroups while at higher concentrations, some molecules 
are located in the centre of the water gap. 185  
Taking all these facts into consideration, the shown phenomenon of the trehalose has to be 
investigated more deeply since the influence of trehalose on the lipoplexes was not completely 
clear. In some of the experiments, differences between 0.27 and 1.31 M were visible and in 
others not. In addition, mRNA interacts with the lipid headgroups and hence, can act as a 
competitor of trehalose. Hence, also the presence of mRNA with different concentrations 
needs to be taken into consideration. Further experiments have to be performed to clarify the 
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insertion of the mRNA in the lipid bilayers and to model the different effects on the membrane 
structure indicated by the d-spacing below and above the charge equilibrium. In addition, the 
effect of trehalose on the lipid membranes has to be investigated more deeply at pharmaceu-
tically realistic high concentration. Therefore, small-angle neutron scattering with its possibility 
for contrast variation is a suitable method.  
5.1.2.  Comparison with lipoplexes for transport of other nucleic acids  
mRNA is one type of nucleic acids which can be incorporated in lipoplexes. In the past, more 
focus was on DNA and several methods were used for characterisation like SAXS 113,114,186 or 
freeze fraction electron microscopy. 187–189 The lamellar organisation is often found, which is, 
in accordance with a mathematical model applied by Dan et al.190, also the most probable 
structure due to its high stability. 190 Nevertheless, the hexagonal HII phase could be found as 
well. Some lipids like DOPE prefer this structure due to their shape so that the stability can 
even be higher than with the lamellar organisation. 191 In hexagonal systems, one DNA strand 
is surrounded by a monolayer of lipids which lead to the formation of cylindrical micelles. 
A monolayer of coated DNA cannot exist in solution, so by the interaction of the lipid layer 
with adjacent lipid layers, the structures connect among each other building a hexagonal lattice 
(“honeycomb”). 58,192 The void in such a micelle has a diameter of around 28 Å, which is again 
sufficient for embedding a DNA strand with two hydration shells. 112 Spaghetti-like structures 
were formed out of supercoiled DNA coated with a lipid bilayer and a total diameter of around 
130 Å. This structure was just visible with monovalent cationic lipids and also dependent on 
the ratio of DC-Chol:DOPE (1/4 to 3/2), while higher amounts of DOPE formed non-bilayer 
structures like the honeycomb. 188,193 Furthermore, these structures seemed to be just margin-
ally stable and always attached to larger liposomal aggregates. 191 Ewert et al.194 described an-
other structure in 2006. Polycationic lipids with 3 to 5 charges alone normally form micelles 
due to the size of the headgroup whereas they form lamellae in presence of DNA. Here, a 
formulation with 20 mol% of a synthesised lipid with a highly charged and hyperbranched 
headgroup led to a lamellar phase which was in coexistence with tubular micelles arranged in 
a hexagonal lattice. The interaxial distance of the micelles was about 81.5 Å. DNA rods were 
embedded in the interstices of the micelles. Since the diameter of micelles is about 41 Å, there 
was enough space for the DNA (25 to 30 Å) in between. 194 A comparable structure was already 
found in 1992 by Ghirlando et al.195 whereby the micelles were formed out of surfactants in-
stead of lipids. 195  
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siRNA is another often used nucleic acid. Bouxsein et al.196 prepared lipoplexes with DOTAP, 
DOPE and DOPC similar as described earlier for the DNA-lipoplexes. Combination of 
DOTAP and DOPE led to lamellar structures with low amounts of DOPE and to hexagonal 
structures with higher amounts of DOPE. Lipoplexes composed of DOTAP and DOPC 
showed lamellar structures with a membrane spacing of around 55 Å for a large proportion of 
DOTAP. With increasing amounts of DOPC, spacing increased first continuously and then 
rapidly for high proportions. This phenomenon was explained as a “pinched” lamellar phase. 
Locally enriched regions of DOTAP are formed and build an anchor for the siRNA. Domains 
rich in DOPC containing large pockets of water are located between domains rich in DOTAP 
which are pinched electrostatically by the siRNA. 196 Such pinched lamellar phases were also 
observed for complexes composed of the anionic polypeptide poly-L-glutamic acid (PGA), 
the neutral lipid dilauroyl-sn-glycero-phosphocholine (DLPC) mixed with the cationic lipid 
didodecyl dimethylammonium bromide (DDAB). 197 
Obviously, several structural organisations occur depending on the composition of the formu-
lation. For a proper comparison, it is necessary to compare the mRNA-lipoplexes to DNA or 
siRNA-lipoplexes with the same lipid composition. Several studies performed similar structural 
investigations on DNA-lipoplexes with DOPC and DOTAP. 112–114 In general, SAXS data re-
vealed multilayer structures with intercalated DNA in between the lipid membranes for these 
compositions. Lipoplexes showed the same peak distribution applied concentrated and diluted. 
First of these measurements were presented by Rädler et al.113 in 1997. Lipoplexes were pre-
pared by mixing a liposomal suspension (25 mg/ml) with a DNA solution (5 mg/ml). Differ-
ent L/D ratios (L=DOPC+DOTAP (1/1), D=DNA) were tested. For low DNA concentra-
tions (L/D=50), globules around 1 µm were visible. With the increase of the DNA concen-
tration, first chainlike structure (L/D=10) and larger aggregates (L/D=5) appeared. 
For L/D=2 with an excess of DNA, size of the complexes decreased again due to repulsion. 
Zeta potential showed a positive charge for L/D higher than 5 and a negative value for 
L/D lower than 5. D-spacing remained stable for different lipid to DNA (L/D) ratios around 
65.1 ± 2 Å. With 39 Å for the thickness of the lipid bilayer, the water gap was determined to 
be 26.1 ± 2.5 Å. A monolayer of DNA including the hydration layer is said to have a diameter 
of 20 Å so that the water gab is just sufficient for one DNA layer. In addition to the Bragg 
peaks, an intermediate peak caused by the DNA-interaxial spacing appeared (dDNA). While the 
spacing caused by the lipid membrane remained constant, the dDNA was around 35 Å for 
L/D lower than 5 and 46 Å for L/D higher than 5. An excess of either liposomes (L/D>5) 
or DNA (L/D<5) is a possible explanation for this phenomenon. 113 Based on this work, 
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Koltover et al.112 showed a similar d-spacing of 66.84 Å for the same formulations. 112 Instead 
of changing the DNA concentration, Salditt et al.114 varied the ratio of DOPC to DOTAP 
while keeping the ratio of DOTAP:DNA = 2.2 to ensure charge neutrality of all tested sam-
ples. With the increase of DOPC from a lipid mass ratio of 0 to 3, lamellar spacing increased 
from 57.8 to 70.3 Å while the interhelical spacing of the DNA increased from 26 to 54 Å. 
Lipid dilution led to an increase of both spacings due to an excess of lipids. 114 
DNA-lipoplexes are studied much more extensively 112–114,118,168,198, but similarities to mRNA-
lipoplexes studied in this thesis can already be seen. Both systems form lamellar structures 
which were affected by the composition. With higher amounts of DOPC, d-spacing of 
mRNA-lipoplexes increased. A possible explanation is lower electrostatic interactions between 
the cationic DOTAP and the anionic nucleic acids. This dilution effect occurred for lipoplexes 
with siRNA as well. In accordance with the developed structural model, the phenomenon of 
a pinched lamellar phase seems not to be likely because it was assumed that there is no con-
nection between opposing membranes. Furthermore, Schiessel et al.199 explained the pinching 
effect for rigid polyanions which would not be applicable for mRNA. 199 Nevertheless, it can-
not be excluded completely.  
However, distinct differences have to be considered for the design of dedicated delivery sys-
tems for mRNA. Like DNA, mRNA phases were organised lamellar with the mRNA sand-
wiched in the hydrophobic slab in between adjacent lipid bilayers. Differences can be seen in 
the detailed internal organisation of the mRNA in between the bilayers. Since mRNA is single-
stranded, it has a much lower secondary order than the double-stranded DNA which makes it 
more like a classical polyelectrolyte binding to a lipid membrane. 200 This higher secondary 
order of DNA caused the interhelical spacing and led to intermediate peaks in the scattering 
curves, which did not occur for mRNA or siRNA. Increasing amounts of DNA led to larger 
d-spacings while d-spacing of DNA-lipoplexes remained constant over a range of DNA con-
centrations. Instead, the interhelical spacing of the DNA rods decreased with more DNA 
which seemed to be logical due to higher packing because of less available space between the 
lipid bilayers. In mRNA-lipoplexes with DOPC and DOTAP, d-spacing increases with more 
mRNA as soon as there is an excess of mRNA (Fig. 15). A lack of available space is not likely 
to be the reason for that since d-spacing of pure DOPC-lipoplexes remained stable even with 
high amounts of mRNA. With pure DOPC, mRNA just floats in between the lipid membranes 
and is not attached to it because a cationic anchor is missing. With the introduction of DOTAP 
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as an anchor, mRNA is attached to one side of the membrane. The cationic charge is compen-
sated by the corresponding amount of mRNA while the excess of anionic charge of the mRNA 
strand led to electrostatic repulsion between the lipid bilayers. In contrast, an excess of 
DOTAP over mRNA led to the same d-spacing as for pure DOPC. A small amount of mRNA 
is necessary to shield the cationic charge of DOTAP.  
In contrast to many earlier studies using DNA or siRNA, only low fractions of mRNA were 
inserted into the hydrophilic slabs in a controlled manner since the used lipid matrix was highly 
concentrated. With the help of formulation parameters like N/P ratio or molar fraction of the 
cationic lipid, this insertion can be adjusted precisely. For DNA, it was possible to achieve an 
extensive insight into coherencies between the molecular organisation and formulation param-
eters could be obtained over the last years. 201–204 Further studies on the systems comprising 
mRNA are needed to clarify these correlations in comparison to the earlier studied systems. 
The insight and ability for accurate assembly of these delivery vehicles will be helpful for the 
rational development of novel mRNA nanomedicines.  
5.2 mRNA-lipoplexes with ionizable lipids 
Cationic lipids are associated with toxic effects which is due to different reasons. After appli-
cation into the bloodstream, positive charge can lead to aggregation due to attachment of com-
ponents like proteins on the surface of the particles forming a protein corona.205 The surface 
properties are modified which lead to a prolonged blood circulation combined with the inhi-
bition of the selective transport. At worst, huge aggregates can cause thrombosis since size can 
increase dramatically. The focus of this works was a local administration so that this problem 
could be neglected. Degradation of the lipids represents another drawback. Depending on 
their structure, some lipids like DOTMA are not biodegradable due to their ether as linker 
structure which can lead to an accumulation. In contrast, some structures like DOTAP with 
an esther as linkage structure are not stable enough so that a premature degradation is possi-
ble. 65 Despite all these drawbacks, cationic charged lipids are requisite for a cellular uptake and 
endosomal release. 173,206–208 Ionizable lipids offer a possibility to overcome this hurdle. De-
pending on the pH, such lipids can be both neutral or positively charged. At a pH around 7.4, 
the lipid is mainly neutral while it becomes cationic with an acidic pH. Consequently, the prob-
lem of aggregation could be avoided while the positive charge necessary for the endosomal 
release is still available. For evaluation of the potency of ionizable lipids, the ionizable lipid 
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DODMA and the corresponding permanently charged lipid DOTMA was formulated in lipo-
plexes and the investigated concerning their molecular organisation. 
5.2.1  pH-dependent structural changes 
First SAXS experiments (Ch. 4.1.1-I) were performed to evaluate whether there are differences 
in the molecular structure of lipoplexes upon incorporating a permanently charged or an ion-
izable lipid. Pure EPC 80 % was tested to ensure a pH-independent behaviour of the base lipid 
which could have been proven. Just a slight decrease of the d-spacing of one lamellar system 
occurred which is likely due to the composition of EPC 80 %. Besides 80 to 85 % of PC, there 
are around 7 to 9.5% of phosphatidylethanolamine (PE) and 2 to 3 % sphingomyelins in this 
lipid mixture. The remaining 5 to 10 % consist of other phospholipids, triglycerides and minor 
components like cholesterol. Due to its natural origin, the composition can vary within differ-
ent batches. This variation is also a possible explanation for the different peak appearance. 
When testing the ionizable lipids, pure EPC 80 % formed double peaks in SAXS (Ch. 8.1-I), 
whereas for the measurement of DOTAP as cationic lipid, EPC 80 % just showed single peaks 
(Fig. 14 [top left]). These double peaks appeared not only for pure EPC 80 % but also for the 
formulations with DOTMA or DODMA. Two lamellar systems which to some extent just 
varied slightly in their properties existed in parallel.  
Interestingly, EPC 80 % membrane behaviour differed after incorporation of DOTMA in 
comparison to DOTAP. A mixed membrane of EPC 80 % and DOTAP led to a loss of struc-
ture indicated by individual bilayer scattering (form factor) (Fig. 14 [top left]). With the incor-
poration of DOTMA, the lamellar system remained although the scattering peaks were less 
distinct as with pure EPC 80 % (Ch. 8.1-I with 0 mol% mRNA). An explanation for this 
phenomenon has to be found. DOTMA and DOTAP just differ in the linkage structure. The 
formulation of pure EPC 80 % with mRNA and either DOTAP or DOTMA demonstrated 
comparable bilayer properties. d-spacing was in the same range and showed the same depend-
ency. With an increase of cationic lipid, the distance between the bilayers decreased and with 
a higher content of mRNA, the d-spacing increased. Therefore, the varied structure of the 
linkage should not cause the above-mentioned variation. A possible explanation is the buffer. 
The samples with DOTAP were prepared in trehalose buffer and contained no salts which 
would otherwise compensate the charge of the cationic headgroups. Consequently, the strong 
membrane repulsion led to this loss of structure. The lipoplexes for the experiments with the 
ionizable lipids were prepared in a buffer containing EDTA and HEPES. The emerging ions 
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could operate as counterions to the cationic headgroups and hence, weaken the electrostatic 
repulsion between the lipid bilayers. After incorporation of mRNA, the effect of the buffer is 
negligible due to a higher charge of the nucleic acids. 
With higher content of cationic lipid, the systems achieved a more distinct order as indicated 
by four single peaks (Ch. 8.1-I). For DOTMA, this distinct order was visible for both pH 
values due to the permanent charge. Lipoplexes with DODMA just formed such a distinct 
order at pH 5. Despite, formulations with DODMA did not behave like pure EPC 80 % mem-
branes. It can be assumed, that DODMA is not completely uncharged at pH 7.5 so that low 
electrostatic interactions changed the scattering pattern in comparison to pure EPC 80 %. As 
expected, ionisation of DODMA changed dramatically at pH 5 leading to a similar scattering 
profile compared to samples with DOTMA. Nevertheless, slight differences like less orders of 
the DODMA systems compared to DOTMA are obvious. An incomplete ionisation of the 
headgroups at pH 5 seems logical if the expected pKa of DODMA incorporated into a lipid 
membrane is between 6 and 7. Hence, the protonation of DODMA is not completely compa-
rable to DOTMA at pH 5. The values for the d-spacing confirm this assumption. Formulations 
with DOTMA showed always slightly larger spacings in comparison to the same composition 
with DODMA, which can be explained with stronger repulsive forces due to a higher degree 
of protonation.  
Until now, only few studies focused either on the structural organisation of lipoplexes con-
taining ionizable lipids or their pH dependent behaviour. In 2004, Li et al.209 investigated the 
influence of DODMA on the structure of dipalmitoleoylphosphatidylethanolamine (DPOPE) 
membranes. Already 2 mol% of DODMA induced the transition from Lα to HII phase which 
happens due to interactions between the positive charge of the amino group of DODMA and 
the negative charge of the phosphate group of DPOPE. 209 Such a transition was not visible 
for the lipoplexes composed of DODMA, DOTMA or even DOTAP. This can be due to the 
different base lipids since PC and PE membranes differ in their lipid shape and hence, in their 
preferred structure. In comparison to DOPE, DOPC hinders cationic lipids to induce a non-
bilayer structure. 96 
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5.2.2  Determination of pKa  
For the application of ionizable lipids, a detailed investigation of this pH-dependent behaviour 
is necessary. The pKa value is defined as the point where half of the molecules are charged and 
hence, represents a suitable parameter for the transition from mostly neutral to cationic.  
The study of Jayaraman et al.148 mentioned earlier in 1.4.5, shows that the pKa is an essential 
parameter for the efficiency of formulations with ionizable lipids like DODMA. Hence, deter-
mination seems reasonable to achieve a predictive indicator for the in vitro and in vivo activity. 
Jeffs et al.101 reported a pKa of 6.8 for DODMA incorporated into a lipid bilayer composed of 
Chol/DSPC/DODMA/PEG-S-DSG (55/20/5/10 mol%) 101 while Heyes et al.147 measured 
a surface pKa of 7.0 for stabilised nucleic acid lipid particles (SNALP) composed of 
DSPC/Chol/PEG-C-DMA/DODMA (20/48/2/30 mol%). 147 
pKa determination of the pure ionizable lipid makes only limited sense since it is normally 
applied in combination with other lipids. This raises the question whether the properties of 
the ionizable lipid remain or change under the influence of other components. Additionally, 
mRNA bound to the ionizable lipid must be taken into consideration as well. These questions 
were answered already by Pierrat and Lebeau 149 in 2015. Several ionizable compounds with 
varying headgroups were synthesised and tested. A formulation with DOPC and 10 mol% of 
an ionizable compound resulted in a pKa of 7.01 149, whereas the same percentage of this ion-
izable lipid led to a pKa of 6.58 in combination with EggPC and cholesterol. 210 In addition, a 
complexation of DNA (N/P=3) caused a left shift with a decrease of the pKa from 8.25 for 
the pure liposomes composed of DOPC and 10 mol% of another synthesised ionizable lipid 
to 7.44 for the lipoplexes. This could be due to changes in the lipid arrangement or a less easily 
protonation of the ionizable lipid due to the electrostatic interactions with the DNA. 149 
The suitability of the TNS assay was proven by Pierrat and Lebeau 149 who showed an influence 
of the composition and the encapsulation on the pKa of the ionizable lipid as mentioned al-
ready above. Moreover, the ionisation was dependent on the concentration. An increase of the 
ionizable lipid from 10 mol% to 90 mol% led to a decrease of the pKa from 7 to 4.88 what can 
be explained with stronger repulsive forces due to shorter distances between the ionizable 
headgroups. This is also a suitable explanation for the drop of the pKa from 6.84 to 5.67 after 
exchanging DOPC with DPPC. For DOPC, the surface per molecule is larger (0.57 nm2) in 
comparison to DPPC (0.41 nm2) which leads to a shorter mean distance between to ionizable 
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headgroups and results in stronger repulsion. In contrast, the addition of NaCl to the test 
medium just led to negligible changes in the pKa. 149  
The mentioned studies proofed, that the composition of the lipid bilayer, as well as the com-
plexation with nucleic acids, has an influence on the ionisation of the ionizable lipid. Hence, 
the pKa needs to be evaluated for the different compositions.  
At the moment, there are no available studies on the pKa determination of mRNA-lipoplexes 
with DODMA as ionizable lipid, so the actual data can just be compared with formulations 
containing siRNA or DNA. The measured pKa value of the present study had several depend-
encies as it was mentioned in earlier studies before. 101,147,149 Higher amounts of DODMA led 
to a shift of the pKa to lower values as is was also shown by Pierrat and Lebeau. 149 The more 
ionizable headgroups are incorporated into the lipid membrane, the more difficult it gets to 
ionise each headgroup and a higher hydrogen ion concentration is needed. Changing the base 
lipid from EPC 80 % to DOPC decreased the pKa from 8.791 to 8.336.  
Comparable to DNA, the complexation of mRNA in this thesis caused a left shift of the pKa 
as long if there is an excess of ionizable lipid (Table 22). Possibly, protonation of the free 
remaining headgroups of DODMA is impeded due to the local attachment of mRNA to the 
lipid membrane. Surprisingly, equal or higher amounts of mRNA led to a higher pKa. This 
would mean that TNS is able to replace mRNA out of the electrostatic interaction with 
DODMA. The left shift of the pKa for samples with an excess of ionizable lipid does not 
necessarily indicate this replacement. Mutual impairment or structural changes like higher d-
spacing due to a higher content of mRNA could lead to a more easy excess of TNS to the 
membrane surface. Nevetherless, this phenomenon was just tested with lower amounts of 
DODMA where higher standard deviations were observed. Hence, these experiments need to 
be repeated with higher amounts of ionizable lipids to achieve better certainty of results.  
Finally, test conditions may not be neglected but their influence is not completely clear until 
now. 10 % DODMA with 5 % mRNA led to similar pKa values when tested with 250 µM of 
ionizable lipid per well (8.502) and with 22 µM of ionizable lipid with the addition of 150 mM 
NaCl (8.791). In contrast to 50 % DODMA, the pKa value changed intensively from 5.754 
when testing 11.8 µM to 6.729 after application of 250 µM of ionizable lipid per well.  
In addition to the TNS assay, SAXS measurements were used to determine the pKa as well 
(Table 18). The previous experiments revealed structural differences of formulations 
containing DODMA at pH 7.5 and 5. The change is caused by a higher grade of protonation. 
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The pKa can be interpreted as a point of structural transition since 50 % of the headgroups are 
charged when reaching this pH.  
SAXS data underlined a dependency on the composition of the lipoplexes. For the samples 
with EPC 80 % as base lipid, a distinct transition was justed visible for 10 % DODMA and 
10 % mRNA. At pH 6, peaks got lost and two lamellar systems fused together forming one 
new lamellar system as indicated by the d-spacing and the peak area. Lower amounts of 
DODMA and/or mRNA showed a gradual transition where structures disappear in the acidic 
pH between 5.5. and 4.5. Using the TNS assay, the formulation with 10 % DODMA and 
5 % mRNA revealed a pKa of 8.5. This pH was not tested with SAXS but it is unlikely, that 
there would be structural changes at an alkaline pH.  
Previous studies discovered that a higher content of DODMA is necessary to achieve a highly 
ordered system (Ch. 8.1-I). The same applies to the pH-dependent transition. Although 
lamellae can also be formed solely by base lipids like EPC 80 % or DOPC, charges are 
necessary to achieve a pH-dependent response. In addition to the content of the ionizable 
lipid, the mRNA concentration may not be neglected as there were also differences of samples 
between 5 and 10 % mRNA. Finally, the interplay between the anionic and cationic charges 
constitutes the driving forces for the structural changes of the membranes due to pH 
variations. 
The replacement of EPC 80 % (Ch. 4.2.1.-I) by DOPC (Ch. 4.2.1.-II) led to lipoplexes with a 
higher order of structure. Furthermore, the data underline the contribution of the mRNA to 
the formation of the lamellar system. The formulation without mRNA shows broad SAXS 
peaks at acidic pH due to electrostatic repulsion between the bilayers whereas this 
phenomenon does not occur if mRNA was present. The transition of these systems was 
characterised by a peak fusion which occurred at higher pH values in comparison to samples 
with EPC 80 % (Table 22). The formulation with 10 % DODMA showed fusion at pH 7 while 
peaks of the sample with 20 % DODMA fused slightly earlier. Using the TNS assay, the 
determined pKa values of the identical samples were a bit higher but showed the same 
tendency. 20 % DODMA had a pKa of 8.839 and both samples with 10 % DODMA a pKa 
around 8.3. to 8.4. These results are in contrast to the TNS data of lipoplexes with EPC 80 %, 
where higher content of DODMA led to lower pKa values.  
Summing up, the molecular structure of the lipoplexes differed with a varied pH while this 
change was dependent on composition or test conditions. The expected pKa of DODMA 
containing formulations is between 6 and 7 which was also proven in earlier studies. 101,147 The 
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TNS assay revealed pKa values between up to 8.9 which seem to be way too high. A pKa higher 
than 7 would result in a stronger protonation of DODMA after application in the bloodstream 
so that there will not be any advantages over DOTMA. The same can be applied for the high 
pKa values for the formulations with DOPC determined by SAXS. Nevertheless, the scattering 
data of the EPC 80 %-containing lipoplexes showed that the transition of the lamellar system 
can also take place in the desired pH range.  
In addition to the TNS assay, other methods like the incorporation of a pH-responsive 
membrane label can also be used to determine the pKa. First experiments with the fluorescent 
lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(carboxyfluorescein) (PE-CF) were 
performed. Since the dye is covalently bound to a lipid, correct location is assured. 
Carboxyfluorescein is a hydrophilic molecule so that it will not interact with the lipophilic part 
of the membrane but reflect only the changes in the hydrophilic area close to the bilayer 211,212. 
PE-CF was incorporated into the lipid film with a concentration of 0.1 % of total lipid 
concentration. Samples were treated the same way as with the TNS assay and fluorescence 
intensity was measured afterwards. Due to protonation, fluorescence differs depending on the 
pH. Unfortunately, the signal was too low for an analysis so that the concentration needs to 
be higher to obtain the desired results.  
5.2.3  Release dependent structural changes 
For further characterisation of the lipoplex formulations, it is important to evaluate the pH 
dependeny of the ionizable lipids. Moreover, it is necessary to understand their behaviour after 
cellular contact. In conventional cell experiments, structural properties cannot be determined. 
Therefore, cellular contact has to be mimicked within the experiments allowing a suitable 
characterisation. For these studies, SAXS was used again and the cellular contact was mimicked 
with the addition of heparin as depicted in Figs. 36 to 39. 95,213 Samples mixed with the 
appropriate amount of heparin were measured time-dependent in pH 7.5 and pH 5 to 
investigate their behaviour at cellular contact and in the endosome.  
In additional experiments, the release of mRNA after mixing with an acidic pH buffer and 
heparin was tested (Fig. 40). DOPG was tested in comparison since anionic lipids or liposomes 
are also used for mimicking cellular contact. Although the test conditions were slightly changed 
in comparison with the scattering experiments, the outcome can be used for first orientation. 
An increase of free mRNA was visible over time but, with a maximum of 18 % of the added 
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mRNA, it was lower than expected. However, mRNA was released and, probably, the low 
amounts of mRNA are enough to induce endosomal release and effective translation. The 
starting point was determined at neutral pH, so mRNA release could also be triggered by the 
acidic pH. Therefore, it has to be evaluated if the acidic pH, heparin or the combination of 
both is needed. Nevertheless, lowering the pH leads to protonation of DODMA which would 
cause an electrostatic interaction with the mRNA. Hence, stronger binding to the lipid 
membrane is more likely than a release of the mRNA. In addition, release could also be shown 
for the DOTMA-containing formulation. The pH should not have a large influence on 
permanently charged lipids. Presumably, the pH buffer alone cannot cause a release of mRNA 
out of the lipoplexes.  
Some findings from the previous studies could be confirmed. Higher amounts of cationic or 
ionizable lipid, as well as mRNA, are necessary to achieve a highly structured lamellar system. 
This was characterised by a lower amount of coexisting lamellar systems and more single and 
pronounced SAXS peaks. Furthermore, evaluation of broader peaks, which arise for 
formulations with a low amount of cationic lipid, can affect the analysis and have to treated 
with caution. Structural changes were characterised by the loss of lamellar systems and varying 
SAXS peak areas which indicate expansion or reduction of one system. Interestingly, 
membrane d-spacing only changed slightly over time. A sufficient amount of cationic lipid was 
also necessary for a response to the addition of heparin. Samples with 2.5 % DOTMA or 
DODMA showed nearly no change over time.   
The data showed that the lipoplexes containing DOTMA behaved similarly when mixed at 
pH 7.5 and 5. The present lamellar systems remained over time and just changed in their 
proportion as indicated by the SAXS peak areas. Slight differences in the peak pattern occurred 
only for the formulation with 10 % DOTMA and 2.5 % mRNA. It was to be expected, that 
DOTMA-containing formulations behave similarly since the pH is supposed to have no 
influence on the protonation of the headgroup. Nevertheless, slight differences arose and 
indicated more stable lipoplexes at pH 5. Probably, the higher amount of free protons interact 
as well with the anionic nucleotides connected to the lipid membrane and hence, stabilise the 
whole system by changing the electrostatic interactions between the lipid bilayers. 
Furthermore, interactions between the free protons and the negatively charged heparin, leading 
to lower impact of heparin, cannot be excluded.  
The formulations with DODMA showed more variations between neutral and acidic pH 
which can be seen for 5 % DODMA and 5 % mRNA. Whereas just one lamellar system 
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remained over the whole time for pH 7.5, three systems occurred for pH 5. The SAXS peak 
pattern at pH 5 was comparable to the pattern of the same sample with DOTMA at neutral 
and acidic pH. This was to be expected since the headgroup of DODMA is protonated at 
pH 5 and DODMA should act like DOTMA. At pH 7.5, DODMA is nearly uncharged and is 
supposed to act more like a pure EPC 80 % membrane. However, the present lamellar systems 
with additional d-spacings around 80 to 90 Å do not occur for pure EPC 80 % membranes as 
shown earlier (Fig. 27). Hence, DODMA has also an influence at neutral pH which can be due 
to some already protonated headgroups. Nevertheless, the described phenomenon is not 
clearly visible for all compositions. Moreover, the samples with 10 % DODMA have smaller 
peak areas for both pH values which indicate lower amounts of ordered structures in 
comparison to DOTMA-containing lipoplexes. Consequently, the properties of DODMA at 
pH 5 cannot be compared completely with the properties of DOTMA. The same results were 
also found earlier in these studies.  
After cellular uptake of lipoplexes, cationic lipids mix with the anionic lipids of the endosomal 
membrane, form ion pairs and hence, mRNA is released (Fig. 6). The formation of the ion 
pairs is accompanied by the formation of inverse hexagonal structures. 96 Unfortunately, such 
lipid structures could not be found in the experiments. The addition of heparin led to changed 
d-spacings and loss of lamellar structures but not to an inversion to other lipid structures. 
Heparin mimics cellular contact due to its high negative charge. Nevertheless, negatively 
charged lipids for the formation of ion pairs were not present. This can be a reason for the 
lack of inversion. Hence, the addition of negatively charged lipids through membrane mimick-
ing liposomes (MML: PC/PE/PS/cholesterol of 45/20/20/15 w/w) 214 or pure DOPG would 
be a possibility to test if the inversion takes place if negative lipids are present. First release 
tests with DOPG have already been performed, but further experiments with SAXS and SANS 
are reasonable. 
Summing up, heparin induced changes in the molecular organisation of the samples, but these 
changes were different than expected. Presumably, an anionic trigger and the acidic buffer is 
necessary to induce a release. Despite, the impact of both factors has to be investigated 
separately as well.  
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5.3 DNA-lipoplexes  
The herein applied lipoplexes are aimed as drug delivery system for a personalised immuno-
therapy. However, most of the presented studies focused on the characterisation of the lipo-
plexes instead of the biological functionality. In this context, lipoplexes with similar composi-
tions incorporating DNA were prepared to investigate their vaccination potential. Instead of 
the lipid film method, samples were prepared with the DAC as a new technique. Since APCs 
play a major role for the antigen-specific primary immune response 215, DCs were used instead 
of C2C12 murine myoblasts.  
DAC facilitates RNase- and DNase-free conditions together with very small batch sizes in a 
simple and fast manner. 216 Hence, it supports the suitability of lipoplexes for individual im-
munotherapy. EPC 100 % was used together with different cationic lipids. Lipoplexes had a 
defined size and zeta potential (Fig. 41 and 42) and showed transfection in DCs depending on 
their composition (Fig. 43). The compositions with DODMA led to larger vesicles. One pos-
sible explanation can be the absence of electrostatic interactions due to low protonation of 
DODMA at neutral pH, although this is conflicting with the high zeta potential values for 
these compositions. A similar behaviour occurred for lipoplex with DC-Chol. Because it is a 
tertiary amine like DODMA, a lower potential due to less protonation would have been ex-
pected. Zuidam and Barenholz 217 found out, that DC-Chol in a 1:1 with DOPE is just proto-
nated 50 %. 218 This is also reflected by the decrease of zeta potential after addition of DOPE. 
Large particles are said to have higher transfection efficiency as shown by several studies 133–
135,137,138,219,220, although the highest transfection was not caused by the largest particles in the 
present study. Probably, the combination of size and composition resulted in the better trans-
fection. 
DOPE is said to be necessary for a successful transfection and hence, investigated intensively 
to find the most effective composition. 95,98,100 For lipoplexes composed of DC-Chol and 
DOPE, effective ratios were 3/2 and 1/1 while 1/2 worked even better. 221,222 In the present 
study, the addition of DOPE just led to minor changes in characteristic as well as transfection 
efficiency (Figs. 41 to 43), although the ratio of 1/1 was applied. Probably, the absolute amount 
of cationic lipid and DOPE was too low since both components represented just 40 mol% of 
the entire formulation. In the above named studies with the tested ratios of 3/2 to 1/2, DOPE 
and DC-Chol were used without the addition of a base lipid. 221,222 At least the combination of 
DODMA and DOPE resulted in higher activity which can be explained through an interplay 
Discussion 
146 
 
between the fusogenic properties of DOPE, the lower toxicity of DODMA due to lower pro-
tonation and the larger size of the vesicles. For a better estimation of the transfection activity, 
lipofectamine can be used as a positive control since jetPEI® as a polyethylenimine derivative 
cannot be completely compared to lipid-based formulations. Finally, it was shown that lipo-
plexes increase the uptake of DNA into cells, while the choice of cationic lipid as well as the 
addition of DOPE influences this uptake.  
Transfecting APCs is a prerequisite for a successful therapy, but it is even more important that 
transfection leads to presentation of the antigen on the cells surface followed by an activation 
of T-cells which starts the immune reaction. Besides presentation of only the tumour protein, 
additional application of a DC-activating molecule is said to achieve a higher transfection effi-
ciency and to overcome the problem of tolerance development. 223 Lipoplexes composed of 
EPC 100 %, DODMA and DOPE incorporating DNA of either the model antigen OVA or 
the activator IKK were applied in different combinations with the protein itself. Higher im-
mune response is accessible with the application of a DC-activating molecule (Fig. 44). Above 
all, for CD4+ cells, IKK seems to be an alternative to the conventional LPS. Since CD8+ cells 
are more important for the antitumour response, the influence of IKK has to be investigated 
precisely. One possibility is the formulation of OVA and IKK as DNA encapsulated in the 
same lipoplex while it is also possible to use LPS in such a delivery system. 
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6 Conclusion  
The formulation and structural characterisation of mRNA-lipoplexes for tumour vaccination 
as a new strategy for cancer therapy was the main objective of this thesis. Personalised thera-
pies offer a chance to overcome low response rates of the current first-line. The mRNA en-
codes for proteins that are specifically expressed on tumour cells. A delivery system is benefi-
cial to ensure a targeted transport and to mediated cellular uptake and endosomal release. Li-
pid-based systems were chosen as drug delivery particles due to their high biocompatibility 
together with a low immunogenicity and toxicity. In order to find a suitable formulation for 
each application, a detailed investigation on the molecular structure of the lipid systems after 
insertion of the mRNA as well as the evaluation of the formulations’ behaviour after admin-
istration into the human body is necessary.  
The majority of the studies performed on structural elucidation of lipid-based systems focused 
only on lipoplexes with DNA. Several advantages of mRNA over DNA justify the use of 
mRNA and also a detailed structural investigation of these lipoplexes. 1,2-Dioleoyl-3-trime-
thylammonium-propane (DOTAP) was chosen as a classical and well-known transfection re-
agent. Embedded in a highly concentrated matrix of neutral lipids like Egg-Phosphatidylcho-
line (EPC) or 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), DOTAP served as an an-
chor for the mRNA.  
The molecular assembly of the lipid membrane systems were characterised with small-angle 
X-ray scattering (SAXS). Zeta potential and the RiboGreenTM Assay was used to evaluate the 
overall charge and the localisation of the mRNA inside of the lipoplexes. The influence of the 
mRNA on the lipid membrane was evaluated with differential scanning calorimetry (DSC). 
The overall molecular organisation was found to be lamellar whereby the exact structure, re-
flected by the membrane distance of multilayer vesicles (d-spacing), was dependent on the 
ratio between DOTAP and mRNA (N/P ratio). Although there was always an excess of water 
in the hydrophilic space between the bilayers, the amount of mRNA affected the d-spacing in 
an analytical manner. In cell culture experiments, the release and the functionality of the 
mRNA was shown and transfection efficiency was dependent on the amount of DOTAP. 
A structural model could be developed where the mRNA forms cluster only on one side of 
the bilayer. The exact position of the mRNA has to be proven in further experiments.  
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Unfortunately, cationic lipids are associated with toxic effects, but the cationic charge is essen-
tial. Hence, ionizable lipids with a pH-dependent charge are used to reduce this toxicity and 
avoid aggregation after administration. At a neutral pH, lipids are expected to be nearly charged 
neutrally whereas at an acidic pH, the headgroups get protonated. For deeper investigation of 
the molecular organisation and its pH-dependent changes, 1,2-Dioleoyl-N,N-dimethyl-3-ami-
nopropane (DODMA) was utilised as ionizable lipid together in comparison to the perma-
nently charged lipid 1,2-Di-O-octadecenyl-3-trimethylammonium-propane (DOTMA). 
A highly concentrated matrix of EPC and DOPC was selected and various compositions were 
tested. As expected, the structure of DOTMA-containing lipoplexes was independent of the 
pH. Lipoplexes with DODMA changed in their appearance. At neutral pH, less ordered sys-
tems occurred. However, the structure was not completely comparable to pure EPC-contain-
ing lipoplexes. At acidic pH, the structure of lipoplexes was comparable but not identical to 
DOTMA-containing systems. Hence, DODMA has a slight charge, even at neutral pH but it 
is not completely charged at acidic pH. The pKa as a characteristic parameter was measured 
with two different methods over a pH range of 3 to 10. With the TNS assay, explicit 
determination was just possible for 50 % DODMA. Using SAXS, samples showed a pH-de-
pendent characteristic behaviour but a relatively accurate determination of pKa was just possi-
ble for the lipoplexes with DOPC. Despite, clear structural changes occurred in the expected 
pH range of around 6. Cellular contact and endosomal release should be mimicked with the 
addition of heparin. Lamellar systems remained over the whole time and varied just in their 
number and proportion. A transformation into inverse hexagonal structures as it would be 
expected during the endosomal release, could not be observed.  
The advantage of ionizable lipids as well as the positive influence of 1,2-Dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE) on the transfection were proven in cell culture with encap-
sulated DNA. The immunological potential of lipoplexes was shown by the activation of im-
mature dendritic cells (DCs). The dual asymmetric centrifuge (DAC) could be introduced as a 
new and feasible preparation method for the encapsulation of nucleic acids in liposomes.  
Summing up, mRNA- as well as DNA-lipoplexes offer great possibilities for the individual 
approach of tumour vaccination. The obtained results for the structural characterisation have 
to be completed with more in vitro and in vivo data to get a better understanding of all the 
chances offered by this pharmaceutical product. 
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7 Outlook  
The aim of this thesis was the detailed characterisation of lipoplexes for tumour vaccination. 
With all the performed experiments, a structural model of mRNA-lipoplexes composed of 
DOPC and DOTAP was developed. Nevertheless, further experiments are necessary to clarify 
open questions. SANS measurements have to be repeated to prove the exact position of the 
mRNA inside of the lipoplexes. In this context, the influence of the trehalose has to be evalu-
ated at pharmaceutically realistic concentrations as well since sugars are often added due to 
their cryoprotectant properties. In addition to the scattering experiments, microscopy tech-
niques are a good option to investigate the overall structure of the MLV. Cryo-TEM is more 
useful for a qualitative analysis, while techniques like SAXS or SANS provide more quantitative 
information. Despite, cryo-TEM implies direct imaging, so that the analysis is easier in com-
parison to indirect methods like SAXS which are more complicated in case the sample contains 
aggregates or has a broad size distribution. Therefore, cryo-TEM pictures for more than the 
one test composition are beneficial. In addition, freeze-fracture electron-microscopy is another 
suitable option to gain useful information on the appearance of the formulations.  
In addition to a further characterisation, improvements of the composition of the lipoplexes 
are conceivable. Lipoplexes transfected C2C12 cells, but a higher transfection would be pref-
erable. Hafez et al.96 showed that DOPC, formulated with DOPS alone and together with 
DODAC, impeded the endosomal release by stabilisation of the bilayer structures. For a suc-
cessful release of the mRNA, the formation of inverted hexagonal HII lipid phases by the 
formed ion-pairs between cationic lipids of the delivery system and negative lipids of the en-
dosome is necessary. The addition of DOPE to DOPC-containing lipoplexes resulted in a 
promotion of the HII lipid phase. 96 Hence, the addition of DOPE to the tested lipoplexes 
would be an opportunity to induce higher transfection efficiency. Further lipids like cholesterol 
can also be used to increase the stability of the systems 224 or increase the circulation time by 
PEGylation 225 for a possible i.v.-injection.  
The addition of DOPE would also be a feasible improvement for the lipoplexes containing 
DODMA as ionizable lipid. Mimicking cellular contact by addition of heparin and triggering 
an endosomal release by decreasing the pH of the buffer, the lamellar system of the lipoplexes 
vanished to a certain amount. Nevertheless, the hexagonal structures supporting the endoso-
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mal release did not appear. Hence, the addition of DOPE could favour the formation of hex-
agonal structures. Furthermore, mimicking of cellular contact can also be performed with 
DOPG or MML instead of heparin to test if this results in a different structural arrangement 
of the lipoplexes. In addition, the release of mRNA has to be tested more detailed and results 
have to be linked to the scattering data. First tests where the free amount of mRNA was tested 
after addition of heparin and DOPG were performed. These tests have to be extended to 
lipoplexes with various N/P ratios to see possible differences between an excess of mRNA or 
ionizable lipid.  
In later investigations concerning the pKa of the lipoplexes, it has to be analysed if the 
determined pH is the actual pKa or if it is the pH where the protonation of DODMA is 
sufficient to cause structural transitions. Perhaps, less than 50 % protonation is enough to 
induce modifications. Furthermore, it has to be clarified which level of protonation is really 
needed for cellular uptake as well as which grade forces an endosomal release.  
To ensure a high encapsulation efficiency, the prepratation with ionizable lipids should be 
done under acidic conditions. Afterwards, a neutral pH for application can be adjusted by 
dialysis. For the present studies, this procedure was not possible due to the lipid film method. 
For further studies, such an improvement is possible by choosing another preparation method. 
Most of the lipoplexes for this thesis were prepared by the lipid film method. For an industrial 
manufacturing, this method is not beneficial. Other techniques like ethanol injection 101 or 
DAC 216,226 with the possibility for a scale-up would be preferable. Due to that, the DNA-
lipoplexes for this thesis were prepared with the DAC. It is a quite new technique which offers 
the possibility for a fast and sterile production of liposomes. Depending on the needs, very 
small amounts for research purposes but also larger amounts for commercial production can 
be prepared. Introducing new preparation methods, it is necessary to investigate the structure 
of samples prepared with these new techniques and evaluate if the structural model developed 
for this thesis apply also for these lipoplexes. In general, a comparison of the molecular struc-
ture of lipoplexes prepared with different methods would be instructive.  
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8 Appendix 
8.1. pH dependent structural changes 
I. Comparison of structures at pH 7.5 and 5 with EPC 80 %-lipoplexes using SAXS  
 
 
Figure (Appendix) 1: Peak pattern of lipoplexes with EPC 80 % and different amounts of mRNA, 
measured in pH 7.5 and 5 (cf. Fig 27) 
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Figure (Appendix) 2: Peak pattern of lipoplexes with EPC 80 % and different amounts of DOTMA 
and mRNA, measured in pH 7.5 and 5 (cf. Fig. 28) 
 
 
Figure (Appendix) 3: Peak pattern of lipoplexes with EPC 80 % and different amounts of DODMA 
and mRNA, measured in pH 7.5 and 5 (cf. Fig. 29) 
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II. Investigation of pH dependent structural transition with EPC 80 %-lipoplexes 
 
Figure (Appendix) 4: Peak pattern of lipoplexes with EPC 80 %, 10 mg/ml DOTMA and 5 mg/ml 
mRNA, measured from pH 8 to 4.5 (cf. Fig. 30) 
 
Figure (Appendix) 5: Peak pattern of lipoplexes with EPC 80 %, 10 mg/ml DODMA and 10 mg/ml 
mRNA, measured from pH 8 to 4.5 (cf. Fig. 31) 
Appendix  
154 
 
 
Figure (Appendix) 6: Peak pattern of lipoplexes with EPC 80 %, 5 and 10 mg/ml DODMA and 5  or 
10 mg/ml mRNA, measured from pH 8 to 4.5 (cf. Figs. 30 and 31) 
III. Investigation of pH dependent structural transition with DOPC-lipoplexes 
 
 
Figure (Appendix) 7: Peak pattern of lipoplexes with DOPC, different amounts of DOTMA or 
DODMA with or without 5 mg/ml mRNA, measured from pH 8 to 4.5 (cf. Fig. 32) 
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8.2. Release dependent structural changes  
I. Investigation on structural changes with SAXS 
 
 
Figure (Appendix) 8: Peak pattern of lipoplexes with EPC 80 %, 10 mg/ml DOTMA or DODMA 
and 5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 (cf. Fig. 36) 
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Figure (Appendix) 9: Peak pattern of lipoplexes with EPC 80 %, 10 mg/ml DOTMA or DODMA 
and 2.5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 (cf. Fig. 37) 
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Figure (Appendix) 10: Peak pattern of lipoplexes with EPC 80 %, 5 mg/ml DOTMA or DODMA 
and 5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 (cf. Fig. 38) 
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Figure (Appendix) 11: Peak pattern of lipoplexes with EPC 80 %, 2.5 mg/ml DOTMA or DODMA 
and 5 mg/ml mRNA after addition of heparin in pH 7.5 and 5 (cf. Fig. 39) 
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